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‘Worldwide, schizophrenia is the eighth largest cause of disability 
and the illness may shorten life expectancy by 10 years. The direct 
effects of schizophrenia are comparable to those of   many infectious 
and chronic physical illnesses that receive more funding for both 
treatment and research. Cost-effective treatment is now available for 
schizophrenia. A public health initiative to subsidise antipsychotic 
medication for the critical first 2 years of psychotic illness could 
greatly improve outcome for psychotic illness worldwide.  
 
Patients with psychosis in low-income and lower-middle income 
countries may be among the most disadvantaged people on earth and 
providing them with access to basic treatment would be a cost-
effective public health measure.’ 
 
Large M. Farooq S; Nielssen O (2008). Duration of Untreated Psychosis in Low and 
Middle income economies: The relationship between GDP and DUP. British Journal of 
Psychiatry, 2008. 193; 272-278. 
 
 
 
 
 
  iii 
 
 
TABLE OF CONTENTS.      PAGE NUMBERS 
Abstract        VI 
Appendix. A: 1 – 13: Full text published studies VII I 
Acknowledgements      X 
List of journals with the impact factors in which papers are published.    XI   
List of commonly used abbreviations   XII 
SECTION: 1 
THE BACKGROUND 
Chapter 1:  An overview of the thesis.       1-3 
Chapter 2:  Setting the scene: mental health services and care for psychosis in 
developing countries.        4- 11. 
2.1 Low and Middle Income Countries.        05 
2.2 The Burden of Disease caused by Neuropsychiatric Disorders in LAMI 
 countries.          05-07 
2.3 Mental Health Services in LAMI countries.       08 
2.4 The Myth of Community Psychiatry in LAMI countries.       08-09 
2.5 The role of mental health research in developing countries.     09 
2.6 The burden of disease caused by Psychosis in developing countries.  09-11 
Chapter 3:  
 The setting: Lady Reading Hospital (LRH), Peshawar.     12-15  
  iv 
 
 
SECTION: 2  
THE CASE FOR A PUBLIC HEALTH ACTION ON EARLY INTERVENTION: 
GATHERING THE EVIDENCE 
Chapter 4:  Publications on epidemiology and course of psychosis in developing 
countries.                  16- 34
   
 
4.1 Puerperal Psychosis (PP) - A preventable presentation of  Psychosis.          18-24  
4.2 Psychosis and homicide.                 24-27 
4.3 Studies on Cannabis abuse in patients suffering from Schizophrenia.            28-33 
4.4 Summary of the publications: 1995-2007.                34 
 
Chapter 5:  The case for a public health action for early intervention - publications on 
Duration of Untreated Psychosis (DUP).       35-54. 
 
5.1 Duration of Untreated Psychosis in developing countries: The relationship between 
Gross Domestic Product (GDP) and DUP.        38-46. 
 
5.2 The relationship between the duration of untreated psychosis and outcome in low and 
middle income countries: Systematic review with meta-analysis.    46-54 
  v 
 
 
 
SECTION:  3 
 PARADIGM FOR  EARLY INTERVENTION IN PSYCHOSIS IN LOWAND 
MIDDLE INCOME COUNTRIES.              55-88 
Chapter 6:  Publications on advocating a new paradigm for Early Intervention in 
Psychosis   in LAMI countries.                 55-64 
6.1 Development of theoretical framework: An overview of the publications. 56  
6.2 Development of a theoretical framework for a paradigm of Early Intervention in 
Psychosis.            56-59 
6.3 Early Intervention for Psychosis in Developing Countries – Learning From 
Tuberculosis?             59-63 
6.4 A paradigm for early intervention in developing countries – Supervised Treatment  
       in Outpatients for Schizophrenia (STOPS).       63-64 
 
Chapter 7:   The proof of the concept – A randomised controlled trial   to  evaluate 
Supervised Treatment in Outpatients for Schizophrenia (STOPS).  65-84 
 
Chapter 8:  Integration and Knowledge Translation:  development and evaluation of 
complex intervention.        85-88 
 
REFERENCES.          89-98 
 
 
 
 
  vi 
 
 
ABSTRACT 
This thesis is based on 13 papers published in peer reviewed journals. These include studies 
on epidemiology and treatment of major psychotic disorders, and metanalysis of studies on 
Duration of Untreated Psychosis (DUP) and its relationship with the Gross Domestic 
Product and the outcome in Low and Middle Income (LAMI) countries. Based on this 
research that highlighted the extent and impact of untreated psychosis, a series of papers 
presented a novel approach for early intervention in psychosis in LAMI countries. The final 
paper presents the randomised controlled trial evaluating this approach. 
Seven publications on puerperal psychosis, homicide by patients suffering from 
Schizophrenia, and the impact of cannabis use on symptomatology and course of 
schizophrenia highlighted significant gaps in the care of schizophrenia in developing 
countries. Only 12 patients (24%), charged with homicide had received some form of 
treatment before the index crime, despite the fact that duration of illness was more than 5 
years in most cases. In a clinical sample of 35 patients suffering from acute episode of 
Puerperal psychosis the mean time between the onset of symptoms and receiving 
psychiatric care was almost a month. Two third of mothers suffering from Puerperal 
psychosis could not breast feed, most showing almost total lack of concern for the baby and 
also other behavior which could result in harm to baby. The publications on Puerperal 
psychosis argued that prevention of the disorder should be feasible in developing countries 
in view of high incidence of the disorder following an identifiable life event (childbirth) 
and the fact that most of the risk factors could be screened in the antenatal period.  
 
A paper published in British Journal of Psychiatry estimated the Duration of Untreated 
Psychosis (DUP) and its impact on the outcome of psychosis. Based on metanalysis of 98 
studies (23 from LAMI countries and 75 were from high-income countries) the DUP of 
LAMI countries (125 weeks) was twice as long as the DUP in high-income countries (63 
weeks, p=0.012). The relationship between DUP and the gross domestic product (GDP) 
purchasing power parity was also examined using the data from International Monetary  
 
  vii 
 
Fund (IMF) and the World Bank. There was a strong negative correlation between DUP 
and GDP ppp, indicating that for every thousand dollars of additional GDP (purchasing 
power parity), mean DUP was reduced by 8 weeks and median DUP was reduced by 5 
weeks. 
A study published in Schizophrenia Research examined the association between DUP and 
at least one of the following outcome measures; psychotic symptoms, cognitive function, 
social disability or mortality. Patients with a longer DUP had a smaller reduction in 
symptom scores after treatment when compared to patients with shorter DUP.  The pooled 
estimate indicated that longer DUP was negatively associated with the degree of reduction 
in symptom scores (random effects Meta analysis; r=−0.290, 95% CI=−0.483 to−0.069, 
z=−2.559, P < 0.011) and longer DUP was associated with greater level of disability (fixed 
effects Meta analysis; r=0.195, 95% CI=0.126 to 0.262, z=5.498, p<0.000; heterogeneity 
Q-value 1.245, p=NS, I2=0.00).  
These studies clearly established the case for Early Intervention in psychosis. However, an 
entirely different approach was needed for this in resource poor settings. This approach is 
described in three papers. This approach termed as ‘Supervised Treatment of Outpatient 
Schizophrenia’ (STOPS) was evaluated in a Randomized Controlled Trial. The paper 
describing this RCT which provided proof of the concept will soon be published by British 
Journal of Psychiatry. In this RCT, fifty five patients were recruited in each arm. Ninety 
five (86.36%) patients completed the study; 49 in STOPS and 46 in Treatment As Usual 
(TAU) group. At one year follow up, 37 (67.3%) patients in STOPS group had complete 
adherence with medication compared to 25 (45.5%) in the TAU group (P<.02). The 
patients in STOPS group also showed more improvement in symptoms (P=0.003) and 
functioning (P<0.011).  
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SECTION - 1 
Chapter 1:  
An overview of the thesis 
This thesis is based on my published work over more than a decade. The thesis covers 13 
publications on related themes of epidemiology, services and a model for early intervention 
in Psychosis in a typical Low and Middle Income (LAMI) country setting. The publications 
arising from this research are given in tables 1 and 2. The format of this thesis will, 
therefore differ essentially in presentation and style from the thesis written generally. 
I will only describe essentials of methodologies and major findings of the studies in the 
main body of thesis. All studies are given as appendix 1 in full text. In the first set of 
studies, which are based in a mental health services at Peshawar, different aspects of 
presentation, epidemiology and services for Psychosis are investigated. A list of the papers 
based on this work is given in table 1. 
The second set of studies consists of the Systematic reviews and meta analysis of all the 
published research from LAMIC countries on Duration of Untreated Psychosis (DUP), its 
relationship with Gross Domestic Product (GDP) and the outcome of Psychosis. This is 
followed by a section which describes studies that advocates a new treatment paradigm for 
Early Intervention for Psychosis in developing countries based on this published research. 
A list of the papers based on this work is given in table 2. Finally a paper published by 
British journal of Psychiatry describes the evaluation of this approach in a randomised 
controlled trial. 
The final chapter integrates the data presented in the thesis and describes how the 
publications presented in this thesis present a coherent body of the knowledge and the way 
in which this is translated into a complex intervention. In the following sections, I have 
described only essential findings of these studies which relate to this thesis.  The details are 
available in appendix 1, in which full text studies are given. The tables and diagrams are 
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also not given in the main body of thesis and are referred to the original studies given in 
appendix 1. 
 
 
TABLE: 1. First set of studies on epidemiology, course and preventable aspects of 
Psychosis in LAMI countries   
1. Rehman IU, Farooq S. (2007,a) Cannabis abuse in patients with schizophrenia: pattern 
and effects on symptomatology. J Coll Physicians Surg Pak. Mar;17(3):158-61. 
2. Rehman IU, Farooq S.(2007b). Schizophrenia and comorbid self reported cannabis 
abuse: impact on course, functioning and services use. J Pak Med Assoc. 2007 Feb; 
57(2):60-4. 
3. Farooq S, Deeba F, Ashfaque M, Iqbal M (2003). Mentally-ill patients charged with 
homicide. J Coll Physicians Surg Pak; 13(4):223-5 
4. Farooq S (2004). Postnatal psychiatric disorders need public health action (Editorial).J 
Coll Physicians Surg Pak. Apr; 14(4):197-8. 
5. Farooq S (1997). The Impact of Psychiatric disorders during pregnancy and puerperium 
of the child- A review of the literature. J Coll Physicians Surg Pak.  Vol. 9, 331-333. 
6. Farooq S (1996). Clinical Features of Puerperal Psychoses. J Coll Physicians Surg Pak. 
Vol. 6 (3) 148-150.  
7. Farooq S (1991). Puerperal Psychiatric Disorders- who cares. (Editorial). Journal of 
Pakistan Medical Association (J.P.M.A). Nov.  267-268.  
 
 
  3 
 
 
 
 
 
 
 
TABLE: 2. Second  set of studies on epidemiology, course and preventable 
aspects of Psychosis in LAMI countries  
8. Farooq S; Large M. Nielssen O, Waheed W. (2009). The relationship between the 
Duration of Untreated Psychosis and outcome in low and middle income countries:  
Schizophrenia Research. Schizophrenia Research. 109 (2009) 15–23. 
9. Farooq S (2008). Public Health Intervention for Schizophrenia in Developing Countries 
– From DOTS to STOPS.JPPS (Journal of Pakistan Psychiatric Society).5(2) 1-2. 
10. Farooq S (2006). Free pharmacological treatment for schizophrenia in developing 
countries – case for a public health intervention. JPPS (Journal of Pakistan Psychiatric 
Society). 3(1), 1-2. 
11. Large M. Farooq S; Nielssen O (2008) Duration of Untreated Psychosis in Low and 
Middle income economies: The relationship between GDP and DUP. British Journal of 
Psychiatry,2008. 193; 272-278. 
12. Patel V, Farooq S, Thara R(2007). What is the best approach to treating schizophrenia 
in developing countries? PLoS Med Jun;4(6):e159. 
13. Farooq S. Nazar Z, Akhter J et al. Supervised Treatment in Outpatients for 
Schizophrenia (STOPS): Randomized Controlled Trial of an innovative approach for 
the treatment of Schizophrenia in developing countries. British Journal of Psychiatry. 
2011, 199:467-472. 
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Chapter 2: 
Setting the scene: mental health services and care for psychosis  
in developing countries 
 
 
STATE  OF CARE AND RESEARCH  FOR  SEVERE MENTAL  ILLNESS  
IN  LOW AND MIDDLE  INCOME COUNTRIES 
 A total of more than 85% of the global population lives in 153  Low- and 
middle-income (LAMI) countries.   
 Most developing nations have more than one third of their population below 
45 years of age- the age group at highest risk of developing Schizophrenia. 
Around 41.7 million people with schizophrenia are in need of care in 
LMICs.  
 Almost a third of countries do not have a public budget specified for mental 
health. About a quarter of low-income countries do not provide even basic 
antidepressant medicines in primary-care settings 
 A very limited amount (6%) of internationally accessible mental health 
literature
 
emanates from low- and middle-income countries 
 Families take care of persons with severe mental disorders and often there is 
little the relatives can do other than to restrain them. One study from Africa 
found ‘The average time spent in chains of the 109 “mental cases”, who had 
been chained at some point during their lives, was 2.7 years (SD = 3.9) and 
the average time being restrained in some other way for the 119 of them 
who had experienced this, was 3.9 years (SD = 5.1). 
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2.1.1 Low and Middle Income (LAMI) Countries  
More than 85% of the global population lives in 153
 
Low- and middle-income 
(LAMI) countries.  Nine of 11 countries with a population of at least 100 million 
belong to the LAMI categories.  These countries are distributed in
 
all parts of the 
world: all of Africa, much of Asia, South
 
and Central America and Eastern Europe. 
(Patel et al 2007). Health systems in these countries have mostly been geared 
towards coping with disorders causing high mortality. However, during the last two 
decades the significant burden of disease caused by Non Communicable Diseases 
(NCD) has been realized mainly as a result of landmark Global Burden of Disease 
report   (Lopez and Murray, 1996). This section will briefly overview the current 
status of burden of disease caused by neuropsychiatric disorders and existing mental 
health services. The   contribution of mental health research in these countries will 
also be highlighted. 
2.2 The Burden of Disease caused by Neuropsychiatric Disorders in LAMI 
countries 
Non-Communicable Diseases (NCD) have become the dominant cause of disability 
in all developing countries. Psychiatric disorders represent a significant proportion 
of the burden of disease amongst the NCD.  The Global Burden of Disease report 
has revealed the scale of the contribution of mental disorders, by use of a measure 
of disease burden that takes into account the disability, called Disability Adjusted 
Life Years (DALYS). DALYs for a specific cause are calculated as the sum of the 
Years of Life Lost (YLL) due to premature mortality from that cause, and the years 
of healthy life lost as a result of disability (YLD).  The YLL are essentially 
calculated as the number of cause-specific deaths multiplied by a loss of function 
specifying the years lost as a function of the age at which death occurs (For detailed 
calculations and formula see Mathers et al, 2006) . Although the size of the burden 
of disease caused by these disorders varies between these countries according to 
income level, the report showed that neuropsychiatric conditions account for up to a 
quarter of all Disability-Adjusted Life-Years (Lopez and Murray, 2006)  
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The neuropsychiatric conditions that contribute the most disability adjusted life-
years are unipolar and bipolar affective disorders, substance-use and alcohol-use 
disorders, schizophrenia, and dementia. As most mental disorders begin in 
childhood or young adulthood and most severe mental disorders begin in the 
younger age group, the attributable burden of disease for adults in the age group of 
15–44 is much higher. Table 3 shows that one of the leading causes of disease 
burden in this age group is mental and behavioural disorders. It is obvious that 
overall Schizophrenia is 8
th
 amongst leading causes of disability both in male and 
females. However, gender wise distribution is different. In females Schizophrenia 
ranks as 5
th
 and in males it ranks as 8
th
. This is due to the fact that in males road 
traffic accidents, substance abuse and violence are responsible for greater burden of 
disease and hence precede Schizophrenia in the table. The neuropsychiatric 
conditions contribute the most to overall burden, more than either cardiovascular 
disease or cancer during the most productive years of life. 
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TABLE: 3. Burden of mental disorders in young adults  
Both sexes, 15–44 
year old 
Total 
(%) 
Males, 15–44 year 
old 
Total 
(%) 
Females, 15–44 
year old 
Total 
(%) 
 
HIV/AIDS 13.0 HIV/AIDS 12.1 HIV/AIDS 13.9 
Unipolar depressive 
disorders 
8.6 Road traffic 
accidents 
7.7 Unipolar depressive 
disorders 
10.6 
Road traffic 
accidents 
4.9 Unipolar depressive 
disorders 
6.7 Tuberculosis 3.2 
Tuberculosis 3.9 Alcohol use 
disorders 
5.1 Iron deficiency 
anaemia 
3.2 
Alcohol use 
disorders 
3.0 Tuberculosis 4.5 Schizophrenia 2.8 
Self-inflicted 
injuries 
2.7 Violence 3.7 Obstructed labour 2.7 
Iron deficiency 
anaemia 
2.6 Self-inflicted 
injuries 
3.0 Bipolar affective 
disorder 
2.5 
Schizophrenia 2.6 Schizophrenia 2.5 Abortion 2.5 
Bipolar affective 
disorder 
2.5 Bipolar affective 
disorder 
2.4 Self-inflicted 
injuries 
2.4 
Violence 2.3 Iron-deficiency  
anaemia 
2.1 Maternal sepsis 2.1 
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2.3  Mental Health Services in LAMI countries 
Despite these startling figures mental health remains a low priority in most LAMI 
countries. Almost a third of countries (31%) do not have a public budget specified 
for mental health. Of  the 101 countries which have a specified mental health 
budget, 21 (with more than 1 billion people), spend less than 1% of their total health 
budget on mental health. This is particularly the case in Africa and Southeast Asia 
where most countries devote less than 1% of their small health budgets for mental 
health services. Comparing gross domestic product (GDP) per head with the 
proportion of the total health budget allocated to mental health, Prince et al 2007 et 
al demonstrated that mental health in low-income countries faces a double 
disadvantage: the poorest countries spend the smallest proportion of their already 
scarce resources on mental health. 
2.4  The Myth of Community Psychiatry in LAMI countries 
The integration of mental
 
health in primary health care has been a mantra for several
 
decades and WHO advocated the Community Psychiatry as the only viable option 
for developing countries since the early 70s. In fact, this has been the widely 
accepted model for provision of the services in these countries. A rather romantic 
notion of the Community Mental Health existed in these countries that led to a myth 
that patients with mental disorders are being provided care in the community and 
somehow stigma was less prevalent in traditional societies.  The Author of this 
thesis challenged the concept more than a decade ago arguing that Community 
Psychiatry is a misnomer and may be misleading when applied in the context of 
developing countries. The term neither fulfils the criteria of a public health 
approach as envisaged in ‘Community Medicine’ nor that of community mental 
health services in any form (Farooq and Minhas, 2001). This has been confirmed by 
the recent literature on mental health in developing countries (WHO 2001). 
Community Psychiatry does not represent more than an isolated existence of a  
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mental health centre here and there in the community. The recent research shows 
that even such a loosely defined community mental health service does not exist in 
many countries. If community-based mental health care is defined broadly, as “any 
type of care, supervision and rehabilitation of patients with mental illness outside 
the hospital by health and social workers based in the community”, then only about 
half the countries in Africa, the eastern Mediterranean, and southeast Asia provide 
such care (WHO, 2005).  About a quarter of low-income countries do not provide 
even basic antidepressant medicines in primary-care settings (Saxena et al 2007).  
2.5  The role of  mental health research in developing countries. 
Health research plays a major role in providing solutions for health problems. 
Inadequate health research from these countries contributes significantly to the 
vicious cycle that leads to lack of investment in mental health systems. Lack of 
evidence for the cost effectiveness of mental health interventions in developing 
countries has been cited as one of the major reasons by development agencies for 
reluctance to invest in mental health services in developing countries (Saraceno et 
al, 2006). A very limited
 
amount (6%) of internationally accessible mental health 
literature
 
emanates from low- and middle-income countries (Saxena et al, 2006). 
Fewer than 1% of more than 11501 trials world wide for the treatment and 
prevention of major psychiatric disorders were from low-income countries. 
Although this has improved to some extent in the last decade (Large et al, 2008), the 
lack of evidence and reliable information is one of the key factors contributing to 
the dismal state of mental health services in these countries. 
2.6  The burden of disease caused by Psychosis in developing countries. 
In this thesis the term ‘psychoses’ will be used instead of a specific diagnostic 
category such as Schizophrenia in line with the literature on the Duration of 
Untreated Psychosis and its consequences, the main theme of the thesis. The 
literature on Duration of Untreated Psychosis (DUP) has used the term ‘psychoses’ 
without any attempt to delineate the diagnostic categories within this broad group. 
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In practice, however this almost always implies Schizophrenia, the most common 
disorder in this category of psychotic disorders.  
This is especially valuable in context of developing countries, as focusing on a 
broad category of psychosis helps to identify a group of disorders which represents 
most severe form of mental illness.  
The median incidence of schizophrenia is around 1.5 per 10,0000 inhabitants 
(McGrath et al, 2004) and the lifetime morbid risk of developing schizophrenia is 
near 0.7% (Saha et al, 2005). Despite this low incidence it is estimated that around 
41.7 million people with schizophrenia are in need of care in LMI countries. This is 
mainly because of the age structure of these countries. Most developing nations 
have more than one third of their population below 45 years of age, the age group of 
maximum risk for developing most psychotic disorders including Schizophrenia.  
Not surprisingly, Schizophrenia is amongst the top ten causes of the years lived 
with a disability in developing countries in this age group (Mathers et al 2006).  
The mental health services in these countries are woefully inadequate as described 
above. With less than one qualified mental health professional for half to one 
million people and about 1% of health budget dedicated for mental health, most 
people with schizophrenia in LAMI countries probably receive little or no formal 
care. Consequently, there is a high prevalence of untreated schizophrenia in the 
form of undetected as well as inadequately and partially treated cases.  
Family is the sole care provider in almost all the cases. The family not only has to 
cope with large economic and social burden due to largely untreated psychosis but 
also the effects of stigma in closely knit societies. A study from China, reported that 
more than half the family members of people with schizophrenia said that the effect 
of stigma on them and their family was such that they had decided to conceal the 
mental illness in their family (Philips et al, 2002). Poverty and social exclusion have 
been well known as risk
 
factors for mental illness. Between 40 and 50% of mental 
health care costs
 
are borne out of pocket in LAMIC (WHO, 2005). The disabling 
effects of mental disorders and social isolation due to stigma leads to the vicious 
cycle of inability to work,  increasing burden on the family and poverty. 
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The care for psychosis in these settings is vividly illustrated in the recent report by 
Vivo, an international Organisation working in conflict zones. In a survey of a 
representative sample of 612 households in Hargeisa Somaliland, authors noted that 
‘Like in many other African countries, the families take care of persons with severe 
mental disorders and often there is little the relatives can do other than to restrain 
them in order to avoid harm being done to others or themselves.  
Of the 169 persons with severe current mental problems 109 had to be chained at 
some point during their lives and 113 had to be restrained in some other way by 
their family (mostly because of aggressive behaviour). At the time of the interview 
48 were kept in chains and 85 were restrained in other ways. The average time spent 
in chains of the 109 “mental cases”, who had been chained at some point during 
their lives, was 2.7 years (SD = 3.9) and the average time being restrained in some 
other way for the 119 of them who had experienced this, was 3.9 years (SD = 5.1).’ 
(Odenwald et al, 2007). 
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Chapter: 3 
The setting: Lady Reading Hospital (LRH), Peshawar. 
 
 
 
 
  The Psychiatry department Post Graduate Medical Institute, Lady 
Reading Hospital (LRH) Peshawar; Pakistan: A tertiary care teaching 
facility with 14 in patient beds, daily clinics with average attendance at 
outpatients of 40. Three consultant psychiatrists, 2 psychologists, 2 
social workers and 4 psychiatric nurses comprise the multidisciplinary 
team.  
 The average length of stay for in-patients is less than two weeks and is 
limited mostly to most acutely ill patients. The services are heavily 
dependent upon the support provided by the family.   
  Peshawar district has population has over 2.5 Millions but patients 
present from as far as Afghanistan and the actual population from which 
patients can present to hospital may well be over 20 Millions. 
  The Lady Reading Hospital is frontline hospital treating all war traumas 
resulting from suicide and other bombing at public places during the so 
called war on terror.  
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Peshawar is the capital of the Khyber-Pakhtunkhwa province (previously known as 
NWFP, North West Frontier Province) and the administrative centre for the 
Federally Administered Tribal Areas of Pakistan, a semiautonomous region 
bordering with Afghanistan. Located about 40 Km from the historic Khyber Pass, 
Peshawar is now officially recognised as being one of the Oldest Living Cities in 
Asia. Peshawar district covers a large area extending over 50 Kilometers and has 
population over 2.5 Millions and is served by three main teaching hospitals.  
Lady Reading Hospital (LRH) Peshawar, was established in 1924. The hospital is 
named after Lady Reading, the spouse of Viceroy of British India and is the biggest 
health facility in the entire Khyber-Pakhtunkhwa province. The hospital is one of 
the two campuses of the only postgraduate medical institute serving the province. 
The hospital does not serve a specific catchment area. Being the biggest health 
facility in the region patients present to the Lady Reading Hospital not only  from 
the province but also adjoining Afghanistan and  sometimes as far as from central 
Asian states.   
A report in The Daily Telegraph on 19 Nov 2009 succinctly put the past and present 
of the hospital as follows ‘Lady Reading Hospital, or LRH as it is known among the 
2.5 million residents of Peshawar, was founded in 1924 when Lord Reading was 
viceroy of India and is now one of Pakistan's largest teaching hospitals. On a visit to 
the area, his wife fell off a horse and suffered an injury, only to find that proper 
treatment was unavailable locally. In England, she collected donations from British 
philanthropists and set up a hospital that ultimately took her name. But the romance 
of its beginnings has vanished under the carnage witnessed in Peshawar and the 
surrounding North West Frontier Province (NWFP) where Taliban bombings and 
military offensives have been concentrated.  "We have dealt with 49 blasts... 2,200 
injured and 576 bodies in bombings," said Dr Ataullah Arif, the surgeon in charge 
of the emergency ward. Tactics are changing. Bombings of crowded markets are  
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beginning to maximise civilian casualties The 1,543 beds are woefully inadequate 
and the hospital is intending to overcome dire shortages by building a 500-bed 
emergency ward. There are fears that a suicide bomber could strike the hospital, a 
soft target (http://www.telegraph.co.uk/expat/expatnews/6604667/Peshawar-
hospital-in-war-time- crisis.html. Last assessed 4th July 2010). 
Although war is not a new phenomenon for the inhabitants of Peshawar being 
located strategically on a route for all invaders of the Indo-Pak subcontinent, the last 
decade has witnessed the worst violence after the so called war on terror.  
The war to fight the Taliban insurgency has resulted in a dramatic increase in both 
physical and psychological trauma. More than 20 thousand people were killed and 
over 3 million were displaced during recent military operations, bomb blasts at 
public places and suicide bombings during Taliban insurgency 
http://en.wikipedia.org/wiki/War_in_North-West_Pakistan). The hospital has also 
been battling with the consequences of the conflict going on in the region for the 
last three decades since early eighties when Soviets invaded Afghanistan.  
The Psychiatry department at LRH provided in patients and community services 
mostly to the Peshawar district. Initially the department had 14 inpatient beds which 
were increased to 36 beds in 2006.  A multidisciplinary team based at the 
department provides modern psychiatric treatment.  The multidisciplinary team 
consisted of three consultant psychiatrists, 2 psychologists, 2 social workers and 4 
psychiatric nurses besides auxiliary staff. The services are heavily dependent upon 
the support provided by the family. The average attendance at daily outpatient 
clinics is around 40 patients. The average length of stay in the in patients is less than 
two weeks and is limited mostly to most acutely ill patients usually suffering from 
Psychotic disorders. This is due to the fact that the department serves large 
populations and there are limited inpatient psychiatric facilities. The family 
provides support and care in community and is able to provide care for acutely ill 
patients. It is difficult to compare this length of stay with UK due to entirely 
different nature of two types of services. However, this appears to be considerably  
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shorter than average stay in developed countries like the United Kingdom.  The 
department is recognized by The College of Physicians and Surgeons, Pakistan for 
the postgraduate training in Psychiatry and is widely recognized in the country as 
centre of excellence for training and research even during the worst violence.    
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SECTION: 2 
THE CASE FOR A PUBLIC HEALTH ACTION ON EARLY 
INTERVENTION: GATHERING THE EVIDENCE 
 
Chapter 4 
 
Publication on epidemiology and course of psychosis in LAMI Countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Puerperal Psychosis has a rather predictable onset (something of a rarity 
in psychiatric disorders), and is precipitated by well established risk 
factors thus making prevention possible and feasible. 
 High fertility rates, infections and other complications of delivery result 
in high incidence and prevalence of psychosis following childbirth in 
LAMI countries,  
 In a clinical sample of 35 women suffering from acute episode of 
Puerperal psychosis the mean time between the onset of symptoms and 
the admission was 27 days. Two third of mothers could not breast feed, 
most showing almost total lack of concern for the baby and also other 
behavior which could result in harm to baby. 
 Only 12 patients (24%), charged with homicide had received some form 
of treatment before the index crime, despite the fact that duration of 
illness was one year in 96% of cases. In this study 38 patients (76%) 
were involved in a single murder, while 12 patients (24%) were 
charged with double/multiple murders. Out of 64 victims of the 
patients, 49 were close relatives.  
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This phase of my work starts with descriptive studies on the clinical features of 
puerperal psychosis, followed by an important paper on homicide by patients 
suffering from Schizophrenia and finally, two publications on the effect of cannabis 
on symptomatology and course of Schizophrenia. These papers highlighted 
important aspects of psychotic disorders as these present in developing countries, 
state of care for those suffering from severe mental illness and the need for a public 
health action in the form of early intervention.  
The details of my initial publications on different aspects of the epidemiology of 
Psychosis which formed the basis of my later work are presented in following three 
major areas: 
 
1. The publications highlighting the distinct epidemiological features of the 
Puerperal Psychosis (PP). This highlighted the potential for preventative 
public health action in view of specific epidemiological features of these 
disorders and the impact on mother and baby. 
2. An original study on homicide by patients suffering from psychotic 
disorders. This study identified that only 12% of patients had any psychiatric 
treatment before being charged with homicide despite the fact that they had an 
average duration of illness of more than a year. 
3. Two original studies on the effects of cannabis on symptomatology, course, 
functioning and service use in patients suffering from schizophrenia. These 
helped to elucidate the extent of cannabis abuse and its effects on the course of 
illness as a preventable factor in the course of a psychotic illness. 
 
In this section, I will present only the salient findings of my studies, with a brief 
background and discussion of relevant results. The details of all the publications are 
available in full text as appendix A 1-6. 
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4.1  Puerperal Psychosis (PP) - A preventable presentation  of  Psychosis  
 
 Background 
 
Most psychiatric disorders are not preventable.  This is mainly due to the fact that 
many risk factors for psychiatric disorders, e.g., stressful life events are not 
predictable. Other risk factors such as genetic predisposition cannot be readily 
identified until the disorders manifest.  Moreover, the manpower and financial 
resources required for early diagnosis and intervention are not readily available in 
Low and middle Income (LAMI) Countries. Postnatal psychiatric disorders on the 
other hand appear to have a rather predictable onset (something of a rarity in 
psychiatric disorders), are amenable to easier screening and are precipitated by well 
established risk factors.  These characteristics of postnatal psychiatric disorders can 
help to initiate a public health strategy in psychiatry. 
My work on Psychosis started in 1989, when I completed a dissertation on 
Puerperal Psychosis. This is 153 pages dissertation submitted to the College of 
Physicians and Surgeons, Pakistan in 1990 as requirement for the Fellowship of the 
College. Initially, I was fascinated by symptomatology and presentation of the 
Puerperal psychosis. However, as the work progressed, I realized the plight of 
patients and families and the potential for a public health action in this field. The 
salient findings from these publications are described below.    
Paper 1. Clinical Features of Puerperal Psychosis.  
(Please see full text article as Annex A1). 
Puerperal Psychosis (PP) is a relatively rare disorder and occurs following .2% of 
all childbirths (Kendell etal, 1987). But, in developing countries like Pakistan which 
have high fatality rate and multiple pregnancies, PP is not a rare disorder (Farooq, 
2004).  The identified high risk factors of PP are perinatal death, a previous history 
of manic depressive illness, previous episode of PP, twin birth and Caesarean 
Section.  
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For mothers with previous history of Bipolar Affective Disorder, the risk of 
psychosis following childbirth is increased 100 fold  to one in five (Kendell et al, 
1987;Kendell et al, 1981; Pfuhlmann et al, 2002). Most Post Partum Psychotic 
Disorders are Bipolar in nature.  The potential for prevention of these types of 
disorders was demonstrated by a Randomised Controlled Trial of Lithium Therapy 
started in the last trimester of pregnancy.  Stewart et al (1991) demonstrated that 
prophylactic use of Lithium initiated either at 34 weeks of pregnancy or within 24 
hours of delivery, was associated with lower risk of relapse in patients with a 
previous history of Bipolar Affective Disorder. 
Most literature on PP is from developed nations. I aimed to investigate the clinical 
features, social determinants and diagnostic breakdown of those suffering from PP 
in a developing country setting.  
Methodology 
All patients referred to a Tertiary Care Teaching Hospital in Peshawar over a 15 
month period with psychotic symptoms after the delivery were assessed, between 
November 1988 and January 1990. The patients were assessed with the help of an 
interview based on Present State Examination. The Puerperal Psychosis was defined 
as onset of psychotic symptoms within 90 days of childbirth. The onset for the 
purpose of this study was defined as “the moment when the patient had important 
symptoms which interfered markedly with her daily activities or abnormality in her 
behaviour was noted”.  The definition of psychosis for the purpose of this study was 
adopted from DSM III. Patients were assessed with the help of research diagnostic 
criteria. The diagnosis was made according to Research Diagnostic Criteria (RDC) 
(Spitzer et al, 1978).  
The data on presenting clinical features, help seeking before the contact with 
psychiatric services, contacts with spiritual healers and effects on the newborn was 
collected with the help of an instrument constructed for this purpose. 
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Salient Results 
 The mean age of 35 women comprising the sample was 24.2 years (SD 7.08 
years).  Thirty (30) mothers were primiparae.  
 The average time between the delivery and onset of symptoms was 14.34 days 
(SD 14.59).  80% of patients had onset of symptoms within 3 weeks of delivery 
and all of them had onset within 2 months.  
 The average delay between the onset of symptoms and the admission was 27 
days.  15 (42.86) patients had some form of treatment from spiritual healers 
before admission, which in the majority was the first psychiatric contact. 
 Schizophrenia was most common diagnosis (28.57%), followed by 
Schizoaffective disorders (22.86%). Table 1 in Appendix A-1 shows the details 
of diagnostic breakdown. 
 Two third of mothers could not breast feed, most showing almost total lack of 
concern for the baby. 
 In four cases (11.74%) mother’s mental state resulted in some harm to the baby 
e.g. repeated bathing for the baby due to obsessive concerns about the 
cleanliness. In seven cases (20%) baby featured in paranoid and nihilistic 
delusions of the mother. However, none of the mothers expressed any 
infanticidal thoughts or inflicted any deliberate harm to the newborn. 
Discussion 
The age of onset of the disorder and the proportion of primiparae mothers in this 
sample were markedly lower than generally reported. However, both of these were 
comparable to other studies from developing countries (Maknjoula, 1982).  This 
was understandable in view of younger age at marriage (80% married before 18 
years of age in this sample) and the subsequent high fertility.  The clinical features 
of PP were found to be broadly similar to that reported in the literature.   
The diagnostic breakdown however revealed some differences. There was low 
prevalence of affective disorders, particularly that of mania, in sharp contrast to 
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most of the studies from western countries.  There was high proportion of organic 
psychosis, i.e., 17%.  Some of the differences could be explained by the differences 
in the use of different diagnostic criteria and the diagnostic practices which vary 
across countries.  However, the diagnostic criteria were broadly similar to those 
reported from other developing countries.  For example, most studies from 
developing countries report a high proportion of organic psychosis (Maknjoula, 
1982). This is understandable in view of the high prevalence of complications of 
postpartum period, i.e., infections, anaemia and various deficiency states. 
In agreement with other studies from developing countries (Makanjoula et al, 1982; 
Shoeb et al, 1990; Ifabumuyi O I, and Akindele MO et al 1985), about half of the 
patients contacted a spiritual healer before admission, which in the majority of cases 
was the first point of contact.  This seems to be the most important factor for 
considerable delay (27 days on average) between the onset of symptoms and 
admission to a Hospital, which may have contributed to the significant physical 
morbidity and result changes in the clinical picture found in this population.   
Paper: 2. The Impact of Psychiatric disorders during pregnancy and 
puerperium on the child- A review of the literature. (Please see full text article 
as Annex A2). 
This Review Article investigated the impact of psychiatric disorders during 
pregnancy and in postpartum period on the child. Building on studies which had 
shown that antenatal stress or anxiety are linked with prematurity or low birth 
weight, this review article highlighted the impact of postnatal depression and PP on 
the emotional, psychological and physical health of the infants. 
The prospective cohort studies showed that the children of postnatally depressed 
mothers may show cognitive deficit defects at 4 years of age, difficulties in 
adjustment and raised level of disturbances leading to difficulties in progress at 
school. I am not aware of studies or duration of untreated psychosis in puerperal 
psychosis.  I researched literature but could not find studies addressing this 
specifically in puerperal psychosis.  This would be shorter, as women are receiving 
regular health care in puerperium. 
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In contrast to the postpartum depression, the effect of postpartum psychosis on the 
child have not been well studied mainly due to the fact that PP is an uncommon 
disorder in developed nations, where most of the research on the subject has been 
done.  However, I argued that the children of the mother’s suffering from PP may 
be exposed to similar cognitive, emotional and behavioural disturbances as has been 
the case for postnatal depression because Postnatal Depression is a much less severe 
disorder than the PP. 
The review article highlighted the fact that the incidence and prevalence of PP may 
be higher in developing countries due to the following reasons: 
1 High fertility rate in developing countries resulting in high risk of 
developing PP after each childbirth. 
2 The risk for postnatal psychiatric disorder is highest in primiparae and 
increases with every subsequent delivery.  Mothers who develop PP after 
first delivery have a 1 in 5 risk of developing a similar illness during 
subsequent childbirth.  This means that the risk of relapses after each 
childbirth actually multiplied. 
3 Certain causes of PP i.e., infection, anaemia and deficiency states giving rise 
to Organic Psychosis following childbirth are much more prevalent in 
developing countries compared to the developed countries. This leads to 
higher incidence of PP in these countries. 
This extensive review of published literature highlighted the fact that even with 
limited healthcare facilities available in many developing countries; women had the 
best chance of being cared for by health professionals in pregnancy.  This is mainly 
due to the fact that women during pregnancy and postpartum period are more likely 
to receive better care from health providers and families during antenatal and 
postnatal period, compared to any other time in their life, in resource poor settings.  
The peak incidence of puerperal psychosis is within the first two weeks after 
delivery.  During this period they are more in contact with health services or other 
sources of help, compared to another period.  If health visitors are sensitized and 
trained to detect postnatal psychiatric disorders, the likelihood of detection and 
treatment of psychiatric disorders is greatly increased.. It is therefore possible to 
  23 
 
focus on the mental health of the mother during the routine antenatal and postnatal 
care.  The potential cases of PP could be identified through a number of well known 
risk factors and both primary and secondary prevention is therefore possible.   
Paper 3: Puerperal Psychiatric Disorders- who cares? 
Paper 4: Postnatal psychiatric disorders need public health action. 
(Please see full text article as Annex A3 and A4). 
Based on the evidence from literature and my original work, I advocated a public 
health approach for early detection and prevention of Puerperal Psychosis in LAMI 
countries. My extensive writings and advocacy in the field prompted two invited 
editorials. 
Even based on an incidence of approximately 1 in 500 deliveries, very high fertility 
rates in many developing countries result in higher prevalence of PP in these 
countries. The literature  reviews highlighted the fact that newborn babies in 
developing countries may be at risk as a result of malnutrition and gastroenteritis 
due to lack of maternal care after the onset of postpartum psychotic disorders, 
something of a rarity in developed nations.  
For example, Makanjoula in his study in the Nigerian population found that 7 
babies died and another 7 became severely ill as a result of malnutrition and 
gastroenteritis due to lack of maternal care after the onset of postpartum psychotic 
disorders.  Therefore, this posed a greater risk than the infanticide which has been 
reported in up to 4% of the cases of PP in western studies.   
Based on the characteristics of PP highlighted above, I argued that these disorders 
need an urgent public health action. This action should be based on following: 
1 Research on the interventions for postnatal psychiatric disorders which 
could be cost effective in developing country settings. 
2 Training for health professionals involved in routine neonatal care for early 
detection, treatment and prevention of postnatal psychiatric disorders.  The 
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high risk factors for postnatal depression and PP must be included in the 
routine antenatal screening of the expectant mothers. 
3 Creating awareness in the public about these disorders on mother and child.  
  
These actions require collaborative efforts between health professionals involved in 
psychiatric, obstetric and childcare, along with health planners and public health 
experts. ‘After all, we need a generation of young infants and children which is not 
only physically healthy but emotionally and intellectually sound as well, brought up 
by mothers who are free of stigma of mental illness’; concluded one of the articles.  
4.2 Psychosis and Homicide 
Paper: 5. Mentally ill patients charged with homicide  
(Please see full text article as Annex A5)  
Background 
Continuing with my work on the epidemiology of Psychosis and its impacts, I 
explored a rather neglected area of research in developing countries i.e. homicide by 
mentally ill patients. This work was result of my involvement with the Standing 
Medical Board of the provincial government which is an expert body comprising of 
psychiatrist and other health professionals to give opinions about the patients with 
history of mental illness and charged with serious criminal offences. Soon after 
joining the Board, I was struck by rather long periods of illness in these patients 
before they committed the index offence which prompted me to examine the 
relationship between homicide and mental illness in detail.  
Most of the research on the association between offending behaviour and mental 
disorder comes from developed nations. The findings from this research are not 
applicable to many low and middle income countries.  Forensic Psychiatric Services 
are almost non existent in the majority of these countries.  This study investigated 
the characteristics of patients charged with homicide and referred for psychiatric 
assessment with a suspicion of mental illness. 
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Methodology 
The notes of all patients who were charged with murder and referred to the Standing 
Medical Board of the Mental Hospital between 1988 and 1998 were reviewed.  The 
Standing Medical Board comprises of at least 2 qualified Psychiatrists who 
provided their opinion offering an assessment and after a period of observation of 
the patients referred for the purpose of assessment.  All case notes were 
systematically reviewed and the details on the following key variables were 
extracted with the help of an instrument.  
 The demographic details of the patient 
 Opinion of the Board regarding the diagnosis, fitness to stand trial and mental 
state. 
 The events related to and leading to the homicide 
 The details of the victim and their relationship with the patient 
 Past psychiatric history and any treatment received before the index offence 
Salient Results 
Following are salient findings of the study (Table III, IV, V: Appendix A5). 
 Fifty patients charged with homicide during this period were assessed.  
Schizophrenia was the most common diagnosis found in 36 (72%) of patients.  
Other diagnoses included Bipolar Affective Disorder, Epilepsy, and Delusional 
Disorder.   
 Out of fifty patients only 2 patients (4%) had duration of illness of less than 1 
year.   
 Almost half (46%) had a chronic illness with duration of illness ranging 
between one year and twenty years.  
  26 
 
 Only 12 patients (24%) had received some form of treatment before the index 
crime.   
 38 patients (76%) were involved in a single murder, while 12 patients (24%) 
were involved in double/multiple murders.   
 Out of 64 victims of the patients, 49 were close relatives.   
Discussion 
This was the first study on the relationship between homicide and mental illness in 
Pakistan and added valuable data to the scarce literature on the subject in 
developing countries. Predominantly male and young population (mean age 32.40) 
charged with homicide found in the study was in general agreement with other 
studies.  Similarly, high proportion of those suffering from Schizophrenia (72%) 
was also in general agreement with the literature.   
With the exception of two patients, the duration of illness in the sample was more 
than 1 year.  Despite the fact that these patients had a long duration of illness, only 
24% had had any contact with psychiatric services or professionals, which was 
broadly defined for the purpose of this study to be any contact with a mental health 
professional in 6 months before the index crime.  It could be argued that at least 
some of these homicides could have been prevented with the provision of proper 
psychiatric services, as it has been shown that violence and crime can be prevented 
by improving the response to the patients who start to relapse. 
The findings of the study that the majority of the victims were either relatives or 
well known to the patients, was also in broad agreement with the literature.  This 
was in line with the findings reported by Taylor and Gunn (1999).  This study also 
showed that the public perception or violence by mentally ill patients was highly 
distorted, as the victims were most likely to be relatives and acquaintances, rather 
than public at large. 
This study was based on the case notes and therefore suffered from limitations of 
retrospective studies.  However, it is worth mentioning that the Mental Hospital at 
Peshawar was the only Hospital providing Forensic Psychiatric Services for the 
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whole of the region. It is therefore, unlikely we may have missed patients suffering 
from severe mental illness and charged with homicide and study sample could be 
considered representative of the population. It is however, possible that due to 
inadequate Forensic Psychiatric services, the sample comprised of only those 
suffering from most severe form of psychiatric disorders.  
In common with the research on Puerperal Psychosis this study again highlighted 
two most important aspects of the Psychosis in LAMI settings. These are, the long 
duration of untreated illness and its impact on the nearest family members. In case 
of PP this had serious impact on the newborn and the spouse, while this study 
showed that the spouses and the close family members risked their lives while 
providing care of those suffering from Psychotic disorders.  
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4.2  Salient findings of Studies on Cannabis abuse in patients suffering from 
Schizophrenia: 
 
 
CANNABIS ABUSE IN PATIENTS WITH SCHIZOPHRENIA EFFECTS ON 
SYMPTOMATOLOGY, COURSE, FUNCTIONING AND SERVICES USE.   
 The National Survey on Drug Abuse in Pakistan showed 3.01 million people 
to be suffering from chronic drug abuse in Pakistan, rising at a rate of nearly 
7% annually; Cannabis being the most common substance being used.  
 About two-thirds of patients (76) met the criteria for Cannabinoid dependence 
syndrome which meant that cannabis was not being used occasionally or only 
for recreational use. 
 The use of cannabis was associated with more florid positive psychotic 
symptoms   such as excitement, grandiosity, poor impulse control, 
uncooperativeness, anger , and difficulty in delaying gratification . 
 The patients with co morbid cannabis abuse had significantly more relapses, 
spent longer time in hospital and had significantly poor compliance with 
treatment compared to control group.  
 The early intervention programmes should target the Cannabis abuse as both 
cannabis abuse and psychosis occur in young populations during the most 
productive years of the life. 
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Paper: 6. Cannabis abuse in patients with schizophrenia: pattern and effects on 
symptomatology. 
 
Paper: 7. Schizophrenia and co-morbid self reported cannabis abuse: impact 
on course, functioning and services use.  
(Please see full text publications as Annex A6 & A7). 
The research so far had focused on important but narrowly defined areas.  Widely 
prevalent cannabis abuse and its detrimental effects on the course of Schizophrenia 
presented an area in which the preventative efforts could have much wider 
application. This led to the research on the effects of cannabis abuse on the 
symptomatology, presentation and service use in patients suffering from 
Schizophrenia.   
 
Background 
Many studies have shown that the rate of substance use in subjects with severe 
mental illness is high; estimates of recent or current abuse for community samples 
range from 20% to 40%. (Meuser et al, 1990).  Patients with comorbid mental 
illness and substance abuse disorders have been a cause for concern because even 
low levels of substance abuse or dependence represent a risk factor for serious 
complications, including suicide, poor compliance with treatment, more inpatient 
stays, violence, and a poor overall prognosis (Smith and Hucker, 1994) 
This comorbidity is associated with poor prognosis and heavy use of expensive 
inpatient care through recurrent "revolving door" admissions (Haywood, 1995). One 
survey in UK observed that  inpatient admission rates among comorbid patients that 
were almost double those of patients with psychosis alone (Menzes, 1996) This high 
prevalence, the problems of clinical management and continued rises in the general 
rate of drug misuse make comorbidity a major public health issue (Lehman, 1995). 
Number of studies also found that cannabis abuse might be an important factor in 
aggression and offending among severely mentally ill individuals. (Scot et al., 1998; 
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Menezes et al., 1996; Drake et al, 1989,) particularly in terms of aggression and 
hostility.  
Cannabis is a one of the most common drug of abuse in many developing countries 
including, Pakistan.  The National Survey on Drug Abuse in 1993 revealed 3.01 
million suffering from chronic drug abuse in Pakistan, rising at a rate of nearly 7% 
annually. Among young people, cannabis is reported to be the most common drug 
used, followed by heroin and alcohol. Nearly 72% of the drug abusers were under 
35 years of age, with the highest proportion in the range of 26-30 (Narcotics Control 
Division, 1993).   
In a hospital based study, in patients admitted between 1996-2001, it was found that 
cannabis was the most frequently used drug of abuse (Dogar et al, 2005). 
Continuing to explore the epidemiological evidence for factors which could be 
amenable to preventive efforts, the author published research which helped to 
elucidate the effects of cannabis use on symptomatology, functioning and service 
use in patients suffering from schizophrenia in a developing country setting 
(Rahman and Farooq, 2007 a, b).  
Methodology (Please see full text publications as Annex A6 & A7) 
A case control design was used for studying the effects of cannabis abuse on the 
course, symptomatology and outcome of those suffering from Schizophrenia and 
cannabis dependence.  In these studies, patients meeting the International 
Classification of Disease (ICD)-10 Criteria for schizophrenia (W.H.O. 1993) and 
admitted to the Psychiatry Department Lady Reading Hospital Peshawar, Pakistan 
were included. Fifty patients with a diagnosis of Schizophrenia and self reported 
misuse of cannabis in the last year were selected as cases for study. Patients 
suffering from Schizophrenia without comorbid cannabis use (n=50) were selected 
as control group. Patients with co-morbid cannabis misuse were interviewed using 
section 12 of Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
(World Health Organisation 1994). Section 12 of SCAN measures the amount of 
illicit drugs used and social, legal, physical, and other problems related to these 
drugs 
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All the questions of interview were translated into Pushto which is the local 
language by a bilingual expert and retranslated by another expert who was blind to 
the first translation. All the patients were also administered PANSS (Positive and 
Negative Syndrome Scale) to assess severity of schizophrenic symptoms. Social 
functioning was assessed with the help of Global Assessment of Functioning (GAF) 
scale.   The effect of cannabis on service use was estimated by recording contacts 
with primary care staff, out-patient services, general hospitals, emergency 
departments, police services within the past year in both groups. Numbers of 
psychiatric admissions, days spent in hospital and compliance were also assessed. 
Compliance was assessed using a 4-point scale that was developed by 
Barrowclough et al (1999) which defined compliance as the extent to which a 
person's behavior coincides with the medical advice given. The definition of non-
compliance included premature termination of therapy and incomplete 
implementation of instructions. 
 
Main Results of the studies   (Please see full text publications as Annex A6 & 
A7) 
 
Following are the salient findings of these studies: 
 About two-thirds of patients (76%) in the cannabis group met the criteria for 
Cannabinoid dependence syndrome which meant that cannabis was not being 
used occasionally or only for recreational use. 
 The use of cannabis was associated with more florid positive psychotic 
symptoms   as measured by the PANSS. The patients using cannabis had 
higher scores on excitement (2.82 v 1.80 P<.005, CI 0.40- 1.63), grandiosity 
(1.74 v 1.12, p< .005, CI 0.21-1.03),  hostility(3.86 v 2.30, p>.005, CI 0.83- 
2.29),  poor impulse control (3.76 v 1.94 p<.005 CI 1.15 -2.49), 
uncooperativeness (3.86 v 1.90, p<.005, CI 1.34- 2.58), anger (4.06 v 2.26, 
p<.005, CI 1.11- 2.49) and difficulty in delaying gratification (3.64 v 1.64, p< 
.005, CI 1.37-2.63) (Table III: Appendix A6 : Comparison of PANSS cluster 
score between cases and control). 
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 Patients suffering from schizophrenia and co morbid cannabis use were 
younger on index admission than non user (25.82 years vs. 30.57 years, 
p=0.001 95% CI of mean difference -7.54 to -1.96).  
 The patients with co morbid cannabis abuse had more relapses as compared to 
those who were not using the substance (2.46 vs. 1.22 Mean difference 1.24 
p<0.011 and 95 % CI of difference 0.21 to 2.19).Overall compliance with 
medication was significantly poorer in patients using cannabis than patients 
who were not using cannabis (P<.085) (Table: 4; Appendix A 7: Comparison 
of drug adherence in last month between cases and control.). 
 Those using Cannabis were also more likely to be admitted to hospitals 
(number of admission 1.04 vs. 0.52 p<0.05; 95 % CI of difference .03- 1.04). 
They also spent more days in hospitals (19.7 vs. 7.22 p<0.047; 95 % CI of 
difference .18 - 23.58) and have greater number of contacts with police (1.70 
vs. 0.20 p<0.000; 95 % CI of difference .96- 2.04).  (Table 3; Appendix A7: 
Comparison of service use (Number of admission and days spent in hospital, 
visits to private clinics and contact with police). 
 The age at onset of illness was earlier in those with comorbid cannabis abuse 
(21.43 years vs. 25.39 years, p=0.005). The duration of illness at the time of 
admission was shorter for cases as compared to controls, probably reflecting 
presentation with more florid symptoms which necessitated earlier admission.  
 
Discussion and implications for the Early Intervention in Psychosis 
 
These publications support now the well established findings (Gupta et al 1996, 
Johns 2001) that those suffering from Schizophrenia and co morbid Cannabis abuse 
have poorer outcomes. Patients using cannabis were more likely to suffer from 
relapses, had significantly higher number of admissions to hospitals and stayed in 
the hospital for significantly longer period as compared to the controls. They also 
had poor compliance with treatment.  
It was found that cannabis was associated with excitement, hostility, 
uncooperativeness, anger, poor impulse, and difficulty in delaying gratification. The 
constellation of these symptoms in PANNS has been found to be associated with a 
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high risk profile requiring institutional care (Kay et al 1987). These findings are 
consistent with the W.H.O 10 country study on schizophrenia which found that the 
use of cannabis during the follow-up predicted more psychotic symptoms and 
periods of hospitalizations (Jablensky et al, 1992).  
These findings are very significant keeping in mind that cannabis users also had 
younger age at admission. Considering that Psychosis mainly affects young 
populations during the most productive years of their lives, it is crucial that early 
intervention programmes target the Cannabis abuse as one of the main targets. The 
cannabis abuse was also found to be associated with poor compliance. It was not 
possible to decide the direction of causation in this study but it was likely that 
cannabis abuse hindered the compliance with treatment regimen. These findings 
helped us to develop the educational interventions as will be explained later in the 
thesis. 
These studies suffer from the methodological limitations associated with 
retrospective research design with possibilities of significant confounding factors 
and recall bias in relatively small sample size.  However, the research highlighted 
the significant adverse effects which use of cannabis could have on the presentation, 
course and compliance with treatment which is now consistent with overall 
evidence from literature. Considering that each relapse in developing country 
settings adds further burden for the family, perpetuates stigma and the vicious cycle 
of poverty and social exclusion, it is crucial that these factors are addressed in a 
public health programme.  The programmes for the treatment and rehabilitation for 
those suffering from Schizophrenia will need to incorporate the interventions to 
prevent and reduce cannabis abuse. 
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4.4 Summary of the Publications 1995-2007 
In summary, my early scholarly work started with a study of Puerperal psychosis. 
This highlighted the fact that Puerperal psychosis is not a rare disorder due to very 
high fertility rates in most developing countries and long delays occur when 
mothers present with psychosis after childbirth despite the florid and serious nature 
of these disorders. In view of serious effects these disorders have on mother and 
baby, the early intervention in Puerperal psychosis must be a priority. This is 
feasible due to fact that this form of severe mental illness occurs following an 
identifiable life event (childbirth) and the risk factors can be screened in the 
antenatal period.  
The research on the homicide by mentally ill patients showed that only 24% of 
patients reported any contact with psychiatric services or professionals, despite the 
fact they had very long duration of illness and some of the patients were charged 
with double or multiple murders.  
Two further publications highlighted the adverse effects of cannabis use on course, 
functioning and service use in patients suffering from schizophrenia in a developing 
country setting, which could be amenable to preventive efforts in an early 
intervention programme.  
This work made me deeply aware of the devastating effects of untreated psychosis 
in resource poor settings. Interestingly, this was the time when the effects of the 
long periods of untreated psychosis before the first presentation to psychiatric 
services   were emerging in literature. This work naturally led to my next research 
focus, the Duration of Untreated Psychosis, it relationship with economic factors 
and the effects of long DUP on the outcome of psychosis. 
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Chapter 5 
The case for a Public Health action for early intervention – publications on Duration 
of Untreated Psychosis. 
 
 
 The public health consequences of long Duration of Untreated Psychosis (DUP) 
include increased co-morbid substance abuse, suicide, increased treatment 
resistance, impairment in cognitive and neuropsychological functions, offending 
behavior, vocational failure and overall poor outcome. 
 DUP is a potentially modifiable prognostic factor. 
 Employing the most comprehensive search strategy used to date for identifying 
studies both for developing and developed countries, the  Duration of Untreated 
Psychosis (DUP) was estimated. The relationship between DUP, Gross Domestic 
Product (purchasing power parity, GDPppp) and the outcome of psychosis was also 
investigated. 
 The systematic review and meta analysis examined  408 papers in full text  and 
finally included 136 papers which included an operational definition of DUP 
 The average mean DUP from LAMI countries was 134.2 weeks which was 
significantly longer than the average DUP reported from High Income countries i.e. 
of 65.5 weeks . 
 There was a strong negative correlation between DUP and GDP ppp, indicating that 
for every thousand dollars of additional GDP ppp, mean DUP was reduced by 8 
weeks and median DUP was reduced by 5 weeks. 
 Longer DUP was associated with at least one measure of a poor outcome.  Longer 
DUP was significantly associated with smaller reduction in symptoms after 
treatment, a greater level of disability and perhaps increased mortality. 
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Background 
My work over a decade, in daily clinical practice as well as in research publications, 
illustrated the devastating consequences of untreated psychosis in developing 
country setting. During this decade the literature revealed the effects of untreated 
psychosis in the initial years of  illness. The concept that there is a critical period in 
illness where effective interventions can prevent much of the disability later in the 
course of illness is now well established and manifested in Early Intervention 
Services in developed countries. I decided to investigate the evidence on Duration 
of Untreated Psychosis in LAMI countries.  
The onset of schizophrenia typically occurs
 
in late adolescence or early adulthood. 
Manifestations of the
 
disorder and
 
symptoms develop gradually over a period of 
weeks or even months. The disorder is preceded by less
 
specific prodromal 
symptoms. Because many of these prodromal phenomena extensively overlap
 
with 
the normal behaviors of persons in the
 
age group at risk, it is difficult to diagnose 
the disorder for long period of time before the help is sought.  The Duration of 
Untreated Psychosis (DUP) denotes the time from manifestation of the first 
psychotic symptom to onset of antipsychotic treatment.  Structured assessment of 
DUP can be done by different diagnostic tools developed for this purpose 
(Lieberman & Fenton, 2007). Studies, mostly from developed nations have revealed 
that individuals suffering the first episode of psychosis experience
 
an alarming delay 
between the onset of psychotic symptoms and
 
the initiation of treatment, typically 
durations of untreated
 
psychosis that averages 1–2 years   
The enormous public health consequences of long duration of untreated psychosis 
are now well documented (Lieberman & Fenton, 2007). These include increased co-
morbid substance abuse, suicide, increased treatment resistance, impairment in 
cognitive and neuropsychological functions, offending behavior, vocational failure 
and overall poor outcome.  
Long DUP in the first episode of psychosis (FEP) is associated with worse short and 
long-term prognosis (Marshal ert al, 2005; Perkins e et al, 2007), an increased risk 
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of suicidal behaviour (Altamura et al 2003; Melle et al. 2006) and possibly serious 
violence (Milton. Jet al,2001.; Verma, 2005; Large  2007). 
Given its relationship with outcome, DUP assumes significant public health 
importance as it is a potentially modifiable prognostic factor. It also has 
implications for understanding the pathophysiology of schizophrenia. Almost all the 
evidence about the delay in initiating the treatment has been limited to well 
established health systems in North America and Europe. The actual period of DUP 
and its effect on the prognosis of psychotic illness in low- and middle-income 
(LAMI) countries is not known. The long DUP may have more severe 
consequences in lower-income countries because people who are mentally ill may 
have limited food, shelter and medical care. In view of the provisions for the mental 
health care which have been highlighted in the first section of this thesis, the 
possibility was that the DUP was associated with economic factors. The treatment 
costs in many LAMI countries are born by patients or families by out of pocket 
expenses. In these circumstances disorder causing mortality and physical morbidity 
such as infections take priority over the psychiatric disorders in which the patients 
and families may suffer in silence over many years before seeking any treatment. 
My publications in this area addressed following questions: 
 What is the mean and median DUP for LAMI countries? (The median is 
more important for measurement of DUP as there is robust evidence in 
literature that mean DUP is skewed by few patients with very long DUP in 
many studies). 
 What is the relationship between DUP and the income as measured by GDP, 
ppp (Gross Domestic Product, purchasing power parity)?   
 What is relationship between mean and median DUP, diagnostic category, 
age and different categories of countries according to income level?  
 What is the relationship between DUP and the outcome of Psychosis? 
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5.1  Duration of Untreated Psychosis in developing countries: The relationship   
between GDP and DUP (For full text article see appendix: A. 8) 
 
This paper aimed to systematically review the studies reporting Duration of 
Untreated Psychosis in order to calculate an average value for DUP for both lower 
and higher income economies. The World Bank classification of Low-Income (LI), 
Lower-Middle-Income (LMI) and Upper-Middle-Income (UMI), referred to 
together as Low and Middle Income (LAMI) economies (also referred to as 
developing economies) was used for the purpose of this paper. The World Bank 
term of High-Income (HI) is used to refer to developed economies (World Bank 
2006). This study investigated the relationship between DUP and the estimates of 
Gross Domestic Product purchasing power parity (GDP ppp) published by the 
International Monetary Fund for 2005. (International Monetary Fund 2005); which 
is first of its kind 
The a-priori hypotheses for the study was that (i) the DUP of patients in LAMI 
economies would be longer than the DUP of HI economies and (ii) there would be a 
negative association between GDP ppp and DUP. The null hypothesis was that the 
mean DUP of studies of DUP from LAMI and HI regions would not differ 
significantly.  
Method 
Search Strategy (Please see diagram 1, Appendix A:11  Flow chart of searches 
for DUP studies from LAMI and High income regions) 
Because of the difficulty in finding data on mental health care in developing 
countries  four separate search strategies were employed.  Firstly, We searched the 
electronic data-bases [Medline], [Embase], [Psychlit] and [PsychINFO] from Jan 
1975 to Jan 2007 with the search terms  ‘duration of untreated psychosis’, ‘delay in 
treatment’, ‘treatment delay’ or ‘initiation of treatment’ cross referenced with the 
terms ‘psychosis’, ‘psychotic disorders’, ‘schizophrenia’, ‘schizoaffective’ or 
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‘schizophreniform’ and ‘first-episode psychosis’.  This yielded 280 publications 
about DUP or first episode psychosis from developed countries but only eight 
studies reporting DUP from developing countries.   
Second we used electronic searches of the text, including letters and conference 
proceedings of six leading Psychiatric journals with the terms 'Duration of 
Untreated Psychosis' OR 'DUP' ; Schizophrenia Research, Schizophrenia Bulletin, 
British Journal of Psychiatry Suplement, Acta Psychiatrica Scandinavica, Journal of 
Clinical Psychiatry, and International Clinical Psychopharmacology. These journals 
were chosen because they were identified as having previously published the 
conference abstracts from international schizophrenia conferences in a PubMed 
search of the title and abstracts using the terms ‘Schizophrenia’ and ‘Conference’ . 
This resulted in the location of two more studies.  
Third we located one further study by searching the first 40 Google hits using the 
names of 152 LAMI economies combined with “duration untreated psychosis”.  
Fourth we examined every abstract from a search of [PubMed] from Jan 1975 to Jan 
2007 using the term “schizophrenia” and the names of 152 LAMI economies. 
Publications on the topics of movement disorder in untreated patients, gender 
differences in the age of onset of schizophrenia and studies of epidemiology of 
schizophrenia in any developing country were examined in full text. Finally, we 
contacted the authors of 12 recent publications about aspects of schizophrenia in 
developing countries to see if they had unpublished DUP data and hand searched 
the references list of all articles for further studies that reported DUP, without 
finding additional studies.  
All the articles identified by [Medline], [Embase], [Psychlit] and [PsychINFO] 
searches and the full text searches of the 6 journals were examined in full text. 
Seven differences in the articles selected that were due to the selection of different 
papers from multiple publications of the DUP of the same subjects were resolved by 
a joint examination of the publications.  
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These searches were cross checked during the subsequent searches of PubMed and 
Google on two occasions three months apart.  One additional articles from a HI 
economy was found in the second set of searches.  
Inclusion and exclusion Criteria.  
We included studies with non-overlapping samples of the DUP or a close 
approximation of DUP. Hence articles that provided the age of onset of psychotic 
symptoms and the age of presentation to treatment, mental health services or 
researchers, to at least one decimal point were also included. We excluded samples 
that mixed subjects from different economies and samples with measures of DUP 
other than the mean or median or from which mean DUP could not be calculated. 
No additional quality assessment was made if the paper provided met the inclusion 
criteria. However, all but two studies used a recognised diagnostic system or a 
structured interview. A number of papers reported samples of male and female 
patients, samples with different diagnostic characteristics or samples collected at 
different times or locations. All such samples were included.  
Data Extraction  
The following data was extracted from all of the samples:  
1. Country of origin of the subjects 
2. Number of subjects in the sample 
3. The end point of DUP (initiation of treatment, contact with mental health 
services or contact with researchers) 
4. Mean age of contact or treatment 
5. Mean and/or Median DUP in weeks 
6. Whether the study included patients with affective psychosis. 
7. Percentage of subjects with a diagnosis of schizophrenia or 
schizophreniform psychosis 
8. Percentage of male subjects 
The data was independently extracted by two researchers. Three differences in the 
DUP data collection were in the HI sample and also three in the LAMI samples. 
These were unambiguously resolved by further examination.  
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Definition of DUP  
The most widely accepted definition of DUP is the period between the onset of 
definite psychotic symptoms such as hallucinations and delusional beliefs and 
adequate treatment (Norman, and Malla, 2001). However, because there were so 
few studies from the developing world, we accepted the broader definition of DUP 
in studies from developing countries which included contact with mental health 
services or researchers, as these patients, particularly those who did not have contact 
with services did not always get antipsychotic treatment.   
We also report on a subset of studies of patients with schizophrenia and other 
related psychosis all of whom had contact with mental health services and thus fit a 
narrower definition of DUP used in some studies of DUP from HI regions.   
Income data  
The LAMI country classification is based on national GDP in US dollars which may 
not reflect actual ability to purchase all the goods and services available in 
developing countries in local currency.  Therefore, in addition to using the LAMI 
groupings, the relationship between GDP ppp and DUP was examined, because it 
takes into account the cost of living in local currency terms.   
Statistical Methods  
The Mean DUP and Median DUP for the 38 samples from LAMI groups were 
compared with the 115 samples from HI countries.  Neither the Mean or Median 
DUP values were normally distributed within either the LAMI and HI groups of 
studies (LAMI, skew of mean 2.6, skew of median 2.4; HI, skew of mean 2.2, skew 
of median 2.6). This skew was a result of minority of samples from both LAMI and 
HI economies having a very long mean and median long DUP. Hence a Mann-
Whitney test was used to compare both the DUP of LAMI and HI groups.  
The number of male patients and the number of patients with schizophrenia in 
LAMI and HI regions were calculated from the percentage of cases in each study 
and a two-tailed chi-square was used to compare these variables. The age at 
presentation and age of onset  were compared using a students two tailed t-test. A 
bonferroni correction for four comparisons was used as age at presentation is not 
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independent of age of onset or DUP. Mean, and Mean and Median DUP were not 
considered to be independent observations. A p-value of 0.05/4=0.0125 was 
regarded as significant.  
Multiple linear regression was used to examine the possible associations between 
the dependant variable of DUP and LAMI status and the co-variables of age, 
gender, the proportion of schizophrenic patient and the year of publication of the 
study. For this analysis DUP was Log10 transformed resulting in normally 
distributed DUP values (skew=0.841). LAMI status was used as an omnibus 
categorical variable in this post-hoc comparison because DUP ppp in some of the 
wealthiest countries was observed to be long. This suggests that there may be a non-
linear relationship between DUP ppp and GDP ppp if all economies are examined. 
In this multivariate analysis the samples were given a weighting according to the 
number of subjects on the assumption that larger samples would have a more 
accurate estimation of mean DUP.  
A linear regression model was also used to examine the relationship between GDP 
ppp and DUP within LAMI regions after an apparently linear relationship between 
these two variables was observed in scattergram. In this analysis the DUP values 
were not Log10 transformed in order to quantify the relationship between GDP ppp 
and DUP. However four samples of patients who never received treatment and who 
on average had been psychotic for nine years or more were excluded.  
The statistical analysis was performed using SPSS, version 15.0. 
Results   
(Diagram 1, Appendix A: 8. Flow chart of searches for DUP studies from LAMI 
and High income regions) 
In total 408 papers in full text were examined and 136 papers were found which 
included a measure of DUP. Twenty eight papers were excluded as the samples 
overlapped with those of other publications. Ten studies were excluded for 
following reasons; two studies from developed countries that were performed in the 
1960s, four other studies of patients who became unwell prior to the advent of 
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antipsychotic medication, two studies that reported DUP in terms of fixed time 
intervals and two studies reporting single samples with subjects from regions of 
differing economic development.  
In all 98 studies met the inclusion criteria, of which 23 were from developing 
countries and 75 were from developed countries (Table DS1 and DS 2; Appendix A 
8). The earliest study from a developing country was published in 1995.  The 23 
studies from developing countries included 21 samples in which DUP was reported 
directly and 17 samples in which Mean DUP could be calculated. All but three 
studies were published in full text in peer-reviewed journals. Five authors were 
contacted for further details and two authors kindly provided more complete 
accounts of their research published in abstract form (El-Adl, et al, 2006; Ranjbar et 
al, 2006). Twenty three samples from LAMI countries specifically reported the 
mean DUP, rather than the interval between the onset of psychosis and contact with 
researchers) of patients with a schizophrenia related psychosis (excluding affective 
psychosis) and met a narrower definition of DUP. (The characteristics of studies 
from LAMI countries are highlighted in table 1) 
All the studies from HI countries were in full text in peer-reviewed journals and all 
but eight studies were published after 1990. The studies from developed countries 
included 115 samples, 109 of which reported DUP directly and in a further 6 
samples from which Mean DUP could be calculated.  
Mean and Median DUP (Appendix A 8:Table 1 Duration of untreated psychosis, 
diagnostic and demographic variables in the LAMI groups and Table DS3). 
Thirty seven of 38 samples from LAMI economies reported mean DUP and had an 
average mean DUP of 134.2 weeks. This was significantly longer than the average 
DUP reported in 107 of 115 samples from HI economies that reported mean DUP 
and had a mean DUP of 65.5 weeks (Table 2 ). The average value of Median DUP 
was also more than twice as long in the 16 samples from developing countries (45.9 
weeks) than the 74 samples from developed countries (18.5 weeks) although this 
apparently large difference did not reach statistical significance.  
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Mean age at presentation but not age of onset was higher in studies from LAMI 
regions than HI regions. Studies from LAMI regions had fewer male subjects and 
fewer people diagnosed with schizophrenia.  
Stepwise multiple linear regression that was weighted by the number of subjects in 
each sample found that the longer DUP found in LAMI groups was independent of 
the proportion of schizophrenic subjects, and the mean age of onset. The proportion 
of males in the samples or the year the research was published was not significantly 
associated with the Log10 of mean DUP. (Tables DS 3, DS 4 and DS 5; Appendix A 
8).  
Given that there were significant diagnostic differences between the groups, and as 
it is known that patients with affective psychosis have a shorter DUP, we also 
controlled for the effects of diagnosis by focusing on the studies that only reported 
schizophrenia related disorders.  In sub-sample of studies we excluded samples of 
patients who only had contact with researchers and may never have received 
treatment.  The Mean DUP of these 23 studies of DUP in schizophrenia related 
psychosis from LAMI economies that met a narrower definition of DUP was 90.5 
weeks (median 83, 95% CI of mean 52.0-118 weeks), was significantly longer that 
the mean DUP of 72.7 weeks (median 55, 95% CI of the mean 47.3-71.0) in the 79 
samples of patients with schizophrenia related psychosis from HI countries (Mann-
Whitney U=1187, two tailed P=0.026). This suggests that the findings of the study, 
that patients from a LAMI region have a longer DUP which is independent of the 
diagnosis and was not a result of including a cohort of untreated patients in the 
LAMI.  
Relationship between GDP ppp and Mean and Median DUP 
In a final analysis we examined the relationship between GDP ppp and Mean and 
Median DUP in LAMI economies. Overall there was a strong negative correlation 
between DUP and GDP ppp, indicating that for every thousand dollars of additional 
GDP ppp, Mean DUP was reduced by 8 weeks (table four) and Median DUP was 
reduced by 5 weeks (Table DS 5; Appendix A 11). An analysis of the mean DUP in 
23 samples that met narrower definitions of DUP (patients with schizophrenia 
related psychosis, all of whom were seen by mental health services) suggested that 
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DUP fell by 7 weeks for each additional one thousand dollars of GDP ppp 
(Appendix A 8: Table 1 Duration of untreated psychosis, diagnostic and 
demographic variables in the LAMI groups).  
Discussion 
Our principal hypothesis, that DUP would be longer in studies conducted in LAMI 
regions was confirmed. However, this finding may require qualification in future 
studies as we found that the small number of studies from UMI regions actually had 
a shorter DUP than those conducted in HI economies. We also found a linear 
relationship between GDP ppp and DUP suggesting that the observed relationship 
between LAMI economies and DUP may be causal.   
GDP has not been previously reported to be an association of long DUP, and the 
treatment delay in HI economies is usually attributed to lack of insight on the part of 
the patient, lack of understanding in families and the gradual onset of psychosis in 
some patients. The reasons for longer DUP in LAMI economies need further 
investigation, but are likely to include the lack of services in many areas as well as 
the relative cost of treatment.  
The cost of treatment is frequently reported as important factor in the lack of 
treatment in Low Income countries (El Adl et al, 2005;  Ran, et al,2003 ; Ran, et al 
2001; Selten  et al., 2005)
 
and Low Middle Income countries (Tang et al, 2007, 
McCreadie et al, 1994;  Grover et al, 2005). For example, in a region of Nigeria the 
only available antipsychotic for those suffering from psychosis was a low dose of 
chlorpromazine for a few weeks per year, provided by a charity (McCreadie et al, 
1994).  
Even if the patient’s family in this context is able to purchase further doses of 
antipsychotic medication, it may be at the expense of other forms of essential 
medical care or even food. In India the direct cost of treating schizophrenia is a 
quarter of the average family income in US dollars (Grover et al, 2005). Hence it is 
not surprising that mean DUP declined with even modest increases of mean GDP 
ppp.  
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This study has only highlighted the initial delay in seeking treatment. The overall 
treatment gap may be much greater as there are number of studies in developing 
countries which describe large number of patients who never receive any treatment 
(Ran, et al 2001; McCreadie et al, 2005;   McCreadie and Ohaeri, 1994). 
5.2  The relationship between the duration of untreated psychosis and outcome in 
low and middle income countries: Systematic review with meta analysis. 
Background: 
After establishing the long delay during the initial episode of Psychosis when 
patients do not receive any treatment, we decided to investigate the relationship 
between DUP and outcome of psychosis. Despite less developed health care 
services, endemic infectious disease, high rates of malnutrition and a shorter life 
expectancy, several large and well conducted studies have reported that that 
schizophrenia has a better prognosis in Low and Middle Income (LAMI) countries 
(World Health Organization, 1973 and 1979; Jablensky et al. 1992; Hopper et al, 
2007). However, a recent systematic review by Cohen et al found no evidence for 
better prognosis for psychotic illness and suggested that methodological issues may 
have contributed to the findings of a better prognosis of psychotic illness in some 
LAMI countries (Cohen et al 2008). 
Cohen et al (2008) suggested that the proportion of patients lost to follow up may 
have biased some studies in the direction of finding a better prognosis and they 
raised excess mortality as an indicator of a poorer prognosis. Mortality may have 
been given insufficient consideration in some outcome studies as high rates of 
mortality, mainly from untreated medical illness and malnutrition is regularly 
reported in studies of psychosis from LAMI countries (Cohen et al 2008, Dube et al, 
1984; Mojtabai et al, 2001, Ran, et al 2007;  Kurihara, 2006). Furthermore mortality 
has been found to be associated with lack of psychiatric treatment in two studies. A 
large prospective study from rural China found that a long duration of untreated 
psychosis (DUP) and the lack of continued treatment were associated with increased 
mortality as well as much worse prognosis (Ran et al 2007) while an earlier study 
from the Indonesian island of Bali found that a DUP of more than a year’s duration 
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was associated with a seven fold increase in mortality in the subsequent decade 
(Kurihara , 2006) 
The adverse effects of long DUP on prognosis have been established in high income 
(HI) countries by two systematic reviews (Marshall, 2005; Perkins, 2005 ). There 
have been relatively few studies examining the association between outcome and 
DUP in LAMI countries, and it is not known if long DUP is also associated with a 
poor prognosis outside of HI countries. A finding that longer DUP is not associated 
with worse prognosis in LAMI countries would support the hypothesis that patients 
with psychosis in LAMI regions do have a better prognosis. 
The aim of this systematic review is to examine the relationship between DUP and 
measures of outcome in psychotic illness in LAMI countries. 
Method 
Search Strategies (Fig. 1. Flow chart of searches for DUP studies from LAMI 
and HI regions; Appendix A 9) 
A wide search strategy was undertaken in an attempt to locate all the studies that 
were available (Fig 1). Firstly, we searched the electronic databases Medline, 
Embase, Psychlit and PsychINFO from January 1975 to March 2008 using the 
search terms  ‘duration of untreated psychosis’, ‘delay in treatment’, ‘treatment 
delay’ or ‘initiation of treatment’ cross referenced with the terms ‘psychosis’, 
‘psychotic disorders’, ‘schizophrenia’, ‘schizoaffective’ or ‘schizophreniform’ and 
‘first-episode psychosis’.  
This method yielded more than 300 publications about DUP from developed 
countries but only eight studies conducted in countries defined as low-income  (LI), 
lower-middle-income  (LMI) or upper-middle income  (UMI) using the International 
Monetary Fund’s LAMI classification (World Bank, 2007). 
A second search was carried out in Pubmed to identify psychiatric journals that had 
published the abstracts of international schizophrenia conferences. Based on this 
identification we electronically searched the text of six leading psychiatric journals. 
In full text searches of the websites of Schizophrenia Research, Schizophrenia 
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Bulletin, British Journal of Psychiatry Supplement, Acta Psychiatrica Scandinavica, 
Journal of Clinical Psychiatry and International Clinical Psychopharmacology, using 
the terms 'duration of untreated psychosis' or 'DUP', two further studies of DUP 
from LAMI countries were located. 
Third, the first 40 results were examined when combining the names of 152 LAMI 
countries with “duration untreated psychosis” using the search engine Google, 
which located one further DUP study from a LAMI country. 
Fourth, 12 studies from LAMI regions were found searching PubMed [from January 
1975 to January 2007] by sequentially entering the names of 152 LAMI countries 
and “schizophrenia” and examining all the abstracts. Publications on movement 
disorder, gender differences or the epidemiology of schizophrenia were examined in 
full text. 
Fifth, the references of DUP studies were hand searched and twelve authors of 
recent publications about aspects of First episode psychosis (FEP) in LAMI 
countries for unpublished DUP data were contacted.  No further studies were found 
by these methods. 
Finally, we examined all the abstracts in electronic databases that specialize in 
journals from developing economies that are not indexed on Medline. The terms 
“schizophrenia” and “psychosis” were used to examine [ExtraMed] for its duration, 
from 1992 to 2000 and [LILACS] was searched from 1982 to 2008. 
Using these methods a total 23 studies were located from LAMI countries that 
reported DUP or the interval between the onset of psychosis and the initiation of 
treatment or contact with services. Eleven of these studies met the inclusion criteria 
for this study as they also; (i) reported an association between DUP and at least one 
outcome measure, defined as level of symptoms, cognitive function, disability, 
quality of life or mortality from any cause (ii) used clinician-rated instruments and 
(iii) included subjects who met the criteria for the diagnosis of a psychotic disorder 
according to either the DSM or ICD classification systems. 
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There are no widely agreed-on quality criteria for studies of DUP as all studies of 
DUP are naturalistic and subjects cannot be randomized to long and short DUP. 
Thus no specific criteria were used to assess quality of the included studies in the 
review.  However quality was assessed using the following criteria proposed by 
Marshall et al, 2005 (table 2. Assessment of the studies' quality using Marshall et 
al.'s (2005) criteria. Appendix A: 9); restricting the population
 
to those with 
schizophrenia on the basis of standardized
 
diagnostic criteria, assessment of outcome
 
blind to DUP status, a
 
follow-up rate of at least 80%, and use of a standardized 
method
 
to determine DUP. The quality of studies as assessed by these criteria is 
reported in table 2. However, due to the small number of studies and the fact that 
none of the studies met all these criteria we did not apply such quality criteria to 
exclude any studies. 
Data Extraction and Analysis 
Using a pilot tested form, the country of origin of the subjects, gender, number of 
subjects, end point of DUP (initiation of treatment, contact with mental health 
services or contact with researchers), mean age at contact or initiation of treatment, 
details of outcome measures reported and percentage of subjects with a diagnosis of 
schizophrenia or schizophreniform psychosis were recorded. SF and a coauthor 
(ML) independently extracted the data and minor differences were unambiguously 
resolved. 
Meta analysis was used to pool the reported associations between DUP and (i) 
positive symptoms at presentation (ii) negative symptoms at presentation, (iii) 
reduction in total symptom scores after treatment and (iv) measures of disability.  
Comprehensive Meta-Analysis, version 2.2.046 was used for the Meta analysis 
using the same computational options as Revman (Borenstein, 2005). The studies 
employed different measures of outcome over varying periods of time. 
Heterogeneity was assessed with Q-value and I
2
 for each analysis although in case 
of small number of studies, between study variance cannot be estimated with 
precision (Cooper, 1994). A fixed model is reported for outcome measures other 
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than the degree of improvement in total symptoms score after treatment which 
exhibited significant heterogeneity and had included the largest number of studies. 
Results 
Characteristics of studies 
Eleven studies conducted in LAMI countries reported an association between DUP 
and at least one of the outcome measures (Ran, 2007. Kurihara,2006 and Table 1 
DUP, diagnostic and demographic variables in the LAMI groups.; Appendix A 9). 
The methods and the quality aspects of the studies are reported in tables 1 and 2 
(Appendix A: 9). All the studies were prospective in the sense that the DUP was 
measured at the time of presentation except one study that reported mortality may 
have been retrospective with respect to the outcome measure (Kurihara, 2006). Only 
one study had a small sample size of 50 or less (Galinska et al; 2005), and only one 
study had a dropout rate of more than 20% (Alptekin et al, 2005). All studies 
reported diagnoses using DSM or ICD diagnostic classifications, in six studies 
supported by a recognized diagnostic interview. All the studies used corroborative 
sources of information to assess DUP but none used a purpose designed structured 
interview and only one study included a measure of inter-rater agreement about 
DUP (Apiquián-Guitart et al, 2006). All together the studies reported on 1538 
subjects in total, of whom 88% met the criteria for a diagnosis of schizophrenia 
(Table 3; DUP, diagnostic and demographic variables in the LAMI groups. 
Appendix A9). 
The data was reported in a variety of formats including odds ratios (Lieberman, 
2003), relative risk (Kurihara, 2006), chi-square statistics for dichotomized groups 
(Apiquian, 2003; . Patel et al, 2001), means and standard deviations in long and 
short DUP groups (Oosthuizen et al, 2005; Galinska et al, 2005; Uçok et al, 
200627), or as a correlation coefficient (Alptekin  et al , 2005; Apiquián-Guitart et al 
2006; Apiquian, 2002; Ayres , 2007; Oosthuizen et al,2005; Ran, 2001). As 
correlation was the most frequently reported measure, meta analysis results are 
reported in this format. Of the five studies that reported comparisons of symptoms at 
baseline and after treatment only one study (Lieberman , 2003) used an ANCOVA 
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to take account of the possibility of the effects of regression to the mean (Vickers et 
al, 2001). 
Association between DUP and symptoms prior to treatment (Figure. 2. Meta 
analysis of the association between DUP and reduction in total symptoms.  
Appendix A9) 
Four studies reported that patients with a longer DUP had lower positive symptom 
scores at presentation (Apiquián-Guitart et al 2006; Galinska et al, 2005, Oosthuizen 
et al, 2005;. Uçok et al, 2006). A meta-analysis of these studies found a modest but 
significant negative correlation between DUP and the positive symptoms on 
presentation (fixed effects meta analysis; r = -0.152, 95% CI=-0.280 to -.02, z=-
2.248, p<0.025; heterogeneity Q-value 1.25, P =NS, I
2 
=0.00, figure 2.) indicating 
that patients with a long DUP may have had less severe symptoms such as 
hallucinations, delusions and thought disorder at the time of presentation. 
Three (Galinska et al, 2005; Oosthuizen et al, 2005; Uçok et al, 2006) studies 
provided data on the relationship between long DUP and negative symptoms. The 
extent of negative symptoms at presentation was not associated with longer DUP 
(fixed effects meta analysis; r = 0.057, 95% CI=-0.0101 to 0.211, z=0.705, p<0.048; 
heterogeneity Q-value 1.01, P = NS,  I
2 
=0.00)  (Fig. 3. Meta analysis of the 
association between  DUP and disability. Appendix A: 9) 
Association between reduction in total symptom scores and DUP after treatment 
(Fig. 4. Meta analysis of the association between DUP and positive symptoms at 
presentation.  Appendix A9). 
Five studies measured the reduction in symptoms after a period of treatment using 
change in the BPRS scores (Uçok et al, 2006; Lieberman et al, 2003)or change in 
total PANNS (Apiquián-Guitart et al,  2006; Oosthuizen et al,  2005; Thirthalli at al, 
2005). All five studies found that longer DUP was significantly associated with 
smaller reduction in symptoms after treatment but associations between DUP had 
statistically significant heterogeneity (Q-value 25.2, P =0.000, I
2 
=84.01). Hence a 
random effects model was used. In all five studies longer DUP was associated with a 
less complete response to treatment (random effects meta analysis; r = -0.290, 95% 
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CI=-0.483 to -0.069, z = -2.559, p<0.011, figure 4.). This analysis suggests that the 
detrimental effect of DUP in LAMI countries may be similar to that reported in 
developed countries. 
Association between DUP and disability after treatment (Figure. 5. Meta 
analysis of the association between DUP and negative symptoms at 
presentation. Appendix A9) 
A study from Turkey found that DUP was significantly associated with social 
disability as measured by the brief disability questionnaire (Alptekin et al, 2005) and 
a study from rural China reported that 35% of patients with a DUP of less than a 
year had a complete remission, in contrast to only 7% with a DUP of greater than a 
year (Ran et al , 2001). The results of these two large studies were similar to smaller 
studies from Mexico that reported patients with a DUP of less than 27 months were 
significantly more likely to make a good social and occupational recovery 
(Apiquián-Guitart et al, 2006), and southern India that found a trend towards an 
improved social and occupational outcome in patients with a shorter DUP (Tirupati 
et al, 2004) . When these somewhat diverse studies were pooled a highly significant 
association between longer DUP and a greater level of disability was found (fixed 
effects meta analysis; r = 0.195, 95% CI=0.126 to 0.262, z=5.498, p<0.000; 
heterogeneity Q-value 1.245, P = NS, I
2
 =0.00 figure 5). 
Cognitive functions: 
Studies from Brazil (Ayres et al, 2007) and Poland (Galinska et al 2005) examined 
the effects of DUP on cognitive function. Neither study found a significant 
association between DUP and cognitive abilities at the time of presentation. There 
was lack of sufficient data to undertake a Meta analysis. 
Mortality 
Kurihara et al (2006) reported on the mortality of 59 consecutive First Episode 
Psychosis patients from Bali (Indonesia) followed up to eleven years. They found 
that patients with DUP longer than one year had 6.7 times the mortality of those 
with DUP of less than 12 months. Ran et al (2007) also found that the mortality of 
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long DUP patients was significantly higher than those who received treatment, 
although long DUP also predicted a failure to receive adequate treatment of any kind 
after presentation. Only a small proportion of patients received ongoing treatment 
and no association between DUP and mortality was reported. 
Discussion 
In this review, nine of eleven studies reported that a longer DUP was associated with 
at least one measure of a poor outcome. Hence it appears that DUP has similar 
adverse effects in LAMI and high-income countries. Long DUP probably accounts 
for as many as a third of patients who do not achieve remission in HI countries 
(Marshall et al, 2005). The same may be true for patients with psychosis in LAMI 
countries. 
Only one study examined the relationship between DUP and mortality (Kurihara et 
al,. 2006), while a second found that the risk of death of patients who had received 
even minimal treatment was significantly lower than those who received no 
treatment (Ran et al, 2007). The reason for the high mortality in the studies from 
China and Bali was untreated medical illness. This suggests that the disability 
arising from untreated mental illness may negatively affect the patient’s ability to 
seek medical care and to provide themselves with adequate food and shelter. 
The only two studies of cognitive function and DUP had significant methodological 
limitations, the most obvious being that they examined cognitive function soon after 
presentation and not after a period of treatment. Thus, no firm conclusions can be 
drawn about the effect of DUP on cognitive function in LAMI countries, although 
the reported findings are consistent with the conclusions of systematic review of 
nine studies in high-income countries, which also found no relationship between 
measures of cognitive function and DUP (Perkins et al, 2005). 
The finding of lower positive symptoms scores in patients with longer DUP suggests 
that less severely unwell patients may wait longer for treatment than those with 
more obvious positive symptoms in LAMI countries. 
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A long DUP in high-income countries has been attributed to the gradual onset of the 
illness, the lack of understanding of the reason for the morbid change by the patient's 
family, the patient's own lack of insight and the effect of some mental health laws 
(Large et al., 2008c). In many LAMI countries the reasons for long DUP include the 
absence of mental health services and the cost of treatment (Large et al., 2008). DUP 
has now a well established association with poor outcome of psychosis but 
methodologically sound studies in LAMI countries are still sparse. There is urgent 
need to conduct methodologically sound studies particularly those, which try to 
establish the effect of treatment in relation to outcome and DUP in a LAMI country. 
Putative protective factors, including family support, that may sometimes be 
responsible for better course of schizophrenia should also be investigated as it 
appears that these factors, if any, have limited protective influence during the long 
period of untreated illness. 
Conclusions 
Lack of treatment for psychotic illness early in the course appears to be associated 
with relatively poor outcomes, irrespective of the income or cultural status of the 
setting. It is time that early intervention services for psychosis are planned for LAMI 
countries as they have been in HI countries. The findings of this review, and the 
related study (Large et al., 2008) support the recommendation to supply subsidized 
antipsychotic medication for at least the first two years of psychotic illness as a way 
of reducing DUP in developing countries (Patel et al., 2007). Providing very low or 
no cost psychiatric care in the same setting as other forms of primary health care has 
been effective in reducing DUP in Zambia (Mbewe et al., 2006) and may be a model 
that could be adopted elsewhere to reduce DUP. 
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SECTION:  3 
A PARADIGM FOR  EARLY INTERVENTION IN PSYCHOSIS IN LOW AND 
MIDDLE INCOME COUNTRIES 
Chapter:  6 
Publication on advocating a new paradigm for early intervention in psychosis in 
LAMI Countries 
 
 
1. Patients suffering from schizophrenia should be provided free supply of 
all essential medication at least during initial two years in the First 
Episode Psychosis, the critical period in the course of schizophrenia. 
This should be in a public health programme which ensures treatment is 
provided following a standardised treatment protocol under the close 
supervision of a family relative or health worker. 
2. Supervised Treatment in Outpatients for Schizophrenia (STOPS), which 
consists of a programme for ensuring free access to antipsychotic 
medication and training a close relative for regular supervision and 
administration of the treatment, could be used for this purpose. 
3.  The early intervention programme should include screening for 
puerperal psychosis in the antenatal period, which will be able to 
identify and prevent a significant proportion of potential cases of 
psychosis. 
4. The use of cannabis must be a major target for early intervention 
programme during the initial two years to prevent relapse and 
deterioration in symptoms and functioning. 
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6.1  Development of theoretical framework: An overview of my publications  
Before presenting the model, which I advocated in my publications for early 
intervention in psychosis, it would be helpful to present an overview of the major 
findings of the studies so far. These studies helped to address following important 
gaps in the knowledge: 
 The treatment for Psychotic disorders in developing countries is at best patchy and 
limited to acute episodes. This was associated with serious consequences, as was 
evident in studies of Puerperal psychosis and those involved in homicide with 
severe mental illness. 
 The Duration of Untreated Psychosis (DUP), quantified on the basis of 127 studies 
both in developed and developing countries, is almost twice long in developing 
countries compared to the developed countries. 
 Within the LAMI group of counties, an additional $1000 per capita GDP 
(purchasing power parity) was associated with a decline in mean DUP of six weeks. 
Hence, there seems to be a possibility of an association between endemic poverty, 
delayed treatment or lack of treatment, poor outcome after treatment and increased 
mortality from psychotic illness in LAMI countries. This established, for the first 
time, an economic case for early intervention. 
 Considering that DUP is the strongest predictor of the long term outcome of 
Schizophrenia, findings of these publications challenge the received wisdom in the 
literature that the disorder has better prognosis in developing countries.  
6.2  The theoretical framework for  Early Intervention in Psychosis 
 
I developed and presented an innovative model for Early Intervention (EIP) for 
Psychosis in a series of papers. This model is based on the research presented in the 
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previous pages, experience of providing psychiatric services over a decade in 
resource poor setting and interactions with other disciplines in Medicine who faced 
similar problems.  
The previous sections dealt mostly with publications based on empirical data. The 
present chapter will present the rationale, concept and the possible model for 
implementation of an early intervention in LAMI countries, as I elaborated this in a 
series of papers published since 2005. Unlike the previous sections these studies are 
not discussed separately for a better understanding of the concept, (The references to 
my publications are in italics to differentiate these from other references). 
I proposed that the model of early intervention for psychosis in these countries 
should be based on the following principles: 
 The large populations in many developing countries have much higher 
prevalence of chronic mental disorders (Patel et al, 2007). The age structure 
of LAMI countries (in Pakistan, for example 42% of population is below 45 
years of age) means that the number of those suffering from first episode 
psychosis will be much higher than those in the industrialized (Farooq et al, 
2008).  This is due to the fact that psychotic disorders predominantly affect 
the younger population (Shiers and Lester, 2004).  Therefore, Early 
Intervention in Psychosis (EIP) will be a cost effective public health 
intervention.   
 In absence of formal social care networks and almost total nonexistent 
rehabilitation services, it is even more important to intervene early. Much of 
the disability associated with Schizophrenia is accumulated in first two years 
in the course of illness, termed as “critical period” (Harrison et al, 2001). 
Interventions later in the course of illness may fail to achieve the functional 
and symptomatic recovery leading to the deficit state which has provided 
headlines for the present state of care for Schizophrenia in LAMI countries 
(Farooq, 2008).  
 The early intervention model in these countries would differ substantially 
from those developed in High Income countries. Such a programme of EIP 
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will need to modeled on a public health model with emphasis on continuity 
of care and reducing the health inequalities associated with access to and 
uptake of mental health treatments.  
 There may be a plausible set of causal links between endemic poverty, lack 
of treatment, poor outcome after treatment and increased mortality from 
psychotic illness in LAMI countries as was evidenced by our study of DUP 
and its relationship with GDP (Large et al, 2008). 
  In many developing countries public health programmes ensure free access 
to the treatment for infectious disorders causing high mortality, such as HIV 
and TB as well as for non communicable disorders. In Diabetes Mellitus, for 
example, at least 67 states around the world including many in developing 
countries are providing state subsidies for Insulin in order to improve the 
adherence and continuity of treatment. The direct effects of schizophrenia 
are comparable to those of many infectious and chronic physical illnesses 
(Farooq et al, 2008; Farooq, 2006). Hence such programme should provide 
all essential antipsychotic medication free of cost (Farooq, 2006; Farooq et 
al, 2008). 
 Such programmes should be incorporated with other physical disorders in 
view of the overwhelming evidence that in developing countries the 
predominant care should be provided in primary care and the fact that lack 
of care and continuity is common with other Non communicable Diseases, 
NCD (Patel et al, 2007). 
 Active case finding will not be feasible for a low incidence disorder like 
schizophrenia in LAMI countries as this would prove too laborious and 
expensive Therefore the programme should initially care for those 
presenting at health facilities with First Episode Psychosis. The access to 
free antipsychotic medication as a part of public health intervention in a well 
defined catchment area will lead to heightened awareness and early help 
seeking, thus identifying all the probable cases (Farooq, 2008).  
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 The EIP intervention should focus on maintaining adherence with treatment 
and continuity of care during the initial critical period of illness. About 59% 
of patients may fail to adhere to their treatment in case of schizophrenia 
(Wieden et al, 2004). The medication status is the strongest predictor of 
relapse; discontinuation of medication increases the relapse risk five folds 
(Robinson et al, 1999). Even a gap as small as 1-10 days in medication over 
one year period  has been found to be significantly associated with increased  
risk of hospitalization with an odds ratio of 1.98  (95% CI = 1.27-3.25) 
(Weiden and Olfson, 1995). Considering that non adherence may be 
responsible for approximately 40% of re-hospitalization cost and is also 
associated with significant increase in other types of service costs (Knap et 
al, 2004), providing access to medication and ensuring compliance with 
treatment may be most cost effective measure, especially early in the course 
of illness (Farooq,2008). 
6.3 Early Intervention for Psychosis in Developing Countries – Learning From 
Tuberculosis? 
I advocated that a public Health Programme based on principles of DOTS (Directly 
Observed Therapy, Short-course), which is a well recognised strategy to control 
Tuberculosis, is adopted for Early Intervention in Psychosis (EIP). Despite the 
differences in the nature of two illnesses the  core problems in management of both 
the disorders is the lack of adherence and continuity of the treatment which results in 
a spiraling costs associated with endemic poverty, a vicious cycle of chronicity and 
increasingly poor response to the well established treatments (Farooq et al, 2008; 
Patel et al 2007). An intervention based on principles of DOTS strategy will help to 
overcome these problems in management of Schizophrenia in the first episode. 
What is DOTS? 
DOTS stands for "Directly Observed Therapy, Short-course" and is the cornerstone 
in World Health Organization (WHO) strategy for global TB eradication 
programme. The DOTS strategy focuses on five main points of action. These 
include government commitment to control TB, diagnosis based on sputum-smear 
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microscopy tests done on patients who actively report TB symptoms, direct 
observation short-course chemotherapy treatments, a definite supply of drugs, and 
standardized reporting and recording of cases and treatment outcomes. (For full 
details please see WHO, 1999). In DOTS programme once a patient with infectious 
T.B is identified, a named supervisor watches and records patient swallowing the 
correct dosage of anti T.B treatment for six to eight months. Various forms of 
supervision and educational interventions for the relatives are described. In many 
developing countries the role of DOTS supervisor is assigned to a family or a 
community member who regularly administers the drugs under close monitoring by 
a health worker. There is a clear line of accountability between the T.B control staff 
and person administering DOTS
 
(WHO, 1999). 
The remarkable improvement in tuberculosis control in many developing countries 
is attributed to this strategy (Squire and Tang, 2004). In China, for example, a 
survey of 375599 individuals selected from 31 mainland provinces showed a 
reduction of 48% in smear positive  cases in the areas in which DOTS was 
implemented compared to only 16% in the districts without the programme
4
 China 
Tuberculosis Control Collaboration, 2004. The World Bank considers DOTS to be 
one of the most cost effective health interventions. DOTS is more cost effective than 
self-administered treatment
 
(Moore RD, 1996
,
 Floyed K, 1997) 
From DOTS to STOPS 
Our team based in Peshawar incorporated these principles of DOTS in an approach 
termed as STOPS. Supervised Treatment in Outpatients for Schizophrenia (STOPS) 
was developed after focus group discussions with staff involved in implementation 
of DOTS programme in tuberculosis. Similar focus groups were held with patients 
suffering from schizophrenia and their families (Farooq, et al 2008; Patel et al, 
2007). The focus group discussions with patients and their relatives revealed that the 
primary concerns of the family and patients related to perception of the illness, the 
treatment and its stigma. The relatives also used number of coercive methods in 
treatment, including violence in dealing with these patients. The pattern of care was 
episodic. Therefore, we incorporated these concerns in the educational package, in 
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addition to administering and supervising medication, which are usual components 
of a traditional DOTS programme.  
Supervised Treatment in Outpatients for Schizophrenia (STOPS) consists of the 
following essential components. 
A. Free access to antipsychotic medication during the First Episode Psychosis. The 
patient is provided free medication as part of the programme one month at a 
time.  
B. A close relative termed as Key Care Supervisor (KCS) is trained in regular 
supervision and administration of the treatment. The KCS is a family member 
living with the patients for at least six months and nominated by the patient. The 
educational package developed as a result of focus group discussions and 
experience in pilot programme, as mentioned above, focuses on the following 
two areas.  
a) The nature of illness, the possible causes and consequences of untreated 
illness. The local explanatory models for the illness are incorporated in the 
training. The use of traditional healers is not discouraged. The relatives are 
encouraged to discuss this with the treating psychiatrist during follow up 
visits and not to discontinue the treatment. The family member is asked to 
contact the treatment centre when the traditional healer advice them to 
discontinue the treatment. 
b) Training in administration and supervision of treatment. Detailed 
education is provided on the type of medications used, how to administer 
these each day and the method of recording the correct dose. Steps involved 
in collecting the tablets from the treatment centre, storage at home, 
administering the tablets and the actual ingestion by the patient and how to 
confirm this are demonstrated. The relatives are provided a treatment card in 
which they are asked to put a tick in each box for patient taking the dose of 
medication. Different coloured cards and symbols are utilized for recording 
  62 
 
this, as the majority of the population is not educated. These cards are 
checked at the next delivery of medication. The emphasis is on how to 
supervise medication without antagonizing or using any coercive methods. 
In case of depot injections, education about the possibility of acute EPS and 
how to seek help for these is also given.  
C. A standardized system of recording cases and their progress in treatment using 
simple measures which could be used in routine clinical care.  
A strategy for communicable illness for a non communicable disorder? 
The major challenge we faced in adopting a strategy devised essentially for an 
infections disorder like TB for a non communicable disease like Schizophrenia, 
is the time course of the illness. Unlike tuberculosis, treatment for schizophrenia 
may be needed for the lifetime of the patient and “cure” would not be achieved 
in the strictest sense. Neither health systems in most low income countries nor 
care givers can be expected to provide a lifelong commitment required for a 
STOPS programme Farooq, (2008). 
To overcome these problems, I suggested that those suffering from 
schizophrenia in the developing world should be treated in a public health 
programme utilizing STOPS model for at least initial two years during the 
course of illness (Farooq, 2008; Patel, 2006). The rationale for the two years 
period is based on the following crucial pieces of evidence. 
The ‘Critical Period’. Initial two years in the course of Schizophrenia have 
been described as a ‘critical period’. The treatment status during this period is 
the strongest predictor of long term outcome and disability (Harisson et al, 
2001). 
Interventions for Non adherence: The evidence from systematic review of 
interventions to address non adherence in Schizophrenia suggest that clinical 
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interventions targeting non adherence should continue for at least 18 months 
(Zygmunt et al, 2002). 
6.4 A Paradigm for Early Intervention in Developing Countries 
Based on the principles and evidence presented above a paradigm for early intervention in 
developing countries could be summarized as below.  
1. All patients presenting with a psychotic disorder in developing countries must be 
supplied all essential medication to treat the illness free of cost as part of a 
public health programme for at least initial two years, the critical period in the 
course of illness. This programme will not aim at active case detection.  
2. A standardized system of recording cases and their progress in treatment using 
simple measures is used to supervise treatment during this period. Supervised 
Treatment in Outpatients for Schizophrenia (STOPS,) is an intervention which 
our team developed to train a close relative for regular supervision and 
administration of the treatment, can provide such mechanism for providing 
supervised treatment during this critical period. 
3. The early intervention programme should include screening for puerperal 
psychosis in the antenatal period, which will be able to identify and prevent a 
significant proportion of potential cases of psychosis. This will also help to 
integrate the early intervention programmes with other public health 
programmes such as mother and child health.  
4. The use of cannabis must be a major target for early intervention programme 
during the initial two years to prevent relapse and deterioration in symptoms and 
functioning.  
My publications (Farooq, 2008; Patel, 2007) stressed that the following three 
tasks need urgent action to implement early intervention programme in 
developing countries: 
a) A global fund to generate the resources for providing free access to 
antipsychotic drugs should to be created. 
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b) Simple, brief and cost effective strategies for enhancing medication 
adherence which can be used by the caregivers in the developing countries 
need to be developed.  
c) Small scale programmes based on the DOTS model should be developed 
locally in developing countries before we can expect the governments to 
support the same. Insulin Demonstration Projects which have been initiated 
to improve the access to the Insulin by the IDF Task Force can provide good 
models for this (International Diabetes Federation, 2004b). 
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Chapter:  7 
 
The proof of the concept  – a randomized controlled trial of STOPS. 
Considering that Schizophrenia has incidence of about 15 per 100000 populations in 
a year, the recruitment of a sample with adequate power to test the effectiveness of 
STOPS in the First Episode Psychosis would require many years. Therefore, we 
decided to evaluate the approach in patients with previous history of Psychosis 
presenting to the Lady Reading Hospital, Peshawar. The trial was registered at 
ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT00392249) and initiated in 
2006..  
This Randomized Controlled Trial aimed at testing the effectiveness of Supervised 
Treatment in Outpatients for Schizophrenia (STOPS). The primary outcome was to 
compare the effectiveness of STOPS in improving the adherence with a regimen
 
of 
standard doses of antipsychotic medication in patients suffering from Schizophrenia 
and Schizoaffective disorders compared to Treatment As Usual (TAU). The study 
design was a two-arm prospective randomized controlled trial over one year period, 
with masking of assessors to the status of the intervention.           
Methods 
The study protocol was approved by the Research Ethics Committee of the Post 
Graduate Medical Institute, Lady Reading Hospital Peshawar, Pakistan. After a 
complete description
 
of the study to each subject and the caregivers, written 
informed consent was obtained. As significant proportion of the patient population 
was illiterate, special care was taken to explain the procedures in Pushto, the 
language spoken by this population. No monetary incentives were provided to the 
participants in the trial. 
 
 
  66 
 
 
Study settings and participants  
The study was conducted at Psychiatry Department of Lady Reading Hospital 
Peshawar. This is one of the two major tertiary care mental health centers which 
serve a large population in North West Frontier Pakistan and adjoining Afghanistan. 
For the purpose of this study we recruited patients only from the district Peshawar 
which has population of about two millions. The inclusion criteria were (1) Age - 17 
to 60 years (2) Diagnosis of schizophrenia
 
or schizoaffective disorder based on the 
ICD-10 criteria and (3) Residence in Peshawar district. The exclusion criteria were 
evidence of organic disorder, mental retardation and severe drug dependence 
requiring
 
inpatient treatment and/or detoxification. We started recruitment to the 
study in November 2006 and the final follow up of the participants was carried out 
in January 2009. 
Based on the literature an average rate of adherence to the medication over one year 
period for those suffering from Schizophrenia was  50 %
.
 (Babiker et al, 1986,  
Weiden et al, 1995).  We expected the rate of medication adherence to be 75% in the 
intervention group.  Thus a sample size of 45 patients per group would have 80% 
power to detect a 25% difference in the rate of adherence to medication between the 
two study groups with a one-sided significance of 5%. To control for non-
compliance and losses to follow-up 55 patients were recruited in each group. 
Randomisation 
Patients who met inclusion criteria and no exclusion criteria
 
were randomly assigned 
to each treatment group using a randomization scheme on 1:1 basis.  The 
randomization was done using computer generated numbers. The random allocation 
of the patients for each group was enclosed in series of opaque envelopes which 
were sealed and numbered sequentially. These allocations were placed away from 
the site of assessment. After assessment and satisfying the inclusion criteria, the 
independent staff in the administration office was asked to open the sealed envelope 
and reveal the treatment arm for each patient. 
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Diagram :1 
The CONSORT  Flowchart.  RCT STOPS vs TAU 
 
       
 
 
 
 
 
 
 
 
 
 
Procedures  
 
 
 
 
 
 
 
Assessed for eligibility 
(n= 147 ) 
Excluded  (n= 37   ) 
 
Not meeting inclusion criteria 
(n= 26   ) 
Refused to participate 
(n= 11   ) 
   
Analyzed (n= 49) 
 
Lost to follow-up (n = 6) 
Drop out = 1
One patient died, killed in 
family dispute 
Discontinued intervention = 4 
     
Allocated to STOPS   (n= 55) 
Received allocated intervention 
 (n= 55) 
Lost to follow-up (n= 9) 
Discontinued intervention = 7 
One Withdrew consent = 1 
Left area = 1 
 
 
 
? 
    (n=     ) 
    Give reasons 
Allocated to TAU    (n= 55) 
Received allocated intervention 
   (n= 55) 
Analyzed (n= 46) 
Allocation 
Analysis 
Enrollment 
Follow-Up 
  68 
 
 
Eligible patients were identified from the outpatients presenting at Psychiatry 
department of the LRH. They were first screened by the trained psychiatrists 
working in the outpatients and subsequently assessed by one of three consultant 
psychiatrists (SF, ZN, JA) to satisfy the ICD-10 criteria for the diagnosis of 
Schizophrenia and Schizoaffective disorders
15
 (World Health Organization, 1992).  
After identifying eligible patients through interview and reviews of previous notes 
therapists were asked to approve their recruitment
 
into the study.  
Intervention and control groups 
The salient features of the two interventions are highlighted in table 1. Psychiatrists 
for
 
the Treatment As Usual (TAU), the Control Group were told to provide 
treatments as they would normally practice in routine outpatient settings. This 
included prescribing evidence based pharmacological treatments, outpatient 
attendance in the Psychiatry department as deemed appropriate by the consultant 
and brief counseling about the treatment and outcome of the disorder. Patients who 
could not afford to buy the medication, had the option to seek the free drug 
treatment from the Social Welfare department of the hospital, which  provided 
treatment for the patients from Zakat Fund (a fund established to provide the 
essential medicine for poor patients from a charity funding based on Muslim Law).   
The patients in Supervised Treatment in Out Patients for Schizophrenia (STOPS) 
received the usual care. In addition, a Key Care Supervisor (KCS) who was a close 
relative in most cases was trained in regular supervision and administration of the 
treatment. Key Care Supervisor was defined as any family member living with the 
patient for at least six months and providing support for the treatment as identified 
by the patient. Specific education was provided to the key care supervisor about the 
nature of the illness, misconceptions about the treatment, relationship between the 
supernatural and biological causes of illness and importance of continuing the 
medication and basic skills in how to administer and supervise medication. The 
medications required were provided one month at a time.  
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The intervention was first implemented in a pilot project over one and half years
 
(Farooq et al, 2008, 2005). Therefore trainers and assessors were adequately trained 
and experienced in providing the intervention. 
The doses in each group were titrated according to the clinical needs
 
of the patient. 
All patients received atypical antipsychotics with the exception of those who were 
already on typical antipsychotics and have been stable on these. Treatment teams for 
both STOP and TAU patients consisted
 
of two consultant psychiatrists, three 
postgraduate trainees with minimum of two years training in Psychiatry, two 
qualified psychiatric nurses and a master's level social worker (Table.1). 
Measurements 
The baseline assessment included a clinical interview to satisfy the ICD-10 criteria 
for the diagnosis of Schizophrenia and Schizoaffective disorders, demographic data 
and illness history, Global Assessment of Functioning (GAF) ratings
 
(American 
Psychiatric Association, 2000), and Positive and Negative Syndrome Scale for 
Schizophrenia (PANSS)) (Kay et al, 1987).  The follow up assessments at 3 months, 
6 months and at the end of one year included; Global Assessment of Functioning 
Scale rating, Positive and Negative Syndrome Scale and medication adherence using 
a scale devised for this purpose.  
Adherence with treatment regimen was measured at interview by using a 
questionnaire
 
with a 5-point scale (1 = always and 5 = never) adopted from Herz et 
al (2000).  The scale has been used in the pilot project by the research workers who 
achieved high degree of reliability in ratings (Patel et al, 2007;
 
Farooq et al, 2008).  
The assessments for the adherence to treatment were done quarterly from the 
baseline with the help of information provided by patients and relatives. The 
information was supplemented by the tablet counts from previous prescriptions 
where available. Complete adherence with medication was defined as patient always 
taking medication as prescribed without any break during the assessment period.  
The non adherence was defined as missing drugs completely for more than a week at 
a time. If the patient took some medication but not on everyday of the week this was 
defined as partial adherence. 
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All assessments were carried out by doctors with at least two years training in 
Psychiatry. The same team of psychiatrists carried out all the follow up assessments. 
The follow up assessments were done by the researchers who were blind as
 
to the 
patient group assignment and were instructed not to inquire about a patient's 
treatment during
 
interviews. To ensure this, the administration of STOPS was kept 
completely separate from the research team assessing the compliance and 
administering the questionnaires for the trial and they were not associated with 
clinical care of the patients in the trial. The patients and relatives were briefed not to 
discuss their treatment with the assessors. All the patients
 
remained in the study 
whether or not they were compliant with treatment, needed hospitalization or 
relapsed. Attempts
 
to maintain contact were made by telephone and/or home visits
 
if 
patients did not appear for clinic visits at follow up assessments.
 
                                                                                                                                                                                                                                                                                                       
Statistical analyses  
Data was analyzed in accordance with the CONSORT guidelines wherein the 
between group comparisons were done by using intention to treat analysis. SPSS 
version 16 was used for the analysis. Descriptive statistics were obtained on patient 
baseline characteristics and the primary outcome measure as a categorical variable. 
Chi-squared tests for difference in proportions were used to compare the distribution 
of baseline variables and compliance scores between the two study groups (95% 
CI’s and p-values). The number of patients in partial adherence group were small in 
follow up assessments. Therefore we combined the partial and non adherence 
together for the purpose of this analysis. This is also in line with the measurement of 
compliance, as described originally by Herz et al (2000).   
Parametric variables were then assessed for simple group differences with t-test. A 
Repeated Measure ANCOVA was used to measure the differences between the two 
groups at four time points. Baseline scores were used as Covariates to take into 
account the initial differences. Kolmogrove-Smirnov test was used to assess 
normality. The number of patients needed to be treated with STOPS to prevent one 
adverse outcome such as one patient not adhering to treatment in one year was 
calculated.  
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Results 
The details of recruitment and follow up are shown in diagram 1.  
Fifty five patients were recruited in each arm. Ninety five (86.36%) patients 
completed the study; 49 in STOPS and 46 TAU group. The mean age of patients in 
STOPS group was 29 (SD= 8.1) which did not differ significantly from the TAU 
group (mean 30 SD = 8.5 P< .699). The baseline sociodemographic and clinical 
variables were not significantly different in two groups (Table 2).  Similarly the 
relationship with the primary care giver as defined by the patients did not differ 
significantly between the two groups. Both groups had long duration of illness (73.6 
months. SD=59 in STOPS Vs 83.8 months in TAU; SD=91 P< .485).  No 
statistically significant difference was found between two groups in PANNS and 
GAF ratings at baseline.  
We compared the two groups at four time points to see if the dosage of antipsychotic 
drugs were different in two groups at any stage. The doses of all antipsychotics were 
converted into the equivalents doses of Chlorpromazine (British National 
Formulary, 2009).  There were no statically significant difference between the two 
groups (P=0.136) in the dosages of antipsychotic received. The number of patients 
on depot medication was also not different between two groups. 
The medication adherence, symptoms and functioning outcomes (table 3 & 4, fig 
1& 2) 
Two groups showed statistically significant difference in the primary outcome 
measure at 3 months (P<.05) and at the end of one year (P<.02), but not at six 
months follow up (P<.23).  
In Intention To Treat analysis at one year follow up  37 (67.3%) patients in STOPS 
group had complete adherence with medication compared to 25 (45.5%) in the TAU 
group (P<.02). The odds for the STOPS group to adhere to medication is 2.46 
(confidence interval = 1.1376 - 3485). The Number Needed to Treat to achieve one 
positive outcome is 5. 
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The patients in STOPS group showed more improvement in symptoms and 
functioning as measured by PANSS and GAF respectively in Intention To Treat 
Analysis. The total score on PANSS (P <0.003), positive symptoms subscale ratings 
(P<0.011) and the General psychopathology subscales (P<0.007) were all lower in 
patients in STOPS group compared to the TAU group. However, for PANSS 
Negative symptoms subscale the difference between the two groups was not 
statically significant (P<0.149). The patients in STOPS group also had better 
functioning as compared to TAU group and the scores on GAF scale was 
significantly better in the STOPS group (P<0.008). 
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Table 1. Comparison of the Supervised Treatment in Outpatients for 
Schizophrenia (STOPS) versus Treatment As usual (TAU) 
 STOPS  TAU 
Setting Community Community 
Therapist’s Contact with 
patient/family 
Patients and an indentified 
family member ( Key Care 
Supervisor ) 
Patient, family 
optional.(any family 
member) 
Access to medication Supplied free by the 
programme 
Had the option of availing 
free drugs  provided by 
social service, may be out 
of pocket, 
Supervision for 
medication 
Medicine administered 
under supervision of KCS 
None. 
Patient and family 
education 
One session at the start to 
educate  KCS to 
administer and supervise 
the drugs  
No specific session, some 
education may be 
provided by therapist 
Frequency Once a month to collect 
the dugs 
Variable  as deemed 
necessary by therapist  
Service provided by Psychiatrist, Social 
worker, 
Psychiatric Nurses 
Psychiatrist, Social 
worker, 
Psychiatric Nurses 
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Table  2.  The differences between STOPS and TAU groups  at the baseline. All 
figures are number (%).     
 STOPS TAU P
1
 
Gender  
Male  
Female  
 
47(85.5%) 
8(14.5%) 
 
47(85.5%) 
8(14.5%) 
 
1.000 
Marital status 
Married 
Unmarried 
  
 Divorced 
(widow/widower) 
 
 
30(54.5%) 
22(40.0%) 
 
3(5.4%) 
 
 
31(56.4%) 
21(38.2%) 
 
3(5.4%) 
 
 
 
0.999 
Employment status 
Unemployed  
Employed-   
Retired  
 Student 
 
 
40(72.7%) 
8(14.6%) 
1(1.8%) 
6(10.9%) 
 
 
41(74.5%) 
12 (21.9) 
0(0%) 
2(3.6%) 
 
 
 
 
0.480 
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Education  
No education  
5 to 9 years 
   
 10 years or more          
  
 
23(41.9%) 
18(32.7%) 
           
              14(25.4) 
 
 
21(38.1%) 
14(25.5%) 
     
20(29.3%) 
 
 
0.520 
 
Relationship with 
caregivers 
 Mother  
Father  
Children  
Spouse    
Brother  
Sister  
Other  
 
 
6(10.9%) 
11(20.2%) 
1(1.8%) 
2(3.6%) 
19(34.5%) 
3(5.5%) 
13(23.6%) 
 
 
4(7.3%) 
16(29.1%) 
4(7.3%) 
5(9.1%) 
16(29.1%) 
4(7.3%) 
6(10.9%) 
 
 
 
 
0.286 
Course  
Continuous 
Episodic  
 
41(74.5) 
14(24.5) 
 
35(63.6) 
20(36.4) 
 
0.216 
 
Cannabis use 
Current  
Past  
 
6(10.9%) 
4(7.3%) 
 
10(18.2%) 
2(3.6%) 
 
 
0.425 
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Never  
 
 
 
45(81.8%) 43(78.2%) 
Diagnoses  
Schizophrenia   
Schizoaffective disorder 
 
45(81.8) 
10(18.2%) 
 
45(81.8) 
10(18.2%) 
 
1.000 
 
1. P values using a X
2
 test. 
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Table 3: Differences in medication adherence between the STOPS and TAU groups  at 
three time points. All figures are number (%).    
Compliance STOPS TAU  P* 
3 Months 
Complete   
 Partial or none  
6 months 
Complete 
Partial or none   
12 months 
Complete 
Partial or none  
 
38(69.1) 
17(30.1%) 
 
40(72.7%) 
15(27.3%) 
 
37(67.3%) 
18(32.7%) 
 
 
28(50.9) 
27(49.1) 
 
34(61.8) 
21(38.2) 
 
25(45.5) 
30(54.5) 
 
0.05 
 
 
0.23 
 
 
0.02 
 
 
 P values using X
2
 test 
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Table 4.  The comparison of STOPS and TAU groups for measures of psychopathology. 
All values are Mean (SD) Number. Higher scores represent more psychopathology on 
PANSS, but not on GAF where reverse is the case. Analyses were carried out using 
Repeated Measure ANCOVA (to compare within subject and between the subject 
differences), with baseline values used as Covariates.  
 STOPS 
Mean (SD) 
Number 
TAU  
Mean (SD) 
Number 
P Values for 
between subject 
differences 
PANSS total scores 
Baseline  
Time 1 
Time 2 
Time 3 
 
101.80(21.0)55 
70.87(23.18)55 
67.38(23.9)55 
67.35(24.66)55 
 
94.6(19.4)55 
77.11(21.29)55 
76.96(20.8)55 
74.33(21.58)55 
 
 
0.003 
Positive symptoms 
Baseline  
Time 1 
Time 2 
Time 3 
 
21.6(6.7)53 
12.6(7.2)53 
12.4(7.0)53 
13.6(6.9)53 
 
21.5(6.3)53 
16.6(6.5)53 
16.6(6.7)53 
15.3(5.5)53 
 
 
0.003 
Negative symptoms 
Baseline  
Time 1 
Time 2 
Time 3 
 
21.3(6.1)53 
17.4(6.0)53 
16.3(6.1)53 
16.2(6.8)53 
 
19.4(6.3)53 
17.1(7.6)53 
17.2(7.2)53 
17.1(7.6)53 
 
 
0.149 
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General symptoms 
Baseline  
Time 1 
Time 2 
Time 3 
 
47.9(10.6)53 
33.7(10.0)53 
31.4(10.9)53 
30.3(10.3)53 
 
44.4(8.9)53 
36.6(10.5)53 
35.2(10.2)53 
33.8(8.8)53 
 
 
0.007 
GAF Scores 
Baseline  
Time 1 
Time 2 
Time 3 
 
42.56(13.54)53 
55.18(14.5)53 
58.71(15.81)53 
62.0(16.70)53 
 
45.95(11.92)53 
52.13(15.8)53 
52.67(16.08)53 
56.05(18.12)53 
 
 
0.008 
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Discussion 
To best of our knowledge this is the first study which has attempted to test the 
effectiveness of a model based on principles of DOTS in a non infectious disease. 
Results showed that Supervised Treatment in Outpatients for Schizophrenia 
(STOPS) which used an educational intervention for relatives to administer and 
supervise the medication and understand the nature of illness and treatment resulted 
in significant improvement in adherence with medication, the primary outcome 
measure. The Number Needed to Treat (NNT= 5) shows that intervention used in 
this trial could be highly effective in improving the adherence with the treatment in a 
developing country setting.   
The timeline of the improvement as depicted in Fig 1&2 shows an interesting time 
effect. The improvement in symptoms and functioning preceded the improvement in 
drug adherence between two groups. This probably shows the strong effect of 
psychoeducational intervention involving the family as the family interventions and 
management of illness has been shown to reduce symptoms and improve 
functioning (Mari et al, 2009). 
The trial was not designed nor did it have enough statistical power to assess the 
effects of treatment on other outcome measures. However, the improvement in total 
PANNS, positive symptoms subscale and GAF scores reflected the improvement in 
the compliance. Interestingly, the score on negative subscale of PANNS did not 
differ significantly between the two groups.  
This may be due to fact that negative symptoms are difficult to treat, as both groups 
had a mean duration of illness of more than five years  and a deficit state may 
already have developed. The improvements in the functioning as manifested by 
highly significant difference (P<.008) between the two groups is encouraging 
showing that maintaining regular treatment and engaging the family can have 
significant impact even in a population with chronic mental illness.  
The information on the effectiveness of strategies for extending care to people with 
severe mental illness is LAMI countries is scarcely available  (Jacob et al, 2001).  
The essential ingredients of the strategy used in this study i.e. monitoring the drug 
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compliance by observing and recording the correct medication by a guardian 
assigned to the patient  has been shown to be effective in a retrospective case control 
study in Rural China (Qui et al, 1994).
 
 Broadly similar approaches have been shown 
to be cost effective and significantly reduced the disability, psychotic symptoms and 
caregiver’s burden in India (Murthy et al, 200; Chatterjee et al, 2003). However, 
these studies employed family or social interventions typically comprising at least 
one session of 1-2 hours every two or four weeks over study period which are more 
akin to assertive outreach programmes employed in developed country settings 
(Chatterjee et al, 2003).  These approaches may be difficult to apply in routine 
clinical practice in LAMI countries. The STOPS approach, in contrast, used a brief 
intervention focusing on family and patient education without directly addressing 
family dynamics or expressed emotion.  The better adherence to the treatment in this 
cohort is consistent with the evidence from systematic review of interventions to 
improve medication adherence in schizophrenia which showed that relatively brief 
interventions (both in terms of duration and frequency) which targeted the behaviors 
related to medication adherence were more effective than longer interventions with 
broader focus on psycho education
 
(Weiden et al, 1995). 
It can be argued that provision of free drugs could have contributed to the better 
outcome for STOPS group. DOTS is a complex intervention and free access to 
medication is an essential component of DOTS programme as applied in TB control 
(World Health Organisation, 2007).   
The patients in TAU group had the option of availing free drugs from the social 
welfare department. Providing free medication as part of the trial would have 
grossly distorted the Treatment As Usual in these settings. Moreover the recent 
evidence suggests that even if drugs were free, non-adherence persists. One recent 
study showed that even among patients who have health plans with no cost sharing 
for medication, rates of non-adherence were nearly 40%. (Doshi et al, 2009).     
Possible limitations in evaluating the results of this study
 
should be recognized. We 
selected standard outpatient care for comparison as in these settings outpatient care 
is most often the only type of mental health care available. It could be argued that 
enhanced care associated with regular assessment of compliance and follow up visits 
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in RCT was not the typical ‘treatment as usual’. It is possible that patients in TAU 
received more support for their treatment from the social services department of the 
hospital, being a focus of attention in a research study. It is also well known that the 
measures which rely on subjective reports of pill taking to measure adherence in 
Schizophrenia tend to overestimates adherence and reduces the likelihood of 
detecting intervention effects
 
(Weiden et al, 1995, Fenton et al, 1997).  These 
limitations should however minimize the difference between two groups. Blindness 
of research interviewers
 
to treatment group could not be completely assured since 
the
 
study was not placebo controlled, with the possibility that
 
research interviewers 
favored STOPS group. The contamination of treatments was also a possibility, i.e., 
the
 
treatment team providing TAU would act more like the team providing the 
experimental intervention over time.  
Implications for service provision and research – A public health approach for 
Early Intervention in Schizophrenia in LAMIC? 
The interventions for providing care for Schizophrenia in LAMI countries should 
primarily target the families as more than 90% of people with schizophrenia live 
with their families in these countries who manage most aspects of patients' lives 
(Mari et al, 2009).   
This study provides preliminary evidence that a package of care based on an 
educational intervention for the families, and supervision and easy access to 
medication as envisaged in DOTS strategy based on a simple treatment regimen can 
be used to scale up the services for Schizophrenia in LAMI countries.  
Improvement in treatment adherence in this cohort is more significant considering 
that impairment in behavioural and cognitive domains resulting from chronic 
Schizophrenia directly affect compliance with treatment regimen. It should be noted 
that we used a minimal exclusion
 
criteria, including patients with
 
substance abuse to 
reflect the population of individuals
 
with schizophrenia being treated in the 
community. This shows that an approach based on DOTS can also be used for 
providing care for other Non Communicable Disorders. The details of how the 
DOTS can be implemented for the Non Communicable Disorders have been 
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described (Patel et al, 2007).  Adopting DOTS model for providing care for NCD 
will also help to bring the infectious and non communicable disorders together in 
public health systems, a major challenge in many developing countries.  
A simple, standardised system of diagnosis and treatment based on passive case 
findings and a brief educational intervention as used in this study could feasibly be 
rolled out in a public health system. The active case finding will be too laborious 
and expensive for a low prevalence disorder like Schizophrenia. The improved 
access to treatment as a public health intervention will also lead to better awareness 
and early help seeking for the cases which at present represent the large untreated 
prevalence. This may help to reduce very long Duration of Untreated Psychosis 
(DUP) in LAMI countries. The present study sample consisted of patients with 
relatively chronic course of illness as recruiting a first episode sample would have 
taken much longer period and was not feasible within the resources. The approach 
suggested in this trial now needs to be evaluated in First Episode Psychosis as 
effective intervention during this period is likely to achieve maximum long term 
gains in the entire course of illness. The cost effectiveness of the approach also 
needs to be tested in future studies.  
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Chapter 8 
 
Integration and knowledge translation: development and evaluation of a 
complex intervention  
 
In this chapter, I will explain how my work and publications resulted in producing 
coherent body of knowledge which is one of the requirements of the thesis. This will 
also present a summary of the publications. 
The systematic identification of evidence and its integration which resulted in the 
development of coherent body of knowledge in my work and publications can best 
be understood by a framework described by Campbell et al (2000). This frame work 
describes the development and evaluation of complex intervention, and is illustrated 
in diagram 1. This frame work describes five stages in the development and 
evaluation of a complex intervention as following: 
 
Step 1: Preclinical: Exploring relevant theory  
Phase I:  Modeling   
Phase II:  Pilot Study and Explanatory stage  
Phase III:  Definitive Randomised Controlled Trial  
Phase IV:  Long term implementation 
 
  86 
 
 
Campbell, M. et al. BMJ 2000;321:694-696 
Using this frame work which is illustrated in above diagram, my research and 
publications described in previous pages, can be summarized as following: 
Step 1: Preclinical: Exploring relevant theory (Section 2; Chapter 4) 
This stage involves exploring the relevant theory to ensure best choice of 
intervention. The hypothesis is identified, major confounders are predicted and 
strategic design issues are explored. As defined by Campbell et al (2000), the 
existing evidence and any theoretical basis for the intervention are explored in order 
to describe the components of the intervention, during this stage. My work on 
puerperal psychosis, homicide by patients suffering from Schizophrenia, and the 
impact of cannabis use on symptomatology and course of schizophrenia identified a 
number of components in the care of schizophrenia in developing countries which 
could be amenable to a public health intervention. These highlighted gaps in the 
knowledge and practice which could be incorporated in such an intervention.  
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Phase 1: Modeling (Chapters 5 & 6) 
During this phase, the components of intervention and underlying mechanisms by 
which these will influence the outcome are identified. Directly Observed Therapy 
(DOTS), as practiced in tuberculosis provided a model for Schizophrenia which 
could be used for ensuring compliance and continuity of care. We had extensive 
liaison with professionals involved in implementation of DOTS in Tuberculosis and 
assessed the acceptability and feasibility of modeling an intervention which could 
also used for a Non Communicable Disorder, like Schizophrenia. The knowledge 
translation at this stage helped to design the pilot study.   
Phase 2: Pilot Study and Explanatory stage (Chapter 6)   
This phase consists of constant and variable components of a replicable intervention. 
During this phase a feasible protocol for comparing intervention with an appropriate 
alternative is also developed (Campbell et al, 2000. The pilot project (Farooq, 2008) 
helped us to evaluate various components of intervention in an uncontrolled study. 
This feasibility of the definitive trial was also tested in this phase. The work on  
determining the length of DUP in developing countries, its relationship with GDP 
and outcome of Schizophrenia (Farooq et al, 2009; Large et al, 2008) helped us to 
identify the barriers in providing early and effective treatment for First Episode 
Psychosis which could be  addressed in incorporated in the intervention  as well in 
the definitive trial. This also established economic case for such an intervention. The 
gains which could be achieved by providing treatment during the critical period of 
illness helped us to formulate the intervention in a time limited period, as is the case 
in an infectious disorder of Tuberculosis.  
Phase 3: Definitive Randomised Controlled Trial (Chapter 7) 
During this phase, fully developed intervention is compared with an appropriate 
alternative using a protocol that is theoretically defensible, reproducible and 
adequately controlled in a study with adequate statistical power. After developing 
intervention, I developed a protocol to compare STOPS against Treatment As usual 
(TAU).  
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The protocol of the trial was registered with the Clinical Trials.Gov, the FDA and 
NIH registry for RCTs. The trial was statistically powered to show difference 
against the TAU for adherence with treatment over one year follow up period, the 
primary outcome of the study. The final trial was implemented in a typical 
developing country setting, as the intervention is primarily aimed for the populations 
in Low and Middle Income countries. 
Phase IV: Long term implementation  
This phase consists of determining whether others can reliably reproduce the 
intervention and results of the RCT in an uncontrolled setting over the long term. 
The results of the RCT which showed statically significant difference for the 
primary outcome measure and other clinical variables have produced convincing 
evidence for this phase. I have presented the results of the trial evaluating STOPS in 
the number of scientific forums and the paper describing this study has been 
accepted by British Journal of Psychiatry for publication. I am advocating the 
implementation of the intervention at community level and actively pursuing the 
intervention as a feasible form of early intervention in a developing country setting.  
At the same time, I am planning for an Early Intervention Service based on this 
model  in three districts in Pakistan. This will provide valuable data as well as 
provide access to medication and services during critical stage of illness. 
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INTRODUCTION
Cannabis is a major drug of abuse in Pakistan. The National
Survey on Drug Abuse in 1993 revealed 3.01 million chronic
drug abusers in Pakistan, rising at a rate of nearly 7%
annually. Among young people, cannabis is reported to be the
most common drug used, followed by heroin and alcohol.
Nearly 72% of the drug abusers are under 35 years of age,
(the most economically productive age group), with the
highest proportion in the range of 26-30 age. 1 In a hospital-
based study, conducted at DHQ Hospital, Faisalabad, in
patients admitted between 1996-2001, it was found that
cannabis was the most frequently used drug of abuse.2
The comorbidity of schizophrenia has attracted considerable
attention in recent years.3-4 It has been shown that the risk of
meeting criteria for substance misused disorder was 4.6 times
higher in those suffering from schizophrenia than in general
population. Schizophrenia was associated with six-fold
increase of developing drug misuse disorder and cannabis
was the most commonly misused drug.5 There are a number
of hypotheses about the relationship between cannabis use
and schizophrenia. One hypothesis is that heavy cannabis use
causes schizophrenia.6 Another hypothesis is that cannabis
use can precipitate the illness in predisposed people and thus
can exacerbate the symptoms in those who have developed
the illness.7-8 Some believe that persons with schizophrenia
are 
more likely to become regular or problematic cannabis user
than a person without it.9
Although cannabis abuse is highly prevalent in Pakistan, the
relationship between cannabis and psychiatric disorders has
rarely been investigated. There has been little research on the
subject. Haroon et al. found in their study that  patients who
consumed  ‘Bhang ’ (a beverage containing cannabis)
ingestion exhibited grandiosity, excitement, hostility,
uncooperative-ness, disorientation, hallucinatory behavior and
unusual thought content.10
The aim of the present study was to determine the relationship
between cannabis abuse and its impact on the short-term
outcome and severity of illness in terms of score on the
Positive And Negative Syndrome Scale (PANSS).
PATIENTS AND METHODS
The study was conducted at Psychiatry Department, Post-
graduate Medical Institute, Lady Reading Hospital, Peshawar
from January to December 2004. All the patients aged
between 15-60 years who qualified the International
Classification of Disease (ICD)-10 research diagnostic criteria
for schizophrenia (W.H.O. 1993) were included in the study in
a case control design.
Fifty schizophrenic patients who self reportedly used cannabis
in the last year were selected as cases and another 50
schizophrenic patients without cannabis use were selected as
control group. The patients using other psychoactive drugs
along with cannabis were excluded from the study.
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Informed consent was obtained from the patients after
explaining the nature and purpose of study in Pushto .  For the
patients who were unable to give informed consent, the same
was obtained from a close relative.
Socio-demographic details and information about the age at
onset, duration of illness (period from the appearance or
detection of psychiatric symptoms to the index admission) was
collected from the patients and their informants who have been
involved with the patients during their illness.
The information about the amount of cannabis used in the last
month was obtained from the patients in terms of frequency
and number of cigarettes used on a 1-6 scale.
All the patients were interviewed and administered PANSS
(Positive and Negative Syndrome Scale) to assess severity of
schizophrenic symptoms. There are 30 items included in the
PANSS, 7 constituting positive scale, 7 forming  negative scale
and the remaining 16 were part of general psychopathology
scale. Each item was rated on 7 points representing increasing
level of psychopathology. The composite score was achieved
by subtracting score on the negative from the positive scale.
Patients with positive composite scale valence (i.e., > 0) were
classified as “positive subtypes.” And those with a negative
valence (i.e., < 0) were classified as “negative subtypes.”
Three supplemental items were used to assess aggression
risk. The cluster score (anergia, paranoid belligerence and
supplemental) was the sum of the score on the individual item
that represented a set of specific psychopathology. Three
supplemental items (anger, difficulty in delaying gratification
and affective lability) were used to assess aggression risk. 
Patients with co-morbid cannabis misuse were interviewed
using section 12 of Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) (World Health Organization 1994).
All the questions of interview were translated into Pushto by a
bilingual expert and retranslated by another expert who was
blind to the first translation.  
Their respective score were entered in a computer base
version of SCAN and results were obtained by running
algorithm to identify patients as having problem use in the past
year.
The data was collected and analysed with the help of statistical
programme SPSS, version 10. Chi-square test for categorical
data and independent t-tests for continuous variable were
used to assess the degree of correlation between different
variables. The statistical significance was calculated at p•
0.05. 
RESULTS 
There was no statistically significant difference between cases
and controls in terms of marital status, socioeconomic status,
living arrangements and employment. However, there was
significant difference in the educational status, age on index
admission and age at onset of illness between the user and
non-user. 
There were only 9 cannabis users who continued their
education beyond primary-middle level against 16 non-users
(Table I).
The schizophrenic patients with comorbid cannabis use were
younger on index admission than non user (25.82 years v
30.57 years, p=0.001 95% CI of mean difference -7.54 to -
1.96). The age at onset of illness was earlier in cases than
controls (21.43 years v 25.39 years, p=0.005) (Table II).
Symptoms were measured and compared using both the
individual scale and cluster scores including positive, negative
and composite scores.
The patients who had cannabis abuse exhibited more positive
symptoms as they scored more on positive score and
composite score. They also scored higher on paranoid and
supplemental score while the non-users scored more on
negative score (Table III).
The patients using cannabis also scored high on different
individual items of PANSS. The patients using cannabis had
higher scores on  excitement (2.82 v 1.80  P<.005, CI  0.40-
1.63), grandiosity(1.74 v 1.12, p< .005, CI 0.21-1.03),
hostility(3.86 v 2.30, p>.005, CI 0.83- 2.29), poor impulse
control(3.76 v 1.94 p<.005 CI 1.15 -2.49),
uncooperativeness(3.86 v 1.90, p<.005, CI 1.34- 2.58), anger
(4.06 v 2.26, p<.005, CI 1.11- 2.49) and difficulty in delaying
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Table I : Comparison of educational status between cases and control.
Level of education Case Control Total
Uneducated 15 15 30
Primary to middle 26 19 45
Secondary to graduation 09 16 25
Total 50 50 100
Pearson chi square Value17.260; p-value.004.
Table II: Comparison of age of patients on index admission and age at onset of illness between cases and control.
Case Control Mean difference P-value 95% CI of mean difference
Mean (sd) Mean (sd)
Age of patient on index admission  (years) 25.82 (5.06) 30.57 (8 .55) -4.75 0.001 -7.54 -1.96
Age of patient at onset of illness (years) 21.43 (4.62) 25.39 (8.47) -3.96 0.005 -6.66 -1.25
sd: Standard deviation;  CI: confidence interval;  Numbers in parenthesis are standard deviations.
Table III: Comparison of PANSS cluster score between  cases and control.
Case Control t P-value Mean 95% CI of the 
Mean (sd) Mean (sd) difference difference
PANSS positive score 18.66 (6.91) 15.24 (6.31) 2.583 .011 3.42 0.79 6.05
PANSS negative score 15.26 (7.02) 22.52 (9.02) -4.490 .000 -7.26 -10.47 -4.05
Composite score 3.80 (12.19) -7.28 (13.29) 4.344 .000 11.08 6.02 16.14
Anergia 8.10 (3.90) 12.64 (4.90) -5.126 .000 -4.54 -6.30 -2.78
Paranoid 10.32 (4.31) 7.24 (3.85) 3.769 .000 3.08 1.46 4.70
Supplemental 18.70 (7.62) 11.68 (5.36) 5.328 .000 7.02 4.41 9.63
sd: Standard deviation  CI: confidence interval; Numbers in parenthesis are standard deviations.
gratification(3.64 v 1.64, p< .005, CI 1.37-2.63). Non users
scored more on blunted affect (3.58 v 2.18, p< .005, CI -.2.06
to -0.74), passive/apathetic withdrawal (3.82 v 2.50, p<.005, CI
-2.02 to -0.62), lack of spontaneity and flow of conversation
(3.56 v 2.12, p< .005, CI -2.12 to -0.74), motor retardation
(3.54 v 2.12, p<.005, CI -2.09 to -0.75), and preoccupation
(3.40 v 2.32, p< .005, CI -1.66 to -0.42).
Out of 50 patients who were using cannabis, 10 (20%) met
ICD-10 criteria of ‘Harmful use of Cannabinoid’, 38 (76%) met
ICD-10 criteria of ‘Cannabinoid dependence syndrome’ and 2
patients did not meet the criteria.
The mean age on index admission was 28.20 years
(SD=7.39). However, the patients who were having
Cannabinoid dependence syndrome were younger (25.08
years SD=5.09), as compared to those who had harmful use
of Cannabinoid (28.70 years SD=4.64, Mean difference 3.62
years. T-value=2.037, p=.047, 95% CI of difference=2.7-7.20).
DISCUSSION 
According to ICD-10, the key features of dependence
syndrome are a strong desire to take substance, progressive
neglect of alternate source of satisfaction, the development of
tolerance and a physical withdrawal state. While harmful use
is defined as a pattern of psychoactive substance use that is
causing damage to health; the damage may be to physical or
mental health.
Younger age on index admission and at onset of illness were
important finding of this study. These findings are in line with
those of Veen11 and Cantwell.12 Different explanations are
possible for these findings.  It may be a confounding factor as
drug dependence is primarily a young age phenomenon.  The
possible mechanism which can explain this association is that
cannabis use had no influence on age at onset and younger
patient were more likely to use this substance before the first
psychotic episode because the use was age related. The
second possibility is that cannabis abuse precipitated the
onset of schizophrenia at an early age in people who were
vulnerable or predisposed to develop the illness. 
It was found that cannabis was associated with excitement,
hostility, uncooperativeness, anger, poor impulse, and difficulty
in delaying gratification. It showed that those who abused
cannabis were more likely to present with acute onset of florid
symptoms characterized by paranoid ideation, irritability and
uncontrolled behavior, a finding supported by W.H.O 10
country study on schizophrenia. There it was found that the
use of cannabis during the follow-up predicted more psychotic
symptoms and periods of hospitalizations.8 However, it was
difficult to delineate the effect of multiple drugs use as there
were overlaps between cannabis and cocaine. The present
study excluded the use of other drug along with cannabis. 
Scot et al.13 also concluded that cannabis abuse might be an
important factor in aggression and offending among severely
mentally ill individuals. These findings also support those of
Menezes et al.14 and reinforce the finding of Drake15
particularly in terms of aggression and hostility. However,
Zisook et al.16 and Cantwell12 reported less adverse
consequences suggesting less adverse impact of cannabis on
symptoms.  This may also explain another finding of this study.
In the present study, it was found that cannabis abuse is
associated with younger age at onset of illness and younger
age on admission, compared to the control group.  It appears
that cannabis abuse not only precipitated the onset of illness
at younger age in vulnerable adults but also resulted in
admission at an earlier age due to florid symptoms. These
findings are also supported by those of Veen11 and Cantwell.12
High score on individual symptoms of excitement, hostility,
poor impulse control, uncooperativeness, anger and difficulty
in delaying gratification pointed toward a specific pattern of
clinical presentation. PANSS suggests that a patient with peak
rating on these individual symptoms may be regarded as one
with high danger profile who (if rating is at least 4) probably
requires institutional care and (if rating are least 6) perhaps
would need direct individual supervision.17 In this study, the
profile was accompanied by high rating on cluster score of
paranoid belligerence. The risk of aggression was punctuated
by paranoid projection. High score on supplemental cluster
score also depicted the high aggression of patients with
comorbid substance abuse.  It was also found that the
cannabis use aggravated the severity of positive symptoms
(hallucinatory behavior, excitement, grandiosity and hostility)
and symptoms of general psychopathology ((poor impulse
control, uncooperativeness) and supplemental items (anger
and difficulty in delaying gratification) related to uncontrolled
violent and impulsive behavior. This is in agreement with
Caspari who found similar results in a case control study.
They showed that cannabis users scored more on
psychopathological syndromes “thought disturbance” and
“hostility”.18
The finding that two-thirds of patients (76%) met the criteria for
Cannabinoid dependence syndrome means that cannabis is
not used occasionally or only for recreational use. This
combined with the finding that the users had significantly
earlier age of onset than the non-users, is in line with the
finding in the literature.11,12 that cannabis plays an important
role in the precipitating schizophrenia at an earlier age. The
finding has an important implication for the treatment of
schizophrenia. Patients suffering from schizophrenia with
comorbid cannabis use may pose high risk of violence and
agitation. Intervention aimed at preventing cannabis use in
these patients may also be helpful in preventing aggression
and promote therapeutic relationship in schizophrenic
patients. The association between cannabis and violence in
this study   does not amount to a causal relationship, given the
possible effect of intervening confounding variable such as
age, gender, personality and social factors.  There is urgent
need to conduct studies with larger sample size while
controlling for age and social factors.
CONCLUSION
The evidence is more consistent with the hypotheses that
cannabis use may precipitate psychosis among vulnerable
individuals at a younger age and schizophrenic patients with
co-morbid cannabis use exhibited more positive symptoms,
violent behavior, and may be more likely to lead to
dependence in persons with schizophrenia.
The explanation for this association remains unclear. Since
early onset is associated with a poorer prognosis of the
disorder, the relationship between cannabis use and the risk of
developing an early onset type of schizophrenia is an
important focus for future research.
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Schizophrenia and Comorbid self reported Cannabis Abuse: impact on course,
functioning and services use
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Abstract
Objective: To examine the impact of cannabis abuse on the short term outcome in terms of relapses, use of
services, compliance and functioning in patients with schizophrenia.
Methods: A case control study was conducted in the Department of Psychiatry PGMI Lady Reading Hospital,
Peshawar from January 2004 to October 2004.  Fifty schizophrenic patients with co-morbid misuse of cannabis
were selected. Fifty schizophrenic patients who were not using cannabis were selected as control group for the
study. Data regarding socio-demographic detail, relapse, compliance to drugs and service utilization was collect-
ed with the help of a Performa. Problem cannabis use in the past year and social assessment of functioning were
assessed with the help of Schedule for Clinical assessment in Neuropsychiatry (SCAN) and Global Assessment
of Functioning (GAF) scale  respectively. 
Results: Schizophrenic patients with cannabis use were younger on admission and had younger age at onset
of illness. They had more number of relapses and more contacts with psychiatric services including the police.
Patients with comorbid cannabis use had poor drug compliance and their relapses were preceded by poor drug
compliance Cases and control did not differ significantly on score of Global assessment of functioning.
Conclusion: Comorbidity of cannabis seems to have adverse effects on almost all domains of the illness includ-
ing course, service use and drug compliance (JPMA 57:60;2007).
Introduction
Problems of substance abuse produce dramatic costs
to all societies in terms of productivity, family and social
disorder, and of course excessive utilization of health care.
The comorbidity of mental illness and substance
abuse has been the focus of attention in recent years. Many
studies have shown that the rate of substance use in sub-
jects with severe mental illness is high; estimates of recent
or current abuse for community samples range from 20% to
40%.1 These rates are higher than those for the general pop-
ulation2, and patients with comorbid mental illness and
substance abuse disorders have been a cause for concern
because even low levels of substance abuse or dependence
represent a risk factor for serious complications, including
suicide, poor compliance with treatment, more inpatient
stays, violence, and a poor overall prognosis.3
Evidence from the United States suggests that half of
all patients with schizophrenia also have a substance misuse
disorder.2 This comorbidity is associated with poor progno-
sis and heavy use of expensive inpatient care through recur-
rent "revolving door" admissions.4 The phenomenon has
also been recognised in the United Kingdom. One survey
observed inpatient admission rates among comorbid
patients that were almost double those of patients with psy-
chosis alone.5 This high prevalence, the problems of clinical
management,6 and continued rises in the general rate of
drug misuse make comorbidity a major public health issue.
Extensive manual and electronic literature search didn't
reveal research pertaining to the subject however studies
have shown that after bhang (a beverage containing
cannabis) ingestion, patients have exhibited grandiosity,
excitement, hostility, uncooperativeness, disorientation, hal-
lucinatory behavior and unusual thought content which
understandably leads to more use of mental health services.7
The present study is aimed to examine the relation-
ship between cannabis abuse and its impact on the short
term outcome in terms of relapses, use of services, compli-
ance and functioning in patients from schizophrenia. We
also assessed the amount, frequency and duration of
cannabis use in schizophrenic patients.
Methods
This case control study was conducted at department
of psychiatry PGMI Lady Reading Hospital, Peshawar from
January 2004 to October 2004. All patients aged between
15-60 years with a diagnosis of schizophrenia (after discus-
sion with a senior investigator) based on the ICD-10
research diagnostic criteria (W.H.O. 1993) and meeting the
following inclusion and exclusion criteria were approached
for informed consent:
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Inclusion criteria
1. Patients who self reportedly used cannabis in the last
year. 
2. Patients aged between 15-60 years. 
Exclusion criteria
1. Patients using other psychoactive drugs along with
cannabis.
2. Patients who were grossly uncooperative for a
meaningful complete intake interview (e.g., mentally
subnormal, in acute intoxication or withdrawal, mute, 
with severe formal thought disorder preventing 
meaningful communication)
Fifty schizophrenic patients with self reported co-
morbid misuse of cannabis in the last year were selected as
cases for study. Fifty schizophrenic patients who reportedly
were not using cannabis were selected as control group.
Information about the following variables was obtained by
interview with the patients and their relatives, using a struc-
tured Performa: Socioeconomic details, age at onset, dura-
tion of illness and duration of untreated psychosis (defined
as the period between the onset of psychotic symptoms and
initiation of treatment). Relapse was defined as contact with
psychiatrist over a one year period with clear evidence for
decline in functioning from the previous level after
improvement in treatment of index episode or exacerbation
in psychotic symptoms requiring change or increase in the
treatment. The number of relapses and their precipitants was
recorded over the last two years.
Service use was estimated by recording contacts
with primary care staff, out-patient services, general hospi-
tals, emergency departments, police services within the past
year. Numbers of psychiatric admissions and days spent in
hospital over the preceding 2 years were also recorded.
Compliance was defined as the extent to which a
person's behavior coincides with the medical advice given.
The definition of non-compliance included premature ter-
mination of therapy and incomplete implementation of
instructions. The patients were asked to rate their current
and past compliance using 4-point scale that was developed
for another study.8
Patients were asked whether they had taken their
medication at least 90% of the time, between 50% and 90%
of the time, between 10% and 50% of the time, or less than
10% of the time during last one month.
The information about the amount of cannabis used
in the last month was obtained from the patients in terms of
frequency and number of cigarettes used on a 1-6 scale. 
Schizophrenic patients with comorbid cannabis mis-
use were interviewed using section 12 of Schedules for
Clinical Assessment in Neuropsychiatry (SCAN) (World
Health Organization 1994). All the questions of interview
were translated into Pushto by a bilingual expert and
retranslated by another expert who was blind to the first
translation. 
Social functioning was assessed with the help of
Global Assessment of Functioning (GAF) scale.  The scale
considers psychological, social and occupational function-
ing on a hypothetical continuum of mental health illness. It
did not include impairment in functioning due to physical or
environmental limitation. Rating was for the current period
of admission. It consisted of range of codes from 100 to 0 in
descending order. 
The data was collected and analysed with the help of
statistical programme SPSS, version 10. Chi-square test for
categorical data and independent t-tests for continuous vari-
able were used to asses the degree of association between
different variables. The statistical significance was calculat-
ed at P< 0.05.
Results
Socio-Demographic
The cases and controls did not differ significantly in
terms of dwelling, marital status, socioeconomic condition,
living arrangement and employment except age on index
admission and age at onset of illness and years of education.
Comparison of cases and control's age at the time of index
admission, at onset of illness and the total duration of illness
are given in Table 1.
The cannabis users were younger on index admis-
sion than non users (25.82 years v 30.57 years), p=0.001
95% CI of mean difference -7.54 to -1.96. The age at onset
of illness was earlier in cases than controls (21.43 years v
25.39 years, p=0.005). The duration of illness at the time of
admission was shorter for cases as compared to controls
Case
n=50
Control
n=50 Mean dif-
ference p-value
95% CI of mean
differenceMean
(sd)
Mean
(sd)
Age of patient on
index admission
(years)
25.82
(5.06)
30.57
(8 .55)
-4.75 0.001 -7.54 -1.96
Age of patient at
onset of illness
(years)
21.43
(4.62)
25.39
(8.47)
-3.96 0.005 -6.66 -1.25
Duration of illness
(months) till index
admission
52.56
(45.68)
64.25
(56.48)
-11.69 0.258 -32.08 8.71
sd: Standard deviation   CI: confidence interval     
Numbers in parenthesis are Standard deviations
Table 1. Comparison of age on admission, at onset of illness and
duration of illness.
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time of admission was shorter for cases as compared
to controls (52.56 months v 64.25 months) (p=0.258). 
The patients in cannabis abuse group had signifi-
cantly less numbers of years of education compared to con-
trol group (Table 2).
Pearson x2 = 17.260    df=5   p=0.004).
Relapses
Sixty two patients had one or more relapse during
their course of illness. The patients using cannabis had more
relapses as compared to schizophrenic patients who were
not using cannabis. (2.46 v 1.22 Mean difference 1.24
p=0.011 and 95 % CI of difference 0.21to 2.19). When the
cases were further subdivided on the basis of severity of
cannabis use according to SCAN algorithm (see below) it
was found that the two groups differed significantly in the
number of relapses in the last 2 years (1.00 vs 2.95 mean
difference of -1.95 p=0.002 & 95% CI of mean difference -
3.16 to -0.73).
Out of 38 patients, who had no relapses, 15 patients
39.5% (8 cases and 7 controls) had their first episode of ill-
ness on index admission while 23 patients 60.5% (10 cases
and 13 controls) did not show any improvement in their ill-
ness and had continuous course.
Among those patients who had a continuous course
the total duration of illness was shorter for cases as com-
pared to controls (53.80 months vs 77.77 months) (p=
0.274). 
All schizophrenic patients irrespective of cannabis
use started their treatment approximately within one year of
onset of illness (12.86 months for cases 11.86 months for
control). The mean period of untreated psychosis was much
longer in this population of continuing illness, with cases
having received their first psychiatric treatment after 31.90
months as compared to 15.23 for controls (p=0.141).
Out of 62 patients who relapsed in the past, 32 cases
and 30 controls had their past relapses preceded by poor
compliance. Cases had a larger number of past relapses pre-
ceded by poor compliance as compared to controls (2.78 v
1.40 p=0.02   mean difference=1.38 95% CI of 0.5-2.26).
Out of 32 cases, who relapsed, 27 (84.4%) patients have
current episode preceded by poor compliance as opposed to
21 controls out of 30 (70%). Pearson's x2=62.00 p=.000
Service Use
Cases were more likely to be admitted to hospitals
(number of admission 1.04 vs 0.52 p=0.05). They also spent
more days in hospitals (19.7 v 7.22 p=0.047).  Cases had
greater number of contacts with police (1.70 v 0.20
p=0.000). 
Controls made more contacts with private psychi-
atric clinics than cases (7.00 v 3.96 p=0.002) Cases were no
more likely than controls to made use of emergency servic-
es and Out door patient department. Table 3.
For drug adherence in the last month, data was
analysed for 84 patients (41 cases and 43 controls). Data for
16 patients was missing as they were either drug naïve or
had first episode of illness on their index admission. The
compliance with medication was significantly poorer in
patients using cannabis than patients who were not using
cannabis (Table 4).
Global Assessment of functioning: Cases and con-
trols did not differ significantly on score of Global assess-
ment of functioning.  (28.70 v 27.08).
Table 2. Comparison of education between cases and controls.
Case Control Total
Uneducated
Primary- middle
Secondary- graduation
15
26
09
15
19
16
30
45
25
Total 50 50 100
Pearson chi square Value17.260                p-value.004
Table 3. Comparison of services use (Number of admission and days
spent in hospital, visits to private clinics and contact with police).
Case Control
Mean dif-
ference p-value
95% CI of
mean differenceMean
(sd)
Mean
(sd)
Number of
Admission
In Hospital
1.04
(1.63)
0.52
(0.86) 0.48 0.05 .03 1.04
Number of days
spent in Hosp.
19.10
(36.91)
7.22
(19.37) 11.88 0.047 0.18 23.58
Number of visits
to Private Psych
clinics 
3.96
(6.07) 
7.00
(6.81) -3.81 0.02 -5.60 -0.48
Number of con-
tact with police.
1.70
(1.89)
0.20
(0.40) 1.50 0.001 0.96 2.04 
sd: Standard deviation   CI: confidence interval     
Numbers in parenthesis are Standard deviations
Table 4. Comparison of drug adherence in last month between cases
and control.
Drug adherence in the last month
Total90 % of
the time 
50-90 %
of the
time
10-50 %
of the
time
less than
10 % of
the time
Case      % (n)
Control  % (n)
Total      % (n)
19.5%(8)
41.9%(18)
31.0%(26)
7.3%(3)
9.3%(4)
8.3%(7)
19.5%(8)
7.0%(3)
13.1%(11)
53.7%(22)
41.9%(18)
47.6%(40)
100%(41)
100%(43)
100%(84)
Pearson's x2 =6.618   df=3    p=0.085
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Discussion
Socio-demographic
In this study it was found that cases were of younger
age on index admission and had younger age at onset of ill-
ness. These finding supported the finding of Veen et al9,
Cantwell et al10 and Bersani et al.11 This could be a chance
association and with the understanding that cannabis has no
influence on risk or age at onset and that younger patients
are more likely to use this substance before the first psy-
chotic episode. A second possibility is that cannabis hastens
the onset of psychosis in subjects who are predisposed to
develop the illness.
Third, it is possible that cannabis makes manifest
schizophrenia in young subjects who are genetically at risk
for developing the disorder.
This study has shown that cases had less number of
education years as compared to controls. A number of
prospective longitudinal studies have indicated that early
cannabis use may significantly increase risks of subsequent
poor school performance and, in particular, early school
leaving12 possible underlying mechanism proposed for such
association can be "amotivational syndrome" or that
cannabis use causes cognitive impairments or the link aris-
es because of the social context in which cannabis is used.
However there appears to be little empirical support for
these hypotheses.
Relapses
The study also found that users have more relapses
since their illness started. This finding is consistent with that
of Gupta et al.13 Johns14; Tomassan and Vaglum,15 that
cannabis use generally provoke relapses.  This finding is
very significant keeping in mind that cannabis users also
had younger age at admission. They probably are more like-
ly to relapse in future. 
It is a well known finding in the literature that the
prognosis in schizophrenia tends to become poor with each
relapse. The increased relapses in patient with dual diagno-
sis cannot be wholly ascribed to cannabis use only as it
might be mediated through poor or non compliance. 
Cases' relapses were significantly more likely to be
preceded by poor drug compliance than controls. Although
this does not prove any causal link, the association points
towards the possibility that increased number of relapses
might be mediated through non compliance rather than
cannabis use. Another possibility is that cases were of
younger age and that being young and male are also known
as risk factors for noncompliance.16
It was seen that 38 patients did not have any relapse
in their course of illness. This suggests that these patients
either did not have any improvement in their symptoms or
presented in early course of their illness. 
Services use
Cases were more likely to be admitted to hospitals and
for long periods as compared to controls. Linszen17,
Menezes5 and Caspari18 also had similar results. Frequent
admissions were more likely due to relapses. In this study
cases made more contacts with police. Cantwell also found
increase service use (contact with police, psychiatrist).10 This
reflected on the greater reporting of crimes against the partic-
ipants due to violent behavior, and police contact for other
reasons, (possession, wandering, handing over to police by
family members because of behavioral disturbance). Increase
contact with private psychiatric clinics by the schizophrenic
without comorbid cannabis abuse is understandable because
of their uncomplicated presentation.
Global Assessment of functioning
Schizophrenic patients with comorbid substance abuse
were no more likely to show any difference in assessment of
social functioning as compared to those without it, though
both groups showed decline on the scale 28.70 v 27.08
p=0.566. This lack of difference in the two groups seems to be
due to the intrinsic quality of the scale itself, as the measure
declines for users because of their violent behaviour and for
non users by decreasing the ability to maintain their personal
hygiene or their impairment in communication. 
Limitations of the study
This study was conducted in a hospital based popu-
lation with a small sample size. Both groups were not con-
trolled for age and patients' allocation to the groups was not
randomized. Further studies are needed with validated
instruments and larger and representative sample while con-
trolling for age.
Conclusion
Comorbidity of cannabis seems to have adverse
effects on almost all domains of the illness including course,
service use and drug compliance.
The youngest cannabis users are most at risk perhaps
because, their cannabis use becomes longstanding. This
should encourage policy and law makers to concentrate their
effort on delaying the onset of cannabis use. At the same
time, further research is needed on the long-term impact of
frequent cannabis use that begins at an early age and on the
possible mechanisms by which cannabis use can lead to psy-
chosis.
During assessment of schizophrenia cannabis abuse
needs to be evaluated. Patients and their relatives need to be
educated about the impact of cannabis and its adverse
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The 2001 World Health Report estimated that only a quarter of all
patients with active psychosis were receiving treatment.1 An area
of particular concern is the delay in initiating treatment during
the critical first episode of psychosis, which is measured as the
duration of untreated psychosis (DUP). Long DUP in first-
episode psychosis is associated with worse short- and long-
term prognosis,2,3 an increased risk of suicidal behaviour4–6
and possibly serious violence.7–10
Increasing awareness of the adverse consequences of pro-
longed DUP in high-income countries has led to calls for a public
health approach to early psychosis11 and the introduction of early
intervention services. The effect of DUP on the prognosis of
psychotic illness in low- and middle-income (LAMI) countries
is not known, as there are very few relevant studies. However, long
DUP may have more severe consequences in lower-income
countries because people who are mentally ill may have increased
difficulty obtaining food, shelter and medical care.12,13
The aim of this study was to conduct a systematic review of
reports of DUP in LAMI and high-income countries. We used
the World Bank classification of ‘low-income’, ‘lower-middle-
income’ and ‘upper-middle-income’ economies, referred to
together as LAMI countries in this paper, and ‘high-income’
economies (referred to as countries here).14 We also examined
the relationship between DUP and the gross domestic product
(GDP) purchasing power parity.15
The a priori hypotheses were that (a) DUP would be longer in
LAMI countries than high-income countries and (b) DUP would
be inversely proportional to per capita income.
Method
Search strategy
In view of the difficulty locating studies of DUP from LAMI
countries we employed six search strategies. First, we searched
the electronic databases Medline, EMBASE, PsychLit and
PsycINFO from January 1975 to January 2007 using the search
terms ‘duration of untreated psychosis’, ‘delay in treatment’, ‘treat-
ment delay’ or ‘initiation of treatment’ cross-referenced with the
terms ‘psychosis’, ‘psychotic disorders’, ‘schizophrenia’, ‘schizo-
affective’ or ‘schizophreniform’ and ‘first-episode psychosis’. This
yielded 312 publications about DUP from high-income countries
and 8 studies from LAMI countries.
Second, we electronically searched the text of six leading
psychiatric journals (Schizophrenia Research, Schizophrenia
Bulletin, British Journal of Psychiatry, Acta Psychiatrica Scandinavica,
Journal of Clinical Psychiatry and International Clinical
Psychopharmacology) that were identified as having published
the abstracts of international schizophrenia conference
proceedings. Two further studies were located from full text
searches using the terms ‘duration of untreated psychosis’ or
‘DUP’ on the journals’ websites.
Third, we examined the first 40 results when combining the
names of 152 LAMI countries with ‘duration untreated psychosis’
using the search engine Google, which located one further DUP
study from a LAMI country.
Fourth, 12 studies from LAMI regions were found using
PubMed (from January 1975 to January 2008) by sequentially
entering the names of 152 LAMI countries and ‘schizophrenia’,
and examining all the abstracts. Publications on movement dis-
order, gender differences or the epidemiology of schizophrenia
were examined in full text.
No further studies were found when hand-searching the
references of DUP studies or by contacting 12 authors of recent
publications (about aspects of first-episode psychosis in LAMI
countries) for unpublished DUP data.
Finally, no additional articles were found by an examination of
all the abstracts in electronic databases that specialise in journals
from LAMI countries that are not indexed on Medline. The terms
‘schizophrenia’ and ‘psychosis’ were used to search ExtraMED
from 1992 to 2000 and LILACS from 1982 to 2008.
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Background
The duration of untreated psychosis (DUP), the period
between the first onset of psychotic symptoms and
treatment, has an important influence on the outcome of
schizophrenia.
Aims
To compare the published studies of DUP in low- and
middle-income (LAMI) countries with the DUP of high-income
countries, and examine a possible association between DUP
and per capita income.
Method
We used six search strategies to locate studies of the
DUP from LAMI countries published between January
1975 and January 2008. We then examined the
relationship between DUP and measures of economic
activity, which was assessed using the LAMI classification of
countries and gross domestic product (GDP) purchasing
power parity.
Results
The average mean DUP in studies from LAMI countries was
125.0 weeks compared with 63.4 weeks in studies from high-
income countries (P=0.012). Within the studies from LAMI
countries, mean DUP fell by 6 weeks for every $1000 of GDP
purchasing power parity.
Conclusions
There appears to be an inverse relationship between income
and DUP in LAMI countries. The cost of treatment is an
impediment to care and subsidised antipsychotic medication
would improve the access to treatment and the outcome of
psychotic illness in LAMI countries.
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Review article
All the articles identified by Medline, EMBASE, PsychLit and
PsycINFO searches in addition to the articles found from the
searches of the six journals were examined in full text by M.L.
and O.N. Thirteen differences in the selection of articles were
found to be due to instances of the selection of different papers
from multiple publications about the same sample and these were
resolved by a joint examination of the publications. These searches
were cross-checked during the subsequent searches of PubMed
and Google by M.L. on two further occasions 3 months apart.
One additional article (from a high-income country) was found
in the second set of searches (Fig. 1).
Inclusion and exclusion criteria
We included studies with non-overlapping samples of DUP that
reported mean DUP or median DUP, or the mean age at onset
of psychotic symptoms and the mean age at presentation to one
or more decimal points from which mean DUP could be
calculated. We excluded samples that included individuals from
both LAMI and high-income countries.
No additional assessment of the quality of the data was
attempted if the paper met the inclusion criteria, although all
but two of the studies from LAMI countries used a recognised
diagnostic system.
Forty-four papers reported more than one sample of DUP. All
of the samples from different regions or different time frames were
used (6 papers), but if a sample was reported in two publications
it was only included once. The other reasons for papers reporting
more than one sample was to compare participants by gender (17
papers) or diagnosis (13 papers), or more rarely by characteristics
such as drug misuse, particular symptom clusters, or the number
of subsequent relapses. Papers that dichotomised individuals
simply on the basis of the DUP were included as a single sample.
The following data were collected from all of the samples:
(a) country of origin of participants
(b) number of people in the sample
(c) the endpoint of DUP (initiation of treatment, contact with
mental health services or contact with researchers)
(d) mean age at contact or treatment, or mean age at onset of
psychosis
(e) mean DUP and/or median DUP in weeks
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Article titles considered (n=8250)
(a) Conventional search strategies including 6 journals
High-income papers (n=312)
LAMI papers (n=10)
(b) Google search of ‘DUP’ and 152 LAMI countries (total n=6080)
(c) PubMed search of ‘schizophrenia’ and 152 LAMI countries
(total n=1538)
(d) LILACS and ExtraMED (total n=310)
Abstracts or full text considered (n=874)
(a) Papers initially read in full text (n=322)
(b) Google abstracts (n=144)
(c) PubMed abstracts (n=177)
(d) LILACS/ExtraMED abstracts (n=231)
Articles read in full text (n=384)
(a) n=322
(b) n=24
(c) n=38
(d) n=0
Articles included, describing 98 studies (n=102)
Studies from LAMI regions (n=23)
Total number of samples in 23 studies (n=41)
Reporting mean DUP (n=41)
Reporting median DUP (n=16)
Not likely to be relevant by title and therefore excluded (n=7376)
(a) n=0
(b) n=5936
(c) n=1361
(d) n=79
Not likely to be relevant after examination of the abstract
and therefore excluded (n=490)
(a) n=0
(b) n=120
(c) n=139
(d) n=231
Excluded because of any one of:
No measure of DUP (227 articles)
Reported DUP in a proportion of treated patients at fixed
time intervals (3 articles)
Duplicate reporting (47 articles, including 3 from LAMI regions)
DUP of patients from regions with different mixed
low-income and LAMI classifications (2 studies)
Studies from developed regions (n=75)
Total number of samples in 75 studies (n=116)
Reporting mean DUP (n=107)
Reporting median DUP (n=75)
6
6
6
6
7
7
7
7
Fig. 1 Flow chart of searches for DUP studies from LAMI and high-income regions.
DUP, duration of untreated psychosis; LAMI, low- and middle-income. (a) Conventional search strategies including of Medline, EMBASE, PsychLit and PsycINFO from January 1975 to
January 2007, and the text of Schizophrenia Research, Schizophrenia Bulletin, British Journal of Psychiatry supplements, Acta Psychiatrica Scandinavica, Journal of Clinical Psychiatry
and International Clinical Psychopharmacology; (b) Google searches of the first 40 results found after sequentially entering all the names of 152 LAMI countries combined with
‘duration untreated psychosis’; (c) PubMed from January 1975 to January 2008 by sequentially entering the names of 152 LAMI countries and ‘schizophrenia’, and examining all the
abstracts. Publications on movement disorder, gender differences and the epidemiology of schizophrenia were examined in full text; (d) LILACS was searched from 1982 to 2008 and
ExtraMED was searched from 1992 to 2000. Hand-searches were performed but found no additional studies for high-income or LAMI regions.
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(f) inclusion of patients with affective psychosis and the proportion
with schizophrenia-related psychosis
(g) proportion of participants with a diagnosis of schizophrenia
or schizophreniform psychosis
(h) proportion of male participants
(i) year of publication.
Data extraction
The data from studies from LAMI countries were independently
extracted by M.L. and S.F. and from high-income countries by
M.L. and O.N. Three differences in the DUP data collection in
both the LAMI and high-income samples were unambiguously
resolved by further examination. A check of the reliability of the
rating of the inclusion of patients with schizophrenia-related
psychosis was performed and was found to have a kappa of 1,
as no differences were found. A final masked check of the
electronic record of all the data points was conducted by M.L.
6 months after the initial data extraction. This found five minor
errors in age at onset and gender that were probably owing to
errors in transcription.
Definitions of psychotic illness
All but five studies used a recognised diagnostic system but there
were differences in the way psychotic disorders were classified and
reported. Some publications only reported the numbers of
patients with the diagnoses schizophrenia, bipolar disorder and
psychotic depression, whereas other studies reported the propor-
tion of people with other schizophrenia-related psychoses such
as delusional disorder and psychosis not otherwise specified. All
the studies stated whether they included patients with affective
psychosis, but the proportion of people who were diagnosed with
schizophrenia was not available for every sample. As patients with
affective psychosis are known to have a shorter DUP than those
with schizophrenia-related psychosis (defined as any functional
psychosis other than bipolar disorder and psychotic depression)
the characteristics of samples of patients with schizophrenia-
related psychosis was also analysed. Schizoaffective disorder was
included in our definition of schizophrenia-related psychosis.
Definition of duration of untreated psychosis
Duration of untreated psychosis has been defined as the period
between the onset of definite psychotic symptoms and the
beginning of adequate treatment.16 We included all the definitions
of what is considered to be the end of DUP, including the
initiation of treatment, the end of adequate treatment and contact
with mental health services. Contact with researchers was also
accepted as an endpoint of DUP in studies from LAMI countries
as there were so few studies. The inclusion of individuals who only
had contact with researchers rather than mental health services
would be likely to increase the estimates of mean DUP for LAMI
countries given the greater likelihood of undetected DUP being
prolonged. Conversely, inclusion of individuals with affective
psychosis would be expected to decrease mean DUP. In an effort
to counter these potential confounders, we examined a subset of
studies of patients in LAMI countries with schizophrenia-related
psychoses, who were recruited as a result of contact with mental
health services and had at least some treatment, to allow a
comparison with similar studies conducted in high-income
countries.
Income data
The LAMI country classification is based on per capita GDP in
international dollars. However, comparing income between
countries in terms of official exchange rates may not reflect the
local cost of goods and services. Therefore we also examined the
relationship between DUP and GDP purchasing power parity.
Statistical methods
Consideration was given to the use of meta-regression in order to
take the degree of variability of the studies into account. However,
meta-analysis requires a measure of the variability of the mean
such as the standard deviation. After emailing the authors of
studies from LAMI countries who did not report the standard
deviation of the mean DUP, only 32 of the 41 data points had
a standard deviation. Moreover, the average mean DUP of studies
from LAMI regions that did not report the standard deviation was
88 weeks and was significantly shorter than the average mean of
138 weeks of studies for which a standard deviation was available.
Hence, the exclusion of these studies would have biased our study
in favour of finding a prolonged DUP in studies from LAMI
countries. Instead, the samples were weighted for regression
analysis by the number of participants, as larger samples would
be expected to have a more accurate figure for mean DUP.
The degree of variation between mean DUP values was also
considered, as mean and median DUP values were significantly
skewed. In order to avoid statistical findings that were unduly
influenced by samples with a very long DUP, the DUP values were
log10 transformed for both the univariate comparisons of the DUP
in LAMI and high-income regions, and a multiple linear
regression analysis of factors associated with the mean DUP. The
distributions of mean DUP values were not significantly skewed
after log10 transformation.
Chi-squared tests were used to compare the proportions of male
participants, the number of participants with a schizophrenia-
related psychosis and the number of participants diagnosed with
schizophrenia in LAMI v. high-income groups. The age at onset
was calculated by subtracting DUP from age at presentation and
was used in preference to age at presentation because it is
independent of DUP. Ages were compared using a two-tailed
Student’s t-test.
A multiple linear regression model was used to examine the
associations between the dependent variable of log10 DUP and
high-income v. LAMI status and the covariables of age, gender
and the inclusion of patients diagnosed with affective psychosis.
A linear regression model using untransformed data was used
to examine the relationship between DUP and GDP purchasing
power parity within LAMI regions after a scattergram showed
an apparently linear relationship between these two variables. Four
studies of patients who came into contact with researchers but did
not necessarily receive treatment were excluded from this analysis
because their DUP was much longer (mean DUP 45 years) than
in other samples. The remaining samples were not significantly
skewed.
All statistical tests were two-tailed and results were regarded as
statistically significant at or below the 5% probability level. The
statistical analysis was performed using SPSS for Windows,
version 15.0.
Results
Results of the searches
We examined 384 papers in full text and found 134 papers that
included a measure of DUP from high-income countries and 26
from LAMI countries (Fig. 1). Forty-seven papers from high-income
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countries were excluded as the samples appeared to overlap with
those of other publications. We excluded two studies from high-
income countries that were performed in the 1960s, four other
studies of patients who became unwell prior to the advent of
antipsychotic medication, three studies that reported DUP in
terms of fixed time intervals and two studies reporting single
samples with a combination of individuals from LAMI and
high-income countries.
There were 98 studies that met the inclusion criteria, of which
23 (26 papers) were from LAMI countries17–42 (see online Table
DS1) and 75 were from high-income countries (Table DS2). The
earliest study from a LAMI country was published in 1995. The
23 studies from LAMI countries included 24 samples in which
DUP was reported directly and 17 samples in which mean DUP
could be calculated; hence, in total there were 41 samples of DUP
for patients from LAMI countries. All but 3 studies were published
in full text in peer-reviewed journals. We contacted 13 authors to
clarify some data points and 2 authors provided some additional
information about their research that had been published in
abstract form.21,38 Twenty-seven samples from LAMI countries
reported the interval between the onset of psychosis and contact
with services in patients with schizophrenia-related psychosis.
All the studies from high-income countries appeared in full
text in peer-reviewed journals and all but eight studies were
published after 1990. Mean DUP was reported directly for 88
samples, and in a further 19 samples mean DUP could be
calculated by subtracting the mean age at onset from the mean
age at presentation.
Results of the study
The weighted mean, average mean DUP and the median mean
DUP were significantly longer in studies from LAMI countries
than in studies from high-income countries. The average
median DUP was longer in studies from LAMI countries than
from high-income countries but the apparently large difference
did not reach statistical significance, probably because of the
small number of samples from LAMI regions and because of
relatively large within-group variability in median DUP
(Table 1).
The longer average mean DUP in studies from LAMI coun-
tries was a result of a prolonged DUP in low-income and lower-
middle-income countries, as the average mean DUP in the studies
from upper-middle-income countries was shorter than that of
high-income countries (Table 1). Mean age at onset and mean
age at presentation were higher in samples from LAMI countries
than high-income countries. Studies from LAMI countries had
fewer male participants but slightly more participants diagnosed
with a schizophrenia-related psychosis. In the LAMI group, more
patients who were diagnosed with a schizophrenia-related psycho-
sis were considered to have a diagnosis of schizophrenia or schizo-
phreniform disorder.
We examined a subset of studies of individuals with schizo-
phrenia-related psychosis who had received some treatment. The
mean DUP in the samples from LAMI countries (85.2 weeks,
s.d.=38.3, 95% CI 70.0–100.3, n=27) was significantly longer that
the mean DUP in samples from high-income countries (70.5
weeks, s.d.=55.3, 95% CI 57.8–83.1, n=76, unpaired t-test. LAMI
v. high-income d.f.=101, t=2.05, two-tailed P=0.04, using log10
transformed mean DUP values). This confirmed that the
difference between the mean DUP of LAMI countries and high-
income countries was not due to the proportion of participants
with affective psychoses in high-income countries or the
proportion of participants who did not receive treatment in LAMI
countries.
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Table 1 Duration of untreated psychosis, diagnostic and demographic variables in the LAMI groups
LAMI subgroups LAMI v. high-income
Low-
income
Lower-middle
income
Upper-middle
income LAMI High-income d.f. Statistic P
Samples, n 14 17 10 41 116
Samples with mean DUP, n 14 17 10 41 107
Samples with median DUP, n 2 8 6 16 75
Samples with patients with
schizophrenia-related psychosis, n
13 13 6 32 81
Patients, n 981 1731 638 3350 10459
Average mean DUP weighted for sample
size, weeks 171.1 173.7 50.3 146.9 61.5
Average of mean DUP,a weeks
(median, s.d., 95% CI)
160.2
(108.4,153.6,
71.4–248.8)
141.3
(64.8, 230.9,
22.6–260.0)
47.8
(48.3,14.6,
37.3–58.3)
125.0
(70.8, 176.3,
69.2–180.5)
63.4
(52.0, 53.3,
53.2–73.6)
146 t=2.56 0.012
Average of median DUP,a weeks
(median, s.d., 95% CI)
132.0
(132, 181,
0–1758)
17.4
(10, 19.0,
1.5–33.3)
21.2
(21.3, 6.9,
14.0–28.5)
33.2
(15.5, 62.1,
0–66.3)
18.6
(13.1,15.0
15.1–22.0)
89 t=0.77 0.44
Age at onset of psychosis: mean
(s.d., 95% CI)
25.7
(4.2, 23.3–28.1)
28.2
(7.1, 24.6–32.0)
27.3
(1.8, 26.0–28.6)
27.3
(5.2, 25.5–28.8)
24.9
(3.9, 24.2–25.7)
155 t=2.83 0.005
Age at presentation: mean
(s.d., 95% CI)
28.8
(5.8, 25.4–32.1)
30.8
(6.6, 27.4–34.2)
28.2
(1.8, 26.9–29.5)
29.5
(5.5, 27.7–31.2)
26.1
(4.1, 25.4–26.9)
155 t=4.08 50.001
Male patients, n (% in income group) 574 (58.5) 901 (52.0) 355 (55.6) 1830 (54.6) 6409 (61.3) 1 w2=46.6 50.001
Patients with schizophrenia-related
psychosis,b n (% in income group)
936 (94.4) 1587 (91.7) 607 (95.1) 3130 (93.4) 9245 (88.4) 1 w2=69.3 50.001
Patients diagnosed with schizophrenia,b
n (% in income group)
936 (94.4) 1528 (88.3) 561 (87.9) 3025 (90.3) 7473 (71.4) 1 w2=494.5 50.001
DUP, duration of untreated psychosis; LAMI, low- and middle-income.
a. Mean and median DUP values were log10 transformed for t-tests but untransfomed means and s.d. are tabulated.
b. Contains some estimates as the proportion of patients with schizophrenia or schizophrenia-related psychosis was not always reported. If a value for either schizophrenia-related
psychosis or schizophrenia was not reported, the other was used; if both values were missing (5 samples) the proportion of patients with schizophrenia in income group was used.
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The univariate finding of a longer mean DUP was confirmed
with a multiple linear regression (using log10 mean DUP as the
dependent variable and weighted for the number of people in each
sample) that found that the association between longer DUP and
samples from LAMI countries was independent of inclusion of
samples with patients whose diagnosis was affective psychosis.
The proportion of males in the samples and age at onset were
not significantly associated with log10 mean DUP (model
summary: r=0.462, r2=0.214, standard error of the estimate=2.92)
(Table DS3).
Relationship between gross domestic product
and mean duration of untreated psychosis
We examined the hypothesised relationship between GDP
purchasing power parity and mean DUP in LAMI countries using
linear regression. For every $1000 of additional per capita GDP
purchasing power parity, mean DUP fell by 6 weeks (model
summary: r=0.497, r2=0.247, standard error of the estimate=
296.3) (Table DS4). An analysis of the mean DUP in the samples
of patients with schizophrenia-related psychosis suggested a fall of
9 weeks of DUP per $1000 of per capita GDP purchasing power
parity (model summary: r=0.644, r2=0.415, standard error of
the estimate=268.1) (Table DS5). No significant relationship
between median DUP and GDP was found, possibly because so
few studies from low-income and lower-middle-income countries
reported a figure for median DUP (n=10; Table 1).
A surprising finding was that mean DUP rose by 3 weeks per
$1000 of GDP purchasing power parity in studies from high-
income countries (r=0.243, r2=0.059, d.f.=106, GDP purchasing
power parity coefficients: B=0.003, s.e.=0.001, t=2.567, P=0.012).
This rise was associated with studies from regions with mental
health laws that required the patient to be assessed as dangerous
before they could receive involuntary treatment.43 Mean DUP
was not associated with GDP purchasing power parity in
high-income countries when the presence of this form of mental
health law was included in the model.
Discussion
A limitation of this study was that despite a comprehensive search,
we were able to obtain DUP data for only 18 of 152 LAMI
countries. Lack of data is likely to be a limitation in any study
of mental healthcare in LAMI countries44 and probably reflects
the poor state of mental health services. Health administrators
in many countries may not even be aware of the extent of the
unmet need for treatment of psychosis.
Long DUP in LAMI countries may be associated with
low income
The hypothesis that DUP is longer in LAMI countries was
confirmed. We also found a linear relationship between GDP
purchasing power parity and DUP in LAMI countries and this
raises the possibility of a causal relationship between low income
and treatment delay. However, this finding is qualified as the DUP
in the small number of studies from upper-middle-income
countries was shorter than the average mean DUP of high-income
countries.
Long DUP in high-income countries is usually attributed to
lack of insight on the part of the patient, the gradual onset of
psychosis in some patients and the families’ lack of understanding
of the need for treatment. The reasons for longer DUP in LAMI
countries warrants further investigation, but is likely to include
the lack of services in many areas as well as the cost of treatment.
The cost of treatment is frequently reported as a barrier to care
in low-income21,36,37,39 and lower-middle-income40,45,46 countries.
For example, in a region of Nigeria the only available anti-
psychotic was a low dose of chlorpromazine for a few weeks per
year provided by a charity.45 In India, the direct cost of treating
schizophrenia is a quarter of the average family income in
dollars.46 Even if the patient’s family were able to purchase some
antipsychotic medication it could be at the expense of other forms
of essential medical care or even food. Hence, it is not surprising
that mean DUP declined with even modest increases in income.
Better prognosis in LAMI countries with long DUP?
The relationship of DUP to outcome in LAMI countries has not
been extensively investigated. Although it is widely believed that
the prognosis of schizophrenia is better in LAMI countries,47 we
found a number of studies reporting a worse outcome in these
regions. For example, both treated and untreated patients from
Morocco were less likely to be employed than a similar sample
from the USA,48 and in rural China where very few patients
received adequate treatment, untreated patients were found to
have marked social and occupational disability and a fourfold
increase in mortality.36,37,49 Another study from the Indonesian
Island of Bali reported an association between long DUP and
increased mortality in the decade after contact with services.28
In Bali and in rural China the excess mortality was not from
suicide, but from a lack of physical care.28,49 Our finding of a very
long DUP in low-income and lower-middle-income countries,
and other studies that found large numbers of patients who had
never received treatment, raises the possibility that a subset of
patients with long DUP in some outcome studies either died or
were lost to follow-up for other reasons.
Subsidised psychiatric treatment may shorten DUP
This study has highlighted the initial delay in receiving treatment
in LAMI countries. The overall treatment gap may be greater, as
there are studies from LAMI countries that describe large
numbers of patients who never receive any treatment.32,36,37,45
Worldwide, schizophrenia is the eighth largest cause of dis-
ability and the illness may shorten life expectancy by 10 years.50
The direct effects of schizophrenia are comparable to those of
many infectious and chronic physical illnesses that receive more
funding for both treatment and research. Cost-effective treatment
is now available for schizophrenia. A public health initiative to
subsidise antipsychotic medication for the critical first 2 years of
psychotic illness could greatly improve outcome for psychotic
illness worldwide.51 Combining subsidised mental health services
with other forms of primary healthcare, as reported from
Zambia, a low-income country where the DUP was comparatively
short,31 could also significantly reduce the delay in treatment and
improve the prognosis of mental illness in poorer countries.
Patients with psychosis in low-income and lower-middle-
income countries may be among the most disadvantaged people
on earth and providing them with access to basic treatment would
be a cost-effective public health measure.
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Untitled pictures (date unknown) by Denis Reed (1917–1979)
Denis Reed was a patient in Glenside Psychiatric Hospital in Bristol during
the 1950s and 1960s. These two images portray everyday life in the hospital
from the patients’ perspective. A sensitive and skilled artist, Reed evokes
the atmosphere and activities of the institution. His sketchy, transparent
style is reminiscent of Toulouse-Lautrec.
Glenside was originally the Bristol Lunatic Asylum, which had opened in
1861 to take patients from the lunatic wards of St Peter’s Hospital. By 1910
it was enlarged to accommodate the increasing numbers of patients being
admitted. During the First World War it became a military hospital and
provided 1460 beds for war casualties. Sir Stanley Spencer drew on his
experience as an orderly there to create the paintings that now adorn
the Sandham Memorial Chapel. Although a second mental hospital, Barrow
Hospital, was opened in 1939, Bristol Mental Hospital became overcrowded
during the Second World War and remained so in post-War years, with a
high proportion of long-stay patients. In 1959, following the Mental Health
Act, Bristol Mental Hospital was renamed Glenside Hospital. Glenside
Museum is situated in the former Chapel at Glenside. It was set up by
Dr Donal Early. Together with the collection of paintings by Denis Reed, it
houses a permanent exhibition of hospital life between 1940 and 1980.
For further information see www.glensidemuseum.org.uk
Researched by Christopher Ramsey & Peter Carpenter, Bristol.
Edited by Allan Beveridge.
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Background: The duration of untreated psychosis (DUP) is deﬁned as the period between the
onset of symptoms of psychosis and the start of antipsychotic treatment. Delay in the initiation
of treatment, resulting in a long DUP, is associated with a poor prognosis in high-income (HI)
countries. It is not known if longer DUP is associated with poor outcomes in Low and Middle
Income (LAMI) countries, where schizophrenia might have a more benign course.
Methods: A systematic review and meta-analysis of studies from LAMI countries that reported
an association between DUP and response to treatment, measures of disability and mortality.
The association between DUP, symptoms and cognitive function at presentation were also
examined.
Findings: Meta analysis of ﬁve studies that reported the association between DUP and the
reduction in total symptoms scores after treatment found a signiﬁcant negative correlation
between DUP and improvement in symptoms after treatment (r=−0.290, 95% CI=−0.483 to
−0.069, z=−2.559, pb0.011). Prolonged DUP was also associated with increased levels of
disability. One study reported that longer DUP was associated with a higher mortality in the
following decade.
Conclusions: Delay in the initial initiation of treatment for psychosis is associated with a poorer
response to treatment and increased levels of disability in LAMI countries.
© 2009 Elsevier B.V. All rights reserved.
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1. Introduction
Several large andwell conducted studies have reported that
schizophrenia has a better prognosis in LowandMiddle Income
(LAMI) countries (World Health Organization, 1973; World
Health Organization, 1979; Jablensky et al., 1992; Hopper et al.,
2007). However the hypothesis that psychotic disorders have a
morebenign course in lowandmiddle income(LAMI) countries
is not universally accepted, in part because lower income
countries are more likely to have poorly developed health care
services, endemic infectious disease, high rates of malnutrition
and a shorter life expectancy. In a recent review of longitudinal
studies of outcome,Cohen et al. (2008) concluded that it was
time to re-examine the presumed wisdom that schizophrenia
carried a better prognosis in low- andmiddle-incomecountries.
Cohen et al. (2008) suggested that methodological issues,
including the proportion of patients lost to follow up, might
have biased some studies of the outcome of psychosis in the
direction of improved prognosis. Cohen et al. (2008) noted that
increased mortality from untreated medical illness and mal-
nutrition are reported in studies of psychosis from LAMI
countries (for example Dube et al., 1984; Mojtabai et al., 2001).
There are two more recent studies reporting an association
between a lack of psychiatric treatment and increasedmortality.
Kurihara et al. (2006) reported that a prolonged duration of
untreated psychosis (DUP) was associated with a seven fold
increase in mortality for patients with schizophrenia on the
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Indonesian island of Bali and Ran et al. (2007) found that a long
DUP and the lack of continued treatment were associated with
increased mortality and a poor prognosis in a large prospective
study from rural China.
The ten-country study of schizophrenia reported that about
80% of patients in both the developed and developing countries
had been unwell for less than six months at the time of
enrollment to the study (Jablenskyet al.,1992).However, recent
systematic review of relationship between DUP and gross
domestic product purchasing power parity (GDP ppp) found
that on average the DUP of LAMI countries (125 weeks) was
twice as long as the DUP in high-income countries (63 weeks,
p=0.012,Large et al., 2008). Moreover within the LAMI group
of counties, DUP declined by six weeks for every additional
$1000 per capita GDP ppp.
Hence thehypothesis that lowpercapita income is associated
with worse outcome in psychotic illness stems from the ﬁnding
that DUP is inversely proportional to GDP ppp and long DUP
might be associated with poorer outcomes possibly including
increased mortality in LAMI countries (Large et al., 2008).
Fig. 1. Flow chart of searches for DUP studies from LAMI and HI regions.
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An association between DUP and outcome has been exten-
sively studied in high income (HI) countries. Two recent
systematic reviews concluded that there was a consistent
association between long DUP and persistent symptoms, poor
overall functioning, and lower quality of life (Marshall et al.,
2005; Perkins et al., 2005). There are a small number of
studies of the association between DUP and various outcome
measures from LAMI countries, but it is not known if long DUP
is also associated with a poor prognosis in these regions. A
ﬁnding that longer DUP was not associated with a poor
prognosis in LAMI countries would support the hypothesis
that schizophrenia had a better prognosis in those countries.
We report a systematic review and meta-analysis of the
relationship between DUP and measures of outcome in LAMI
countries.
2. Methods
2.1. Search strategies
A wide search strategy was undertaken in an attempt to
locate all the available studies (Fig. 1). Firstly, we searched the
electronic databases Medline, Embase, Psychlit and Psy-
chINFO from January 1975 to March 2008 using the search
terms ‘duration of untreated psychosis’, ‘delay in treatment’,
‘treatment delay’ or ‘initiation of treatment’ cross referenced
with the terms ‘psychosis’, ‘psychotic disorders’, ‘schizophre-
nia’, ‘schizoaffective’ or ‘schizophreniform’ and ‘ﬁrst-episode
psychosis’. This method yielded more than 300 publications
about DUP from developed countries but only eight studies
conducted in LAMI countries deﬁned as (LI), lower-middle-
income (LMI) of upper-middle income (UMI) using theWorld
Bank and International Monetary Fund's LAMI classiﬁcation
(World Bank, 2005).
Second, the journals Schizophrenia Research, Schizophre-
nia Bulletin, British Journal of Psychiatry Supplement, Acta
Psychiatrica Scandinavica, Journal of Clinical Psychiatry and
International Clinical Psychopharmacology were searched in
full text because these journals had published the abstracts of
international schizophrenia conferences. Two additional
studies were located using the terms ‘duration of untreated
psychosis’ OR ‘DUP’.
Third, we examined the ﬁrst 40 results after combining the
names of 152 LAMI countries with “duration untreated
psychosis” using the search engine Google. This located one
further study of DUP from a LAMI country.
Fourth, 12 studies reporting DUP from LAMI regions were
found by examining the abstract of every article located using
the names of 152 LAMI countries AND “schizophrenia” in
PubMed [January 1975 to January 2007]. Publications on
movement disorder, gender differences or the epidemiology
of schizophrenia were examined in full text.
Fifth, we hand searched the references of DUP studies and
contacted the authors of twelve recent studies of ﬁrst episode
psychosis (FEP) in LAMI countries, which located no further
relevant studies.
Finally, no studieswere found by examining all the abstracts
located using the terms “schizophrenia” and “psychosis” in
searches of ExtraMed [1992 to 2000] and LILACS [1982 to 2008].
LILACS and ExtraMed index journals from developing regions
that are not found on Medline.
2.2. Inclusion criteria
Using these methods a total of 23 studies were located
from LAMI countries that reported DUP or the interval
between the onset of psychosis and the initiation of treatment
or contact with services (Large et al., 2008). Twelve of the 23
studies did not contain outcome data, but eleven studies met
our inclusion criteria, as they reported an association between
DUP and at least one of the following:
(i) (a) the degree of symptomatic improvement attribu-
ted to antipsychotic treatment measured using
recognized instruments
(b) disability, using the results of disability scales,
social and occupational functioning or global
outcome
(c) mortality
(d) measures of symptoms or cognitive function at
presentation
(ii) used clinician-rated instruments and
(iii) reported subjects who met the criteria for the
diagnosis of a psychotic disorder according to either
the DSM or ICD classiﬁcation systems.
There are no widely accepted criteria for assessing the
quality of studies of DUP. All studies of DUP are naturalistic and
it is not possible to randomize subjects to longor short DUP. The
quality of the studies was assessed and is reported using the
criteria proposedbyMarshall et al. (2005,Table 2): restriction of
the population to those with schizophrenia using accepted
diagnostic criteria, assessmentof outcomeblind toDUP status, a
follow-up rate of at least 80%, and use of a standardizedmethod
to measure DUP. However, as there were so few studies and
none of the studies met all of these criteria, we did not exclude
any of the studies on quality grounds.
2.3. Data extraction and analysis
The following data were collected: the country of origin of
the subjects, the proportion of males, number of subjects,
mean age at contact or initiation of treatment, details of
outcomemeasures reported and percentage of subjects with a
diagnosis of schizophrenia or schizophreniform psychosis.
Details of outcome measures are provided in Table 1.
SF and ML independently extracted the data and minor
differences were resolved after independent re-examination
by both authors.
Meta analysis was used to calculate a pooled estimate of
the associations between DUP and the outcome measures of
(i) reduction in total symptom scores from base line (ii) levels
of disability, measured either by the use of established
disability scores or by measures of global function and
occupational outcome after treatment.
The associations between DUP and cognitive function,
positive symptoms and negative symptoms assessed prior to
treatment were also examined. While these measures are not
measures of treatment outcome, they are of interest in LAMI
countries because a signiﬁcant proportion of patients with
psychosis never receive treatment.
Comprehensive Meta-Analysis (CMA), version 2.2 was
used for the analysis. CMA employs the same algorithms that
are used by the Cochrane collaborators to assess effect size
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Table 1
DUP, diagnostic and demographic variables in the LAMI groups.
Reference Site, World
Bank
income status
Diagnostic criteria Deﬁnition of DUP Study
analysis
time points
Outcome
variable
Deﬁnition of
remission or outcome
Results
Alptekin
et al. (2005)
Multi-center
study, Turkey.
UMI
DSM IV
Schizophrenia
Duration between the
appearance of the ﬁrst
identiﬁable psychotic
symptom to the beginning of
antipsychotic treatment
Baseline
and three
monthly
for one
year
BPRS
BDQ
No or Minimal
disability as deﬁned
by a BDQ score b7
DUP was a moderate
predictor of disability at
one year.
Apiquian
et al.
(2002, 2006)
Mexico City,
Mexico. UMI
DSM III-R (SCAN)
for affective and
non-affective
psychosis
Duration of psychotic illness
until at least four weeks of the
equivalent of 5 mg of
Haloperidol.
Baseline
and at
12 months.
PANSS
PAS
None DUP negatively
correlated with positive
symptoms and positively
correlated with the PAS
general subscale.
Ayres et al.
(2007)
Sao Paulo.
UMI Brazil
DSM IV patients
with functional
psychosis, 98
schizophrenia
spectrum, 71
affective psychosis
(SCID)
Onset of psychosis to contact
with mental health authorities
Baseline PANSS
Tests of
memory
and
verbal
ﬂuency
None No relationship with
DUP was found.
Galinska
et al. (2005)
Bialystok,
Poland. UMI
ICD 10 and DSM IV
Schizophrenia
The period between the onset
of delusions or hallucinations
and antipsychotic treatment
Baseline WCST
WAIS-R
GAF
PANSS
Correlations with
Cognitive measures,
PANSS and GAF
No relationship with
DUP found
Kurihara
et al. (2006)
Bali,
Indonesia.
LMI
DSM III
Schizophrenia
Duration between meeting
criteria for schizophrenia and
initial treatment
Eleven
years
Measures
of
Mortality
Survival Patients with a DUP of
longer than 12 months
had 6.7 times the
mortality of those with a
DUP of less than
12 months.
Lieberman
et al. (2003)
Beijing, China.
LMI
DSM IV
Schizophrenia
Duration between the ﬁrst
psychotic symptom and entry
into drug trial for ﬁrst episode
patients
Twelve
weeks and
52 weeks
BPRS
SANS CGI
GAF
Remission deﬁned as
50% reduction in BPRS
and BPRSb3 on 5
psychosis items of
BPRS
Patients with longer DUP
had higher BPRS scores
at 12 weeks. Every year
of DUP reduced the
likelihood of remission
by 15% at 52 weeks.
Oosthuizen
et al. (2005)
Cape Town,
South Africa.
UMI.
DSM IV
Schizophrenia,
schizophreniform
or schizoaffective
disorder (SCAN)
Duration between overt
hallucinations and delusions
and the initiation of
antipsychotics. DUP was not
reliably established in seven
subjects and two subjects with
very long DUP were excluded.
Non Parametric measures of
correlation were used.
Baseline,12,
18, 21 and
24 months.
PANSS Correlations with
PANNS Scores,
At 21 months and
24 months DUP
positively correlated
with negative symptom
scores
Ran et al.
(2001, 2003,
2007)
Xinjin count,
China LMI
ICD 10
Schizophrenia
(PPHS)
No operational deﬁnition of
DUP, included patients who
had received traditional
treatments.
Cross
sectional
PSE SDSS
PSS
The presence of
current or marked
and current
Symptoms
DUP negatively
correlated with level of
remission.
Thirthalli
et al. (2005)
Bangalore,
India. LI
ICD-10
Schizophrenia
Duration between the onset of
any psychotic symptoms and
presentation for treatment
Four weeks PANSS Percentage
improvement in
PANNS Score
DUP negatively
correlated with change
in PANNS at 4 weeks.
Tirupati
et al. (2004)
Chennai,
India. LI
ICD 9
schizophrenia
(PPHS)
Duration between deﬁnite
psychosis measured by care
givers and initiation of
treatment
Base line
and one
year
PSE PPHS Good or Poor outcome
in clinical, social and
occupational
functioning
DUP less than 5 years or
less were more likely to
have a good clinical and
social outcome.
Uçok et al.
(2006)
Istanbul,
Turkey, UMI
DSM-IV for
schizophrenia
(SCID)
“The period between the ﬁrst
positive symptom of psychosis
estimated by a senior
psychiatrist and all sources of
information and initial
hospitalisation.
Initially
and at
6 months
BPRS
SAPS
SANS PAS
Percentage decrease
in BPRS.
Long or short DUP status
was not a signiﬁcant
variable predicting
outcome in multiple
linear regression
analysis.
PANSS = Positive and negative symptom scale, BPRS = Brief psychiatric rating scale, PSE = present state examination, SAPS = Scale for Assessment of Positive
Symptoms, SANS = Scale for Assessment of Negative Symptoms, SDSS = Social disability screening schedule, PPHS = psychiatric and personal history schedule,
BDQ = Brief disability questionnaire, CGI = Global Clinical Impression, GAF = Global assessment of functioning. SCAN = Schedule for clinical assessment in
neuropsychiatry, SCID = Structured Clinical Interview for DSM-IV, SCAN = Schedule for clinical assessment in neuropsychiatry, PSE = present state examination
LI = low income, LMI = lower middle income, UMI = upper middle income.
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and study weight, the latter by the inverse variance method
(Borenstein et al., 2005).
The studies employed different measures of outcome over
varying periods of time. Raw data and the results of univariate
associations between DUP and outcome and symptoms were
used in the meta analysis. Hence, no correction was made for
possible confounding variables such as the length of DUP and
possible association between DUP and gender (Large and
Nielssen 2008a).
Heterogeneity was assessed with Q-value and I2 for each
analysis. The between study variance cannot be estimated
with precision in meta analysis of a small number of studies
(Cooper and Hedges, 1994). A ﬁxed model is reported for
meta analysis of four or fewer samples. The choice of random
effects model in the analysis of the degree of reduction in total
symptoms scores from baseline after treatment, reported in
ﬁve studies, was made on the basis of a ﬁnding of statistically
signiﬁcant between-study heterogeneity.
3. Results
3.1. Characteristics of studies
Eleven studies conducted in LAMI countries reported an
association between DUP and at least one of the following:
the degree if reduction in total symptoms scores, measures of
disability, the level of positive or negative symptoms,
cognitive impairment or mortality (Table 1).
The methods and the quality aspects of the studies are
shown inTables 1 and 2. All the studieswere prospective in the
sense that the DUP was measured at the time of presentation.
One study had a sample size of less than 50 (Galinska et al.,
2005), and one study had a dropout rate of more than 20%
(Alptekin et al., 2005). All studies reported diagnoses using
DSM or ICD diagnostic criteria, conﬁrmed by a recognized
diagnostic interview in six of the studies. All the studies used
corroborative information to measure DUP but none of the
studies used a purpose designed structured interview to asses
the length of DUP. One study included ameasure of inter-rater
agreement about DUP (Apiquian et al., 2002). The studies
reported a total of 1538 subjects of whom88%were diagnosed
with schizophrenia (Table 3).
The association between DUP and measures of symptoms,
disability and mortality was reported in variety of formats
including odds ratios (Lieberman et al., 2003), relative risk
(Kurihara et al., 2006), chi-square statistics for dichotomized
groups (Apiquian et al., 2002; Tirupati et al., 2004), means and
standard deviations in long and short DUP groups (Galinska
et al., 2005; Oosthuizen et al., 2005; Uçok et al., 2006), or as a
correlation coefﬁcient (Alptekin et al., 2005; Apiquian et al.,
2002;Ayres et al., 2007;Oosthuizen et al., 2005; Ranet al., 2003,
2007; Thirthalli et al., 2005). The most frequently reported
measure of the associations with DUP was a correlation. Hence
the results of the meta analysis are reported in this format. Of
the ﬁve studies that reported reduction in symptoms from
baseline after treatmentonlyone study (Lieberman et al., 2003)
used an ANCOVA to take account of the possibility of the effects
of regression to the mean (Vickers and Altman, 2001).
3.2. Association between reduction in total symptom scores and
DUP after treatment
Five studies reported the extent of the reduction in
symptoms from baseline at presentation after a period of
treatment using established instruments (BPRS inLieberman
et al., 2003, Uçok et al., 2006; PANSS inApiquián-Guitart et al.,
2006; Oosthuizen et al., 2005; Thirthalli et al., 2005). All ﬁve
studies reported that patients with a longer DUP had a smaller
reduction in symptom scores after treatment when compared
to patients with shorter DUP who had greater reductions in
symptom scores. The ﬁve studies had a statistically hetero-
geneous effect sizes (Q-value 25.2, p=0.000, I2=84.01).
Hence a random effects model was used. The pooled estimate
indicated that longer DUPwas negatively associated the degree
of reduction in symptom scores (random effects meta analysis;
r=−0.290, 95% CI=−0.483 to−0.069, z=−2.559, pb0.011,
Fig. 2).
Table 2
Assessment of the studies' quality usingMarshall et al.'s (2005) criteria.
Study N Drop out
rate %
Blind rating
used for any
measure
Measure of
inter-rater
agreement
ANCOVA
used in
analysis
Thirthalli
et al. (2005)
76 17 Yes No No
Tirupati
et al. (2004)
75 19 No No No
Alptekin
et al. (2005)
382 56 No No No
Apiquian
et al. (2002,
2006)
63 10 Yes No No
Ayres et al.
(2007)
179 5.5 No No Yes
Galinska
et al. (2005)
30 Unknown No No No
Kurihara
et al. (2006)
59 0 No No Nr
Lieberman
et al. (2003)
171 5.2 Yes No Yes
Oosthuizen
et al. (2005)
57 15.7 No Yes No
Ran et al.
(2001, 2003)
510 2 No Yes No
Uçok et al.
(2006)
79 0 No Yes No
NR = not relevant.
Table 3
DUP, diagnostic and demographic variables in the LAMI groups.
LAMI country group
LI LMI UMI• Total
No. of samples 4 5 6 14
No. of subjects 626† 389 523 1538
mean age of onset (weighted) 29.8# 28.9 25.6 28.2
Percentage with male gender 54.4 49.0 55.9 55.6
Percentage with schizophrenia 92.8 69.4 95.5 87.85
†Only 354 of 510 subjects in Ran et al. (2001, 2003) ever received treatment.
•Uçok et al. (2006) not included as the same subjects were included in
Alptekin et al. (2005).
# Age in study by Tirupati [14] taken from McCreadie [25].
LI = low income. LMI = low middle income. UMI = upper middle income.
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3.3. Association between DUP and disability after treatment
A study from Turkey found that DUP was signiﬁcantly
associated with social disability as measured by the brief
disability questionnaire (Alptekin et al., 2005) and a study from
rural China reported that 35%of patientswith aDUPof less than
a year had a complete symptomatic and social remission, in
while 7% with a DUP of greater than a year (Ran et al., 2003).
The results of these two large studies were similar to two
smaller studies. A study from Mexico reported that patients
with a DUP of less than 27 months were signiﬁcantly more
likely to make a good social and occupational recovery
(Apiquián-Guitart et al., 2006) and study from southern India
that found a trend towards an improved social and occupational
outcome inpatientswith a shorterDUP (Tirupati et al., 2004). A
pooled estimate of these diverse outcome measures found a
signiﬁcant association between longer DUP and a greater level
of disability (ﬁxed effects meta analysis; r=0.195, 95%
CI=0.126 to 0.262, z=5.498, pb0.000; heterogeneity Q-value
1.245, p=NS, I2=0.00 Fig. 3).
3.4. Association between DUP, symptoms and cognitive function
at baseline
Four studies reported the association between DUP and
positive symptom scores at baseline (Apiquián-Guitart et al.,
2006; Galinska et al., 2005; Oosthuizen et al., 2005; Uçok et al.,
2006). Meta-analysis of these studies found a negative associa-
tionbetweenDUPand thepositive symptoms(ﬁxedeffectsmeta
analysis; r=−0.152, 95% CI=−0.280 to − 0.02, z=−2.248,
pb0.025; heterogeneity Q-value 1.25, p=NS, I2=0.00, Fig. 4).
Three studies reported the association between long DUP
andnegative symptoms (Galinska et al., 2005;Oosthuizen et al.,
2005; Uçok et al., 2006). Longer DUP was not associated with
the extent of negative symptoms at baseline (ﬁxed effects meta
analysis; r=0.057, 95% CI=−0.0101 to 0.211, z=0.705,
pb0.048; heterogeneity Q-value 1.01, p=NS, I2=0.00 Fig. 5).
Studies fromBrazil (Ayres et al., 2007) and Poland (Galinska
et al., 2005) examined the effects of DUP on cognitive function
at baseline. Neither study found an association between DUP
and cognitive abilities. There was insufﬁcient data for a meta
analysis of cognitive function.
3.5. Mortality
Kurihara et al. (2006) reported on the mortality of 59
consecutive ﬁrst episode psychosis patients in Bali who were
followed up after eleven years. Patients with a DUP of longer
than one year had 6.7 times themortality of thosewith DUP of
less than 12 months. Ran et al. (2007) also found that the
mortality of patients with a long DUP was signiﬁcantly higher
than thosewho received treatment earlier, although long DUP
was also associated with inadequate later treatment. Only a
small proportion of patients received ongoing treatment and
Fig. 2. Meta analysis of the association between DUP and reduction in total symptoms. Correlations inverted such that a relationship between longer DUP and a
poorer outcome are expressed as a positive value, and are represented by studies on the right.
Fig. 3. Meta analysis of the association between DUP and disability.
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a deﬁnite association between DUP and mortality could not
be inferred.
4. Discussion
The main ﬁnding of this study is that, after controlling for
symptoms at baseline by measuring the degree of reduction in
symptoms score after treatment, a longer period of DUP was
associated with a poorer response to treatment in all of the
ﬁve relevant studies from LAMI regions and by meta analysis.
Hence there appears to be a similar association between long
DUP and a poor response to treatment in LAMI countries to
that found in HI countries.
We also found evidence of an association between long
DUP and subsequent disability, although the available data
did not allow us to control for levels of disability at the time
of presentation. Hence, we could not exclude a possibility
that both the poor prognosis and the long DUP might have
been due to a higher level of disability in the pre-morbid
period.
The ﬁndings of a negative correlation between positive
symptoms and DUP and the absence of an association
between DUP and negative symptoms are of interest, but
should be interpreted cautiously. Positive symptoms might
hasten treatment and negative symptoms might delay the
treatment of some individuals.
The main limitation of this study is the small number of
relevant studies from LAMI countries, which is likely to be
common to other reviews of other reviews of psychiatric
research in LAMI countries (Patel and Sumathipala, 2001). A
consequence of the lack of data was that we elected not to
exclude studies according to strict quality criteria, in keeping
with other reviews of research in LAMI regions (seeMirza and
Jenkins, 2004). The studies were all relatively recent and
employed adequate methodology, but none of the studies
employed optimal methods. Perhaps the most signiﬁcant
limitationwas that none of the studies used a semi-structured
interview to measure DUP. Although the use of semi
structured instruments do not contribute to the between
study heterogeneity of mean DUP in reported studies (Large
et al., 2008b) the main independent variable (DUP) may not
have been accurately recorded in all cases.
With these limitations, themain implication of this study is
that long DUP has a similar effect in LAMI countries as it has in
HI countries. Studies in HI countries have not yet conclusively
established that prolonged DUP is the cause of a poor outcome
found to be associated with prolonged treatment delay.
However, if it is accepted that long DUP is a cause of poor
outcome in HI countries, this study suggests it is likely to have
similar adverse effects in LAMI countries.
Based on the studies included in this review it is not
possible to rule out the possibility that factors such as an
insidious onset contributed both to poor outcome and a
longer DUP. Conversely, patients with mild forms of illness
might have delayed treatment in countries where there is
little available care, lessening the observed association
between DUP and outcome. Outliers with an extremely long
DUP that skew the distribution of DUP might be more
common in studies from LAMI countries. However, the
studies included in this review used appropriate methods
such as non-parametric statistics and log transformation in
order to minimize the potential for results that were unduly
inﬂuenced by a minority of subjects with long DUP (Large
et al., 2008b). Furthermore, in HI countries the association
between DUP and outcome appears to be independent of the
degree of skew in DUP distributions and other variables
(Marshall et al., 2005; Perkins et al., 2005). This is probably
the case in LAMI countries as well.
One study examined the relationship between DUP and
subsequent mortality (Kurihara et al., 2006), while a second
found that the risk of death of patients who had received even
minimal treatment was signiﬁcantly lower than those who
received no treatment (Ran et al., 2007). The main reason for
the premature death of subjects in the studies from China and
Bali was untreated medical illness. Hence the beneﬁcial effects
of psychiatric treatment could be even greater in LAMI
countries than in HI regions because untreated patients may
have difﬁculty obtaining life saving medical care in LAMI
countries.
Our ﬁndings are consistent with the conclusions reached
by Cohen et al. in a comprehensive review of evidence on
outcome of schizophrenia in developing countries i.e. lack of
proper biomedical treatment is associated with relatively
poor outcomes in schizophrenia irrespective of the income or
cultural status of the setting. This is more evident in present
review as we studied outcome in relation to well deﬁned
income categories instead of a broad category of ‘developing
countries’. Despite considerable heterogeneity within the
LAMI group of countries the outcome seems to be universally
poor when DUP is long.
Fig. 4. Meta analysis of the association between DUP and positive symptoms at presentation.
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A long DUP in high-income countries has been attributed
to the gradual onset of the illness, the lack of understanding of
the reason for the morbid change by the patient's family, the
patient's own lack of insight and the effect of some mental
health laws (Large et al., 2008c). In many LAMI countries the
reasons for long DUP include the absence of mental health
services and the cost of treatment (Large et al., 2008).
DUP has now a well established association with poor
outcome of psychosis but methodologically sound studies in
LAMI countries are still sparse. There is urgent need to conduct
methodologically sound studies particularly those, which try
to establish the effect of treatment in relation to outcome and
DUP in a LAMI country. Putative protective factors, including
family support, that may sometimes be responsible for better
course of schizophrenia should also be investigated as it
appears that these factors, if any, have limited protective
inﬂuence during the long period of untreated illness.
5. Conclusions
Lack of treatment for psychotic illness early in the course
appears to be associated with relatively poor outcomes,
irrespective of the income or cultural status of the setting. It
is time that early intervention services for psychosis are
planned for LAMI countries as they have been in HI countries.
The ﬁndings of this review, and the related study (Large et al.,
2008) support the recommendation to supply subsidized
antipsychotic medication for at least the ﬁrst two years of
psychotic illness as a way of reducing DUP in developing
countries (Patel et al., 2007). Providing very low or no cost
psychiatric care in the same setting as other forms of primary
health care has been effective in reducing DUP in Zambia
(Mbewe et al., 2006) and may be a model that could be
adopted elsewhere to reduce DUP.
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THE CHALLENGE
It is ironic that while the early intervention for psy-
chosis is a major priority in high income countries, the
mental health professionals in the LAMICs face an en-
tirely different challenge; to provide some treatment for
those suffering from psychosis.
More than half of these countries have either no or
less than 1% of health budget for mental health and the
treatment gap for psychiatric disorders is close to 90%.
Most individuals are, therefore left to cope with severe
mental illness on their own1. Consequently, there is high
untreated prevalence of schizophrenia in the form of
undetected as well as inadequately and partially treated
cases. While it may be difficult to reach for the undetec-
ted cases, the present level of untreated cases in pa-
tients who have had some contact with mental health
services represents a catastrophic failure of mental
health policy and services in these countries.  In this
article, we will argue that a public health intervention
based on the principles of DOTS could be an effective
strategy for coping with schizophrenia in these coun-
tries.
WHAT IS DOTS?
A single case of tuberculosis can spread the dis-
ease to 10-15 persons on average2. DOTS (Directly Ob-
served Treatment, Short course) was devised as a re-
sponse to the public health challenge of non-adherence
and maintaining long term treatment for tuberculosis.
DOTS has the following essential components. (For
the discussion of all the five components of DOTS and
its implementation see WHO, 1999)2.
(a) A regular uninterrupted supply of all essential Anti
TB drugs backed by governments’ commitment to
sustained TB control activities.
(b) Standardized treatment regimen of six to eight
months chemotherapy under supervision.  In many
LAMICs the role of DOTS supervisor is assigned
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to a family or a community member who regularly
administers the drugs under close monitoring by
a health worker.
The World Bank considers DOTS to be one of the
most cost effective health interventions. DOTS are more
cost effective than self-administered treatment3, 4.
Supervised treatment for schizophrenia in commu-
nity - What is the theoretical rationale?
We believe that there is urgent need for a public
health intervention based on the principle of DOTS in
developing countries in view of the following:
1. The longer duration of untreated schizophrenia
is associated with very serious Public health
consequences.
The enormous public health consequences of long
duration of untreated psychosis is well documented in
context of literature on duration of untreated psychosis5.
These include increased co-morbid substance abuse,
suicide, increased treatment resistance, impairment in
cognitive and neuropsychological functions, offending
behavior, vocational failure and overall poor outcome.
The medication status is also the strongest predictor of
relapse; discontinuation of medication increases the
relapse risk five folds6.
2. The cost effective interventions for schizophre-
nia are available.
Out of 20 recommendations for optimal treatment
suggested by Schizophrenia Patient Outcome Research
Team (PORT), 14 relate to pharmacological interven-
tions. These were also rated to be highest on the ease
for implementation7. These can be implemented in
LAMICs provided essential drugs are made available. It
has been argued that such an optimal treatment can at
least avert 22% of burden of schizophrenia in devel-
oped countries8. In LAMICs where the treatment gap is
very wide a much greater burden of illness could be
averted by optimal pharmacological treatment.
3. Patients suffering from Schizophrenia need su-
pervision and it is possible.
About 59% of patients may fail to adhere to their
treatment in case of schizophrenia9 which unlike TB, is
also complicated by impaired insight and cognitive func-
tioning. Supervision by the family members is therefore
of critical importance if the therapy is to succeed.
One of the essential ingredients of DOTS i.e. moni-
toring the drug compliance by observing and recording
the correct medication has also been described in a
number of interventions aimed at improving treatment
adherence in the treatment of schizophrenia10-12. A re-
view of interventions to improve medication adherence
in schizophrenia found that relatively brief interventions
(both in terms of duration and frequency) which targeted
the behaviors related to medication adherence were
more effective than longer interventions with broader
focus on psycho education13.
4. We owe it to the family.
In LAMICs the family has largely ‘subsidized’ the
treatment of schizophrenia for the society and the state
at large by providing the social, psychological, residen-
tial and occupational support which constitute the major
proportion of the cost of treatment for this disorder. Pro-
vision of free drugs to these patients as a part of DOTS
programme would only help to share this burden in a
small but very significant way.
5. A strategy for communicable illness for a non
communicable disorder?
It could be argued that a strategy adopted for an
infections disorder is unlikely to succeed for a non com-
municable disease, which runs a much longer course. It
must, however be realized that the core problems in
both the disorders is the lack of adherence and continu-
ity of the treatment which results in a spiraling costs  and
a vicious cycle of chronicity and increasingly poor re-
sponse to the well established treatments. Providing free
access to the treatment and supervision by the family
member should significantly reduce these problems.
From DOTS to STOPS (Supervised Treatment in Out
Patients for Schizophrenia)?
Based on the rationale described above we started
a small pilot project which incorporates the principles of
DOTS. This is termed as Supervised Treatment in Out
Patients for Schizophrenia (STOPS). This is a
programme which aims to stop preventable relapses in
schizophrenia through:
a. Provision of free psychotropic medication.
b. Training relatives in supervision of administration
of medication to improve patient adherence with
the drugs as well as training relatives in the iden-
tification of early signs of a relapse.
EVALUATION OF STOPS - A PILOT
PROJECT
We started a pilot project based on principles of
STOPS in Lady Reading Hospital, Peshawar. The pa-
tients suffering from Schizophrenia and schizoaffective
disorder were recruited and we trained the on of the
close relatives, termed Key Care Giver to supervise the
medication adherence. We assessed the outcome with
Global assessment of Functioning14 and compliance with
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the help of a structured questionnaire at baseline and
follow up appointments. Ninety two patients were en-
rolled in this pilot project. As this was a pilot project we
recruited all the patients irrespective of duration of ill-
ness. The mean duration of illness in these patients was
56.40 years (SD=60.69).
We developed a standard regimen for treating
schizophrenia which was administered by under the
close supervision of a relative. The patients were re-
quired to collect the medication monthly when treatment
adherence and improvement was also assessed.
At one year follow up the mean GAF for the group
was 61.43 (SD = 23.76) compared to 41.46 (SD = 28.84)
at baseline. 70.7% had complete compliance with the
treatment compared to 42.3% at baseline (Further de-
tails available from authors on request). The most en-
couraging aspect was that a number of patients started
working early in the programme after some improve-
ment thus actively supporting their families, instead of
being burdens on them.
The average drugs cost per month for a case of
schizophrenia with was RS.127 (1 US Dollar= Rs.86)
with conventional anti-psychotics. For those patients
receiving  atypical anti-psychotics using the most eco-
nomical local brand of Risperidone available in Paki-
stan the same cost was about three times this figure.
Considering that in schizophrenia there are no addi-
tional costs of laboratory investigations and radiogra-
phy used for T.B control activities, this compares quite
favorably with six to eight months treatment of Tubercu-
losis in DOTS programme which ranges from Rs.1350 to
3130, depending upon the type and combination of drugs
used. Encouraged by this success we commenced a
Randomized Controlled Trial to evaluate the effective-
ness of STOPS versus Treatment As Usual (TAU). The
trial is registered at Trails.Gov, the one of the registers
for RCTs and further details are available at
www.clincaltrials.gov.
CONCLUSIONS AND FUTURE DIRECTIONS
It is suggested that those suffering from schizo-
phrenia in the LAMICs could at least be supplied phar-
macotherapy for two years under close supervision, if
not for the whole duration of illness. This will help to
overcome the non adherence for a period of illness which
has been shown to be the strongest predictor of long
term outcome and disability15.
Three tasks need urgent action:
a) A global fund to generate the resources for pro-
viding free access to antipsychotic drugs should
to be created.
b) Simple, brief and cost effective strategies for en-
hancing medication adherence which can be used
by the caregivers in the LAMICs need to be devel-
oped.
c) Small scale programmes based on the DOTS
model should be developed locally in LAMICs in
collaboration with international organizations be-
fore we can expect the governments to support
the same. Insulin Demonstration Projects which
has been initiated to improve the access to the
Insulin by the IDF Task Force can provide good
models for this16.
Free access to the treatment has been provided
not only for disorders like TB but also for many non com-
municable disorders in other disciplines. In Diabetes
Mellitus, for example, at least 67 states around the world
including many in LAMICs are providing state subsidies
for the Insulin17.  A community based intervention based
on the principles of DOTS for a relatively low prevalence
disorder like Schizophrenia could also help to put the
mental health strongly on the agenda of public health.
Unlike non-multi drug resistant tuberculosis, treat-
ment for schizophrenia would be needed for much
longer period and “cure” would not be achieved in the
strictest sense. Nor is there incentive to address
the schizophrenia because a sufferer is not infectious
to those around him or her.  However, maintaining
regular treatment in up to 2/3rd of cases for the critical
two years period would not be a mean achievement.
The improved access to treatment as a public health
intervention will also lead to better awareness and early
help seeking for the cases which at present represent
the large untreated prevalence. Most importantly,
perhaps it can also help to reduce the stigma for the
disorder as effectively as the advent and effective
implementation of anti tuberculosis treatment did for
tuberculosis.
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One of the most significant  recent developments
in treatment of schizophrenia has been the early inter-
vention for psychosis. Unacceptably long duration of
untreated psychosis (DUP) has been considered as a
major challenge for psychiatric services. The studies
from developing countries report a DUP almost twice as
long as that in developed countries; thus necessitating
an action for early intervention1. An even more alarming
trend reported in many studies is large number of cases
which remain untreated for many years, often in inhu-
man condition. Malik and Bokharey2  reported what they
described as ‘human zoo’ for a group of patients which
according to authors provided ‘cure’  for patients suffer-
ing from schizophrenia  “ chained to the trees in the open
spaces around the shrine— through the chilly winter
nights and the blazing heat of summers for days, months
and at times for years”.
Souza et al3 identified 49 patients only in two
months period in Darfur region of Sudan by active case
findings. Some patients were in such dramatic situa-
tions as being chained to their beds. Srinavasan et al4
describe a cohort of 72 never-treated chronic schizo-
phrenia patents in Chennai, India. Similar untreated
cohorts are rported from china and number of other
devloping countries.
Almost all these studies report serious effects in
term of psychological, physical and social outcomes. A
common problem is high mortality. In  rural China where
very few patients received adequate treatment, untreated
patients were found to have marked social and occupa-
tional disability and a fourfold increase in mortality5,6.The
high mortality reported in these studies is not due to
suicide, the commonest cause of higher mortality in
schizophrenia but due to malnutrition, infectious disease
and other physical causes.
Ironically, number of these studies have focused
on these patients as ‘interesting’ cases, in which details
and manifestations of a chronic mental illness are ex-
amined in microscopic details without much attention to
the challenges these cases pose for the service provi-
sion. Few isolated programmes have tried to address
the need for provision of some treatment for these pa-
tients2. However there is need for more systematic and
coherent approach in addressing the large gap in treat-
ment these populations pose.
Lack of treatment for many years in patients suffer-
ing from Schizophrenia is related to many factors and
there is little evidence for effective interventions to ad-
dress this issue. Srinivasan et al4 found that unemployed
status of male patients, living in a joint family setting and
families initially unaware of the psychiatric nature of the
problem were the factors that related to failure to seek
treatment. Patient’s sex, age, education, marital status,
economic status, age at onset and duration of illness,
degree of disability and clinical symptoms (except self-
neglect) were not related to taking treatment.
Cost of treatment is an important barrier. Medi-
cines account for 20–60% of health spending in devel-
oping and transitional countries,7 compared with 18% in
countries of the Organisation for Economic Co-opera-
tion and Development8. Up to 90% of the population in
developing countries purchase medicines through out-
of-pocket payments,3 making medicines the largest fam-
ily expenditure item after food. People with severe men-
tal illness who have increased difficulty obtaining food,
shelter and medical care9.  are most vulnerable to these
effects.
There is urgent need to devise effective public
health interventions to improve the access to the phar-
macological treatment for those suffering from Schizo-
phrenia in developing countries. Isolated programmes
in many countries have shown that it is possible to pro-
vide standardized regimen of antipsychotic treatment.
However these programmes have rarely been replicated
outside model programmes. An article in this issue10
describes such an approach. It is interesting to note that
the approach  described in this article is based on prin-
ciples of DOTS, an intervention originally proposed for
Tuberculosis. Although TB has nothing in common with
schizophrenia two disorders share some rather inter-
esting historic facts. Tuberculosis is perhaps the only
physical disorder which needed treatment in institutions
like schizophrenia .The stigma associated with TB has
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been bad as we have today for Schizophrenia. How-
ever, implementation of an effective treatment at public
health level changed the situation dramatically for Tu-
berculosis. The success story of Tuberculosis  demon-
strates that an effective interventions applied optimally
at the public health level is the most effective way of
reducing the stigma. Interestingly, since  DOTS like treat-
ment approach was suggested for Schizophrenia, it  has
been advocated for other Non Communicable Disease
as well to overcome the problem of poor access to the
treatment. At present it seems that any intervention for
psychosis is the early intervention for this serious disor-
der in Low and Middle Income Countries (LAMIC). It is
now time that early intervention for psychosis is consid-
ered as major public health priority in developing coun-
tries.
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Background to the debate: Schizophrenia affects an estimated 25 million people in low- and middle-income 
countries, with an average lifetime risk of about 1%. The 
illness is associated with excess mortality from a variety 
of causes. A 2001 Institute of Medicine report on mental 
illness in developing countries found that in 1990, over 
two-thirds of people with schizophrenia in these countries 
were not receiving any treatment (http://www.nap.edu/
catalog/10111.html). The report found no evidence that the 
proportion of treated people in the developing world had 
increased since 1990. There is now a debate among mental 
health professionals in low-income countries over how best 
to improve patient care. In this article, three psychiatrists 
give their different viewpoints on the current status of 
treatment efforts for schizophrenia in the developing 
world and the measures that can be taken to increase the 
proportion of patients receiving treatment.
Vikram Patel’s Viewpoint: Non-Specialist 
Community Health Workers Should 
Play a Key Role in Delivering Care
Although schizophrenia is relatively rare, it is also arguably 
the most severe mental disorder. In many individuals, the 
disorder runs a chronic and relapsing course, leading to 
progressively worsening disability, loss of livelihoods and 
social networks, and increased risk of discrimination and 
human rights abuse. To consider what might be the best 
approach for treating schizophrenia in low- and middle-
income countries (LAMIC), we must ﬁ rst address three 
questions: What is the burden of this disorder? What are the 
resources available for care? And what is the evidence base for 
the treatment of this disorder in LAMIC?
Assuming that the point prevalence of schizophrenia in 
LAMIC is the median ﬁ gure reported in a recent systematic 
review—4.6 per 1,000 population [1]—and that the 
population of LAMIC is 5.3 billion [2], then about 25 million 
people with schizophrenia live in LAMIC. The health systems 
of LAMIC are woefully unprepared to address the myriad 
health and social needs of people with schizophrenia; in most 
parts of LAMIC, there is less than one qualiﬁ ed mental health 
professional for half a million to a million people [3] (which 
will include about 2,500 to 5,000 people with schizophrenia). 
Therefore most people with schizophrenia in LAMIC 
probably receive little or no formal care.
What impact does this lack of care have on patients’ lives? 
A recent household study from Mozambique reported that up 
to half of the patients with psychotic disorders were reported 
by key informants in their households to be currently in poor 
health [4]. Traditional medicine was by far the most common 
type of health care accessed. Lack of services contributes to 
delayed treatment, which in turn leads to poorer long-term 
outcomes [5], higher direct and indirect costs of treatment 
with antipsychotic drugs [6], and increasing mortality [7–9].
Thus, the lack of evidence-based care, exacerbated by rapid 
changes in social and economic conditions in less developed 
countries that compromise the ability of informal systems to 
care for people with schizophrenia [9], represents a looming 
mental health crisis in these countries. Despite these scarce 
resources, there is now growing evidence that antipsychotic 
drugs and community-based, family-focused interventions are 
effective treatments in LAMIC [10]. The latter help reduce 
stigma, improve adherence to medication, and strengthen 
social integration.
How can these treatments be delivered in low-resource 
settings? The most appropriate model of care is a community-
based program that is affordable, feasible, acceptable, and 
evidence based. Who are the key health professionals needed 
to deliver such a model? Given the scarce specialist resources in 
LAMIC, the lion’s share of the service delivery would need to be 
the responsibility of non-specialist health workers. Indeed, the 
front line of the community mental health-care system need not 
even be represented by health workers at all, but may be made 
up of people who live in the community and are trained to 
provide a range of family- and community-based interventions.
Such care models are now being implemented by a number 
of community-based organizations such as Basic Needs (a 
mental health non-governmental organization operating in 
a number of developing countries and based in the United 
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Kingdom), and have been shown in quasi-experimental 
designs to be superior to simple outpatient care on clinical 
and functional outcomes [11]. These programs still require a 
health practitioner—who could be an appropriately trained 
physician or nurse practitioner—with sufﬁ cient skills in 
diagnosis and drug treatment. The role of specialists may 
need to be carefully redeﬁ ned; where available, outreach 
services provided by specialists in collaboration with local non-
governmental organizations are a clinically effective and cost-
effective approach that produces signiﬁ cant improvements 
in functioning and decreased burden on the family [12]. In 
many places, however, the most feasible role for specialists 
might be to design programs, build capacity of non-specialist 
health workers, and supervise the quality of care delivered.
The ﬁ rst step in a population-based model must be to 
improve awareness about the disorder and the service. The 
community mental health worker needs to establish close 
networks with members of grass-root, health service, and 
social welfare organizations. Next, the community mental 
health worker must identify probable cases of schizophrenia, 
preferably as early as possible after the onset of the disorder. 
The ideal model for case identiﬁ cation is likely to be through 
the use of key informants (individuals who are familiar with 
the health status of members of the community they live in), 
a cost-effective method for identifying mental disorders in 
LAMIC [13]. Then the skilled health practitioner should 
make the diagnosis and initiate drug treatment. Health 
practitioners must also play close attention to the physical 
health needs of their patients, given that physical health 
problems are common in people with schizophrenia and are 
often neglected, contributing to higher mortality [14]. Health 
practitioners should also have access to an inpatient unit for 
the short-term care of patients who are acutely disturbed.
After this predominantly clinical phase, the focus of care 
shifts back to the community, involving three strategies: 
(1) Strengthening opportunities for paid employment; (2) 
building individual and family capacity to cope with the 
disorder (e.g., to support medication adherence); and (3) 
ensuring that the costs of long-term care are at least partly 
borne by an equitable ﬁ nancing system, such as a voucher 
system, insurance plan, or ﬁ xed monthly payments. The role 
of the community worker may extend to care for people 
with other severe neuropsychiatric disorders, such as mental 
retardation and epilepsy, which share many characteristics 
with schizophrenia (e.g., chronicity, disability, stigma, and 
loss of livelihood), and are also more likely to occur together. 
Community-based residential care will still be needed for the 
few individuals who are severely disabled and cannot continue 
to live either independently or with their families.
The model that I have outlined is not a pipe dream. It 
is an affordable prescription for a commitment to ensure 
that people with schizophrenia receive the basic minimum 
package of evidence-based care in LAMIC, care that meets 
their human rights.
Saeed Farooq’s Viewpoint: Directly Observed 
Therapy (DOTS) Is an Approach Worth Testing
In developing countries, treatment for schizophrenia 
is limited mostly to acute episodes and seldom involves 
primary care physicians. Developing countries typically 
spend less than 1% of their health budget on mental health 
[15], and one of the consequences of this under-spending 
is a high prevalence of untreated schizophrenia in the form 
of undetected as well as inadequately and partially treated 
cases. In Bihar, one poor state in India, there are more 
people suffering from schizophrenia than in the whole of 
North America [16]. The high prevalence in developing 
countries is partly explained by the predominantly younger 
population of the developing world (schizophrenia is a 
disease of young adults).
One approach to tackling the burden of untreated 
schizophrenia in low-income countries that may prove 
effective is directly observed therapy. This approach is the 
cornerstone of current global efforts to tackle tuberculosis 
(TB). Successful TB treatment, and the prevention of multi-
drug resistant TB, requires long-term therapy and high 
adherence rates. The internationally recommended TB 
strategy known as DOTS (Directly Observed Therapy, Short-
Course) [17] has two essential components: (1) a regular 
uninterrupted supply of a standardized treatment regimen of 
six to eight months chemotherapy, and (2) its administration 
under the supervision of a health worker or trained close 
relative who watches and records the patient swallowing the 
correct dose of drugs. A discussion of all ﬁ ve components of 
DOTS and its implementation is found in [17].
The DOTS strategy has led to remarkable improvements 
in TB control in many developing countries [18,19]. The 
World Bank considers DOTS to be one of the most cost-
effective health interventions, more cost-effective than 
self-administered treatment [20,21]. I would argue that the 
principles underlying the DOTS strategy could form the basis 
for an effective public health intervention to cope with the 
burden of schizophrenia in developing countries.
Providing a regular supply of antipsychotic medication 
and supervising its administration may be one mechanism 
for addressing the enormous public health burden of long-
term untreated psychosis in developing countries. This 
burden includes increased co-morbid substance abuse, 
suicide, treatment resistance, impaired cognitive and 
neuropsychological function, offending behavior, vocational 
failure, and overall poor outcome [22]. In addition, 
the strongest predictor of relapse is discontinuation of 
medication, which increases the relapse risk 5-fold [23]. 
Even a very short break from taking medication (just one to 
ten days over a one-year period) is signiﬁ cantly associated 
with increased risk of hospitalization (odds ratio 1.98, 95%, 
conﬁ dence interval 1.27–3.25) [24].
Long-term antipsychotic medication for treating 
schizophrenia in developing countries is a cost-effective 
intervention. Out of 20 recommendations for optimal 
treatment suggested by the Schizophrenia Patient Outcome 
Research Team, a research team funded by the US National 
Institute of Mental Health, 14 were related to pharmacological 
interventions [25]. These interventions were also rated 
highest on ease of implementation and can be implemented 
in developing countries, provided access to the drugs is 
ensured through a programme akin to DOTS. The cost of 
antipsychotic medication, including recent atypical drugs, is 
surprisingly very low in many developing countries [16].
We surely owe it to the families of patients with 
schizophrenia in poor countries to provide free drugs. The 
families have largely subsidized schizophrenia treatment 
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for society and the state at large by providing the social, 
psychological, residential, and occupational support that 
constitutes the major proportion of the cost of treatment 
for this disorder. Provision of free drugs to these patients as 
a part of “DOTS-type” programme would help to share this 
burden in a small but very signiﬁ cant way.
Drug treatment for schizophrenia is likely to be more 
effective if its administration is supervised. Such a system of 
supervision is feasible in low-income settings in view of the 
family’s integral involvement in the patient’s care. About 
60% of patients with schizophrenia may fail to adhere to their 
treatment [26], in part because the disease itself leads to 
impaired insight and cognitive functioning. Approaches that 
are broadly similar to DOTS, entrusting the monitoring of 
drug compliance to a relative, have been found to be effective 
in improving treatment adherence for schizophrenia in 
developing countries [27,28,11].
I suggest that patients with schizophrenia in the developing 
world be supplied free access to drugs for two years under 
close supervision. This will help to overcome non-adherence 
during the period of the illness (i.e., the ﬁ rst two years) that 
has been shown to be the strongest predictor of long-term 
outcome and disability [29]. Indeed, a recent systematic 
review of interventions to address non-adherence in 
people with schizophrenia also recommended that clinical 
interventions targeting non-adherence should continue for 
at least 18 months [30]. In our pilot project, we found that 
a supervised treatment approach was associated with greater 
adherence rates. Encouraged by this ﬁ nding, we have started 
a randomized controlled trial of “Supervised Treatment 
of Outpatient Schizophrenia (STOPS)” to evaluate its 
effectiveness versus usual care (further details available from 
author on request and at http://www.clinicaltrials.gov/ct/
show/NCT00392249?order=1).
Would direct observation of schizophrenia treatment be 
overly coercive? In view of the wide treatment gap, there will 
always be a large population of those with schizophrenia who 
will be willing to take treatment under supervision, and they 
must be provided with effective interventions. Moreover, in 
view of the present poor state of mental health legislation 
in many developing countries, patients with untreated 
schizophrenia are likely to suffer from much greater human 
rights abuses than those who are treated.
Effective treatments for schizophrenia have neither 
been applied optimally nor advocated as public health 
interventions in developing countries. A public health 
intervention for schizophrenia modeled on DOTS may lead 
to greater awareness of the beneﬁ ts of treatment and may 
encourage untreated patients to seek help earlier in the 
course of their illness. Promoting awareness of the beneﬁ ts of 
treatments may help to reduce the stigma of schizophrenia, 
just as the advent and effective implementation of anti-
tuberculosis treatment did for TB. A community intervention 
for schizophrenia based on the principles of DOTS could 
also help to put mental health strongly on the public health 
agenda.
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R. Thara’s Viewpoint: We Must Tackle Stigma 
by Offering Proven Treatments
The incidence and prevalence of schizophrenia does 
not vary widely enough across the world to merit markedly 
different local treatment approaches or programmes [1,31]. 
However, the reality is that there are widespread differences 
in the treatment that people with schizophrenia receive in 
different parts of the world. Understanding the reasons for 
these differences is the key to improving the care of people 
with schizophrenia in developing countries, including India, 
where I work.
An important reason underscoring these differences is that 
many developing countries have far too few mental health 
professionals [3], reﬂ ecting the very low priority accorded 
to mental health by many governments. In many low-income 
countries, there is an urgent need to improve and expand 
mental health services.
Community care in India is almost synonymous with family 
care. There are no organized community-based programmes 
for people with chronic mental illness. The commonest 
site of treatment is the mental hospital, many of which are 
large and isolated, with little contact with the community 
they serve. Efforts are under way to improve the conditions 
of many of these hospitals. While the number of general 
hospital psychiatry beds has increased in the last decade, 
the total number is still grossly inadequate. Most private 
psychiatrists are located in urban areas. There are very few 
non-governmental organizations, and these are largely 
concentrated in the southern part of the country.
India’s National Mental Health Programme did envisage 
the diffusion of mental health skills to primary health-care 
centres at the village and district levels, and the integration of 
mental health with primary care. However, poor monitoring 
and lack of coordination with the local state governments 
meant that such diffusion and integration efforts were 
not implemented, with the exception of a few sporadic 
programmes.
In India, people with chronic mental illness do not 
generally receive any welfare beneﬁ ts, except for some minor 
beneﬁ ts in just a few areas. Medical insurance seldom covers 
treatment of mental disorders. The result is that families have 
to bear the entire costs of the treatment and ongoing care 
of these patients. A heavy ﬁ nancial, physical, and emotional 
burden is therefore imposed upon family members. Indeed, 
over 90% of patients with schizophrenia live at home with 
their families [32]. Such family involvement is not merely 
a result of close kinship ties, but is also due to inadequate 
treatment facilities. Religious and traditional modes of 
intervention are still widely practiced, especially in rural 
areas, where mental health services are almost non-existent. 
Families are equal partners in all stages of intervention, be it 
choice of a drug, detection of side effects, or early symptoms 
of relapse, ensuring compliance with medication and 
supporting the affected family member through life events 
such as jobs or marriages.
Stigma, and the presence of competing and conﬂ icting 
explanatory models of mental illness (often based on 
“magico-religious” beliefs), have also contributed to the non-
use of existing treatment facilities. A study that we conducted 
at the Schizophrenia Research Foundation in Chennai found 
that women with schizophrenia were more stigmatized than 
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men with schizophrenia, and that female caregivers were 
more sensitive to stigma than male caregivers. Being single 
or divorced compounded the problem of stigma even further 
[33]. Stigma is an all-encompassing phenomenon and a 
profound barrier to effective help seeking.
In terms of the availability of medication for treating 
schizophrenia in India, both ﬁ rst and second generation 
antipsychotics (risperidone, olanzapine, clozapine, quetiepine, 
and sulpiride) are available at fairly low prices. Both groups 
of drugs are being used as ﬁ rst-line medication. In my clinical 
experience I have found that Indian patients require a much 
lower dosage of medicines than patients in the West, in both 
the acute and maintenance phases of treatment. However, 
more research is needed to document whether there are 
indeed different dosage requirements in Indian patients and, 
if there are, to critically address the actual reasons for this 
difference. Unfortunately, a large proportion of patients in 
both rural and urban settings remain untreated [34,35]. Even 
when patients are prescribed medication, non-compliance 
during the symptomatic phase is common in India. In our 
study of patients attending an urban outpatient care center, 
we noted that when the patients were acutely ill and refused 
to take medication, in half the cases the families administered 
medication to them without the patients’ knowledge, under 
the supervision of the psychiatrist [32].
Given all of these different factors affecting the current 
management of schizophrenia, what can be done to improve 
such care? Ensuring that patients receive effective treatments 
promises to be the best antidote to stigma. When patients’ 
conditions improve, especially in the restoration of their 
social functioning, the community’s explanatory model 
of schizophrenia often shifts from a magico-religious to 
a medico-social viewpoint. The National Mental Health 
Programme will have to be scaled up to ensure that 
mental health care reaches the masses. At the same time, 
the government should plan and implement awareness 
programmes for schizophrenia all over the country, as it did 
for leprosy and tuberculosis.
Efforts will simultaneously have to be made to prevent Indian 
psychiatrists from going abroad, since their numbers have 
dwindled rapidly in the last few years. More psychiatry tuition 
in the undergraduate medical curriculum is also critical. 
Unless all these measures are implemented urgently and in a 
comprehensive manner, mental health care will continue to 
languish in the backyards of the health-care system. 
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Maintaining long-term treatment in non-communicable diseases
is a major public health challenge faced by many low- and
middle-income (LAMI) countries, where these disorders are likely
to account for more than 40% of the burden of disease by 2040.1
The situation is particularly alarming for chronic mental
disorders. In LAMI countries only 13% of people with bipolar
disorders receive treatment compared with 51% and 77% of those
with asthma and diabetes.2 With less than one qualified mental
health professional for half to one million people and about 1%
of the health budget dedicated to mental health,3 most people
with schizophrenia in LAMI countries probably receive little or
no formal care. One manifestation of this is a very long duration
of untreated psychosis (DUP) in the first episode in LAMI
countries: 125 weeks compared with 62.5 weeks reported in
high-income countries.4 This poses a major public health problem
considering that around 41.7 million people with schizophrenia
may need care in LAMI countries.5
Poverty is a major barrier to adherence to treatment in
schizophrenia in these countries.5 It is estimated that rates of
adherence to treatment 1 year after discharge from hospital are
only around 50%.6,7 The actual rate of non-adherence may be even
higher, as these estimates do not account for individuals who refuse
treatment or drop-out of follow-up studies8 and are based on studies
from health systems where drug treatment is at least partially
subsidised. Moreover, there is little evidence to suggest that newer
antipsychotics are associated with better rates of adherence
compared with first-generation antipsychotics.9 The result is high
relapse rates, spiralling costs and perpetuation of stigma.
We suggested that a framework based on the principles of
DOTS (directly observed therapy, short course), devised originally
for tuberculosis, could be used to overcome the public health
challenge of non-adherence and maintaining long-term treatment
in people with schizophrenia in resource-poor settings.10,11 The
strategy promoted by the World Health Organization as DOTS
has been the cornerstone of a policy package to provide the
complete course of treatment in tuberculosis, which is crucial to
avert the emerging challenge of highly dangerous multiple-drug-
resistant tuberculosis arising from partially treated cases.12 We
argued that the essential ingredients of the DOTS approach –
registration and recording of individuals, free access to essential
medication, and monitoring drug adherence by observing and
recording the correct medication – could be used to treat
schizophrenia in LAMI countries.
These principles of DOTS were incorporated in an inter-
vention entitled STOPS9,10 (supervised treatment in out-patients
for schizophrenia). The intervention was developed after focus
group discussions with staff involved in implementation of DOTS
in the local tuberculosis control programme in order to learn
about the principles of DOTS that could be incorporated into
the care of those with schizophrenia. Focus group discussions
were also conducted with people with schizophrenia and their
families. This revealed that the primary concerns for family
members centred on misconceptions about treatment, stigma
and supernatural beliefs about the illness. Therefore, we
incorporated psychoeducation in the intervention to address these
concerns, in addition to techniques for administering and
supervising the medication.
The rationale and details of the approach are fully described
elsewhere.9,10 Briefly, STOPS comprises the following components.
(a) Registration and recording of all people presenting with a
diagnosis of schizophrenia/schizoaffective disorder from a
geographically defined catchment area.
(b) Training a key care supervisor, identified by the patient and
usually a close relative, in administering and supervising the
medication. The key care supervisor took responsibility for
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Background
Most people with schizophrenia in low- and middle-income
(LAMI) countries receive minimal formal care, and there are
high rates of non-adherence to medication.
Aims
To evaluate the effectiveness of an intervention that involves
a family member in supervising medication administration –
supervised treatment in out-patients for schizophrenia
(STOPS) – in improving treatment adherence and clinical
outcomes.
Method
Individuals (n=110) with schizophrenia or schizoaffective
disorders were allocated to STOPS or to treatment as usual
(TAU) and followed up for 1 year. The primary outcome was
adherence to the treatment regimen. Positive and Negative
Syndrome Scale for Schizophrenia and Global Assessment
of Functioning scores were also assessed.
Results
Participants in the STOPS group had better adherence
(complete adherence: 37 (67.3%) in STOPS v. 25 (45.5%) in
TAU; P50.02) and significant improvement in symptoms and
functioning.
Conclusions
STOPS may be useful in enhancing adherence to treatment
for schizophrenia in LAMI countries.
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collecting the medicine from the health facility, administering
the correct dosage of all the medication and recording
adherence with treatment.
(c) Uninterrupted drug supplies to provide drug treatment
following a simple standardised treatment protocol. The
treatment protocol was adapted from the American Psychiatric
Association guidelines for treatment of schizophrenia.13 The
sequence of treatment was simplified to reflect the services
and resources available in a LAMI country setting. Medicines
were provided every month at the health facility. Both the
patient and the carer reported on adherence with treatment.
(d) Standardised monitoring of therapy and outcome. This
consists of adherence with the medication and assessment of
functioning using the Global Assessment of Functioning
(GAF) scale.14
The present study describes a randomised controlled trial
(RCT) aimed at testing the effectiveness of STOPS. The primary
outcome was to compare the effectiveness of STOPS in improving
adherence with a regimen of standard doses of antipsychotic
medication in participants with schizophrenia and schizoaffective
disorders compared with treatment as usual (TAU). The study
design was a two-arm prospective RCT over a 1-year period, with
masking of assessors to the status of the intervention. The trial is
registered at ClinicalTrials.gov (NCT00392249).
Method
The study protocol was approved by the Research Ethics
Committee of the Postgraduate Medical Institute, Lady Reading
Hospital, Peshawar, Pakistan. After a complete description of the
study was given to the participant and the caregiver, written
informed consent was obtained from both. Since a significant
proportion of the patient population was illiterate, special care
was taken to explain the procedures in Pushto, the language
spoken by this population. No monetary incentives were provided
to the participants in the trial.
Study settings and participants
The study was conducted at Psychiatry Department of Lady
Reading Hospital, Peshawar. This is one of the two major tertiary
care mental health centres that serve a large population in Khyber
Pukhtunkhwa province (previously known as North West Frontier
Province) of Pakistan and adjoining areas of Afghanistan. For the
purpose of this study we only recruited people from the Peshawar
district, which has a population of about two million. The
inclusion criteria were: (a) aged 17 to 60 years; (b) a diagnosis of
schizophrenia or schizoaffective disorder based on the ICD-10
Research Diagnostic Criteria (RDC);15 and (c) residence in
Peshawar district. The exclusion criteria were evidence of organic
disorder, ICD-10 ‘mental retardation’, and severe drug dependence
requiring in-patient treatment and/or detoxification. Recruitment
to the study started in November 2006 and the final follow-up of
participants was carried out in January 2009.
Based on the literature, an average rate of adherence to medi-
cation at 1 year for those with schizophrenia is 50%.6,7 We
expected the rate of medication adherence to be 75% in the inter-
vention group. Thus, a sample size of 45 participants per group
would have 80% power to detect a 25% difference in the rate of
adherence to medication between the two study groups with a
one-sided significance of 5%. To control for non-adherence and
losses to follow-up 55 people were recruited in each group.
Procedures
Eligible individuals were identified from the out-patients present-
ing to the psychiatry department at Lady Reading Hospital.
They were first screened by trained psychiatrists working in the
out-patients department and subsequently assessed by one of three
consultant psychiatrists (S.F., Z.N., J.A.) to satisfy the ICD-10
criteria for the diagnosis of schizophrenia and schizoaffective
disorders.15 After identifying eligible individuals through interview
and reviews of previous notes, therapists were asked to approve
their recruitment into the study. Individuals who met inclusion
criteria were randomly assigned to each treatment group. The
random allocations of patients to each group were enclosed in
opaque envelopes which were sealed and numbered sequentially.
These allocations were placed away from the site of assessment.
After assessment and satisfying the inclusion criteria, the staff
which were not part of the study were asked to open the sealed
envelope and reveal the treatment arm for each patient.
STOPS and control groups
The salient features of the two interventions are shown in the
Appendix. Psychiatrists for the TAU (control) group were asked
to provide treatments as they would normally deliver in routine
out-patient settings. This included prescribing evidence-based
pharmacological treatments, out-patient attendance in the
psychiatry department as deemed appropriate by the consultant
and brief counselling about the treatment and outcome.
Participants who could not afford to buy medication had the
option to seek free drug treatment from the social welfare
department of the hospital, which provided treatment for the
participants from the Zakat Fund (a fund established to provide
essential medicine for patients who are poor from a charity
funding based on Muslim law). The participants in the STOPS
arm received the usual care and in addition they each had a key
care supervisor, defined as any family member living with the
individual for at least 6 months and providing support for the
treatment as identified by the participant. Specific education was
provided to the key care supervisor about the nature of the illness,
misconceptions about treatment, the relationship between super-
natural and biological causes of illness and the importance of
continuing the medication, as well as basic skills in how to
administer and supervise the medication. It was emphasised that
participants should not be antagonised and violence should never
be used in case of refusal to accept the treatment. Steps involved in
collecting medicine from the treatment centre, storage at home,
administering tablets and their ingestion by the participant and
how to confirm this were demonstrated. The medications required
were provided 1 month at a time. The intervention was first
implemented in a pilot project over 1.5 years9 and therefore
trainers and assessors were adequately trained and experienced
in providing the intervention.
Doses in each group were titrated according to the clinical
needs of the individual. All participants received atypical anti-
psychotics with the exception of those who were already on typical
antipsychotics and were stable on these. Treatment teams for both
STOPS and TAU participants consisted of two consultant
psychiatrists, three postgraduate trainees with a minimum of
2 years training in psychiatry, two qualified psychiatric nurses
and a master’s level social worker.
Measurements
The baseline assessment included a clinical interview to satisfy the
ICD-10 RDC criteria for diagnosis of schizophrenia and schizo-
affective disorders, demographic data and illness history, GAF
ratings14 and the Positive and Negative Syndrome Scale (PANSS)
for Schizophrenia.16 The follow-up assessments at 3 months, 6
months and at the end of 1 year included: GAF ratings, PANSS
and medication adherence using a scale devised for this purpose.
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Adherence with medication was measured at interview using a
questionnaire with a 5-point scale (where 1 is always and 5 is
never) adapted from Herz et al.17 The scale was used in the pilot
project by the research workers with a high degree of reliability.9
The assessments for adherence to treatment were done quarterly
from baseline with the help of information provided by participants
and relatives. The information was supplemented by the tablet
counts from previous prescriptions where available. Complete
adherence with medication was defined as participants always
taking medication as prescribed without any break during the
assessment period. Non-adherence was defined as missing drugs
completely for more than a week at a time. If a participant took
some medication but not on every day of the week, this was
defined as partial adherence.
All assessments were carried out by doctors with at least 2
years’ training in psychiatry. The same team of psychiatrists carried
out all the follow-up assessments. The follow-up assessments were
done by researchers who were masked to participant group
assignment and instructed not to enquire about a participant’s
treatment during interviews. To ensure this, the administration
of STOPS was kept completely separate from the research team
assessing adherence and administering questionnaires for the trial
and they were not associated with clinical care of the participants
in the trial. The participants and relatives were briefed not to
discuss their treatment with the assessors. All the participants
remained in the study whether or not they were adherent with
treatment, needed hospitalisation or relapsed. Attempts to
maintain contact were made by telephone and/or home visits if
participants did not appear for clinic visits at follow-up assessments.
Statistical analyses
Data were analysed in accordance with the CONSORT guidelines
wherein the between-group comparisons were done using an
intention-to-treat analysis.18 The intention-to-treat analysis was
performed with the last observation carried forward. SPSS Version
16 for Windows was used for the analysis. Descriptive statistics
were obtained on participants’ baseline characteristics and the
primary outcome measure was analysed as a categorical variable.
Chi-squared tests were used to compare the distribution of
baseline variables and adherence scores between the two study
groups (95% CIs and P-values). The number of participants who
had partially adhered to treatment was small in the follow-up
assessments. Therefore, we combined the results for those with
partial and non-adherence together for the purpose of this
analysis. This is also in line with the measurement of adherence,
as described originally by Herz et al.17 Parametric variables were
then assessed for simple group differences using the t-test. A
repeated-measures ANCOVA was used to measure the differences
between the two groups at four time points (within- and between-
group analyses). Baseline scores were used as covariates to take
into account the initial differences. The Kolmogrove–Smirnov test
was used to assess normality. The number of participants needed
to be treated with STOPS to prevent one adverse outcome such as
one participant not adhering to treatment in 1 year was calculated.
Results
The details of recruitment and follow-up are shown in Fig. 1.
Fifty-five individuals were recruited in each arm and 95 (86.4%)
participants completed the study; 49 in STOPS and 46 in the
TAU group. The mean age of participants in the STOPS group
was 29 years (s.d. = 8.1), which did not differ significantly from
the TAU group (mean age 30 years (s.d. = 8.5), P= 0.699). The
baseline sociodemographic and clinical variables were not
significantly different in the two groups (Table 1). Similarly the
relationship with the primary caregiver as defined by the
participants did not differ significantly between the two groups.
Those in the STOPS group had mean durations of illness of
73.6 months, compared with 83.8 months in the TAU group
(P=0.485). No statistically significant difference was found
between the two groups for PANSS and GAF ratings at baseline.
We compared the two groups at four time points to see
whether the mean dosage of antipsychotic drugs was different in
the two groups at any stage. The doses of all antipsychotics were
converted to chlorpromazine equivalents.19 The differences were
not significant for the time effect (Wilks’ lambda 0.94,
F(3,93) = 1.89, P= 0.136), and between-participant effect
(F=0.24, d.f. = 1, P=0.878). The number of participants on depot
medication also did not differ between the two groups.
Medication adherence, symptoms and functioning
outcomes
The two groups showed a statistically significant difference in the
primary outcome measure at the end of 1 year. In the intention-
to-treat analysis at 1-year follow-up 37 participants (67%) in
the STOPS group had complete adherence with medication
compared with 25 (45%) in the TAU group (P50.02) (Table 2).
Using relative risks, it is estimated that participants in the STOPS
group were 1.59 times more likely to adhere to medication than
those in the TAU group (95% CI 1.03–2.53). The number needed
to treat to achieve one positive outcome is five for STOPS.
The participants in the STOPS group showed significantly
more improvement in symptoms and functioning, as measured
by PANSS and GAF in the intention-to-treat analysis. Differences
between the STOPS and TAU groups over time were measured
using analysis of covariance, with baseline scores being used
as covariates to account for the initial differences. Statistically
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Fig. 1 The CONSORT flow chart for the randomised controlled
trial of supervised treatment in out-patients for
schizophrenia (STOPS) v. treatment as usual (TAU).
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significant differences existed for PANSS total scores, (time effect:
Wilks’ lambda 0.90, F(3,105) = 3.54, P= 0.017 and between-
participant effect: F=9.0, d.f. = 1, P=0.003) and PANSS positive
symptoms (time effect: Wilks’ lambda 0.91, F(3,102) = 3.31,
P= 0.011 and between-participant effect: F= 5.9, d.f. = 1,
P= 0.003) in favour of STOPS. However, for PANSS negative
symptoms neither time effect (Wilks’ lambda 0.94,
F(3,102) = 1.2, P= 0.303) nor between-participant effect
(F= 2.11, d.f. = 1, P= 0.149) was significant. The GAF scores
significantly improved over time in the STOPS group compared
with the TAU group (time effect: Wilks’ lambda 0.90, F(3,106)
d.f. = 3.66, P= 0.036 and for between-participant effect: F=7.3,
d.f. = 1, P=0.008). Table 3 shows the descriptive statistics.
Discussion
Main findings
To our knowledge this is the first study that has attempted to test
the effectiveness of a model based on the principles of DOTS in a
non-infectious disease. A framework based on the DOTS strategy
has been suggested to overcome the problems of non-adherence
and continuity of care for non- communicable disorders in LAMI
countries10,20 and has also been used for the delivery and
monitoring of antiretroviral therapy for HIV/AIDS in resource-
poor countries.20 However, the effectiveness of the approach has
not been tested in an RCT.
We found that STOPS, which used an educational inter-
vention for carers to administer and supervise the medication
provided free of cost as part of a treatment programme, resulted
in a significant improvement in adherence with medication. The
trial did not have the statistical power to assess the effects of this
experimental intervention on symptoms and functioning but the
participants in the STOPS group showed a significant improve-
ment in symptoms and functioning compared with TAU. The
mean duration of illness in the two groups was more than 6 years.
The improvement in symptoms and functioning in the STOPS
group shows that maintaining regular treatment and engaging
the family can have a significant impact even in a population with
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Table 1 Differences between the supervised treatment in
out-patients for schizophrenia (STOPS) and treatment as
usual (TAU) groups at baseline
STOPS, n (%) TAU, n (%) Pa
Gender 1.000
Male 47 (85.5) 47 (85.5)
Female 8 (14.5) 8 (14.5)
Marital status 0.999
Married 30 (54.5) 31 (56.4)
Unmarried 22 (40.0) 21 (38.2)
Divorced, widow/widower 3 (5.4) 3 (5.4)
Employment status 0.480
Unemployed 40 (72.7) 41 (74.5)
Employed 8 (14.6) 12 (21.9)
Retired 1 (1.8) 0 (0)
Student 6 (10.9) 2 (3.6)
Education 0.520
No education 23 (41.9) 21 (38.1)
5–9 years 18 (32.7) 14 (25.5)
10 years or more 14 (25.4) 20 (29.3)
Relationship with caregivers 0.286
Mother 6 (10.9) 4 (7.3)
Father 11 (20.2) 16 (29.1)
Child 1 (1.8) 4 (7.3)
Spouse 2 (3.6) 5 (9.1)
Brother 19 (34.5) 16 (29.1)
Sister 3 (5.5) 4 (7.3)
Other 13 (23.6) 6 (10.9)
Course 0.216
Continuous 41 (74.5) 35 (63.6)
Episodic 14 (24.5) 20 (36.4)
Cannabis use 0.425
Current 6 (10.9) 10 (18.2)
Past 4 (7.3) 2 (3.6)
Never 45 (81.8) 43 (78.2)
Diagnosis 1.000
Schizophrenia 45 (81.8) 45 (81.8)
Schizoaffective disorder 10 (18.2) 10 (18.2)
a. w2-test.
Table 2 Differences in medication adherence in the
supervised treatment in out-patients for schizophrenia
(STOPS) and treatment as usual (TAU) groups at three
time points
Adherence STOPS, n (%) TAU, n (%) Pa
3 months 0.05
Complete 38 (69.1) 28 (50.9)
Partial or none 17 (30.1) 27 (49.1)
6 months 0.23
Complete 40 (72.7) 34 (61.8)
Partial or none 15 (27.3) 21 (38.2)
12 months 0.02
Complete 37 (67.3) 25 (45.5)
Partial or none 18 (32.7) 30 (54.5)
a. w2-test.
Table 3 Comparison of the supervised treatment in
out-patients for schizophrenia (STOPS) and the treatment
as usual (TAU) groups for measures of psychopathologya
STOPS (n=55)
mean (s.d.)
TAU (n=55)
mean (s.d.) P
Positive and Negative Syndrome
Scale total scores 0.003
Baseline 101.80 (21.0) 94.6 (19.4)
3 months 70.87 (23.18) 77.11 (21.29)
6 months 67.38 (23.9) 76.96 (20.8)
12 months 67.35 (24.66) 74.33 (21.58)
Positive symptoms 0.003
Baseline 21.6 (6.7) 21.5 (6.3)
3 months 12.6 (7.2) 16.6 (6.5)
6 months 12.4 (7.0) 16.6 (6.7)
12 months 13.6 (6.9) 15.3 (5.5)
Negative symptoms 0.149
Baseline 21.3 (6.1) 19.4 (6.3)
3 months 17.4 (6.0) 17.1 (7.6)
6 months 16.3 (6.1) 17.2 (7.2)
12 months 16.2 (6.8) 17.1 (7.6)
General symptoms 0.007
Baseline 47.9 (10.6) 44.4 (8.9)
3 months 33.7 (10.0) 36.6 (10.5)
6 months 31.4 (10.9) 35.2 (10.2)
12 months 30.3 (10.3) 33.8 (8.8)
Global Assessment
of Functioning scores 0.008
Baseline 42.56 (13.54) 45.95 (11.92)
3 months 55.18 (14.5) 52.13 (15.8)
6 months 58.71 (15.81) 52.67 (16.08)
12 months 62.0 (16.70) 56.05 (18.12)
a. Higher scores represent more psychopathology on the Positive and Negative
Syndrome Scales, but not on the Global Assessment of Functioning scale where the
reverse is the case. Analyses were carried out using repeated-measures ANCOVA
(to compare within-participant and between-participant differences), with baseline
values used as covariates.
Supervised treatment in out-patients for schizophrenia
chronic mental illness. This is consistent with other studies that
reported similar improvement in symptoms and functioning
at 9 months after discharge in participants receiving family
education,21 and at 12- and 18-months follow-up in participants
receiving a family-based intervention.22
There is little available information on the effectiveness of
strategies for extending care to people with severe mental illness
in LAMI countries.23 The essential components of STOPS (i.e.
monitoring drug adherence by observation and recording of the
correct medication by a guardian assigned to the patient) has been
shown to be effective in a retrospective case–control study in rural
China.24 Broadly similar approaches have been shown to be cost-
effective and significantly reduced disability and psychotic
symptoms.25,26 However, these studies employed family or social
interventions typically comprising at least one session of 1–2 h
every 2 or 4 weeks over the study period, which is more akin to
an assertive outreach programme and may be difficult to apply
in LAMI countries. The STOPS approach, in contrast, used a brief
intervention of initially one session, which was reinforced on
subsequent visits, without directly addressing family dynamics
or expressed emotion. The better adherence to treatment and
improvement in symptoms in this cohort is consistent with the
evidence from a systematic review of interventions to improve
medication adherence in schizophrenia that showed that relatively
brief interventions (both in terms of duration and frequency) that
targeted the behaviours related to medication adherence were
more effective than longer interventions with a broader focus on
psychoeducation.7
Most of the key care supervisors were first-degree relatives.
Spouses were involved only in 3.6% and 9.1% of STOPS and
TAU groups respectively, despite the fact that more than half of
the participants in both groups were married. This reflects the
routine involvement of the extended family in the care of those
with a severe mental illness. Involvement of family members as
treatment supervisors to improve treatment adherence could have
adverse consequences for the family members and possibly for
patients in the form of coercion to take treatment. The latter was
specifically addressed during the pilot phase and the development
of the intervention.9,10 Psychoeducational programmes are generally
found to decrease the family burden and improve aspects of family
functioning such as problem-solving, communication and inter-
personal relationships.21,26 These aspects of care were, however, not
evaluated in this RCTand will need to be addressed in future studies.
Limitations
It can be argued that the provision of free drugs could have
contributed to the better outcome in the STOPS group. The
average cost of medication for a month using atypical drugs is
about 900 rupees (£1 is equivalent to approximately 136 rupees),
which can be quite costly for patients and families from lower
socioeconomic backgrounds presenting in a public hospital such
as Lady Reading Hospital. The DOTS is a complex intervention
and free access to medication is an essential component of the
DOTS programme as applied in tuberculosis control.12 The
participants in the TAU group had the option of accessing free
drugs from the social welfare department. Providing free
medication as part of the trial would have grossly distorted the
TAU condition in these settings. The evidence, however, suggests
that even if drugs were free, non-adherence persists. One recent
study showed that even among people who have health plans with
no cost-sharing for medication, rates of non-adherence were
nearly 40%.27
Other limitations in evaluating the results of this study should
also be recognised. We selected standard out-patient care for
comparison, which is most often the only type of mental
healthcare available in these settings. Treatment as usual is
criticised as a comparator in evaluation of complex interventions
as the healthcare system in which the treatment programme is
embedded is known to have important consequences for
outcome.28 The drug supply for the TAU group could vary in
supply and quality, being dependent upon local pharmacies. It
can be argued that the participants in the STOPS group had
increased contact with the team to collect medication, which
could have contributed to better adherence. However, this should
be balanced against the fact that participants in the TAU group
received more support for their treatment from the research and
social services department of the hospital, being a focus of
attention in a research study. Enhanced care associated with
regular assessment of adherence and follow-up visits in this
RCTwas not typical ‘treatment as usual’. It is also well known that
the measures that rely on subjective reports of pill taking to
measure adherence in schizophrenia tend to overestimate
adherence and reduces the likelihood of detecting intervention
effects.8 These limitations should, however, minimise the difference
between the two groups. The masking of research interviewers to
the treatment group could not be completely assured since the
study was not placebo-controlled, with the possibility that research
interviewers favoured the STOPS group. The contamination of
treatments was also possible, i.e. the treatment team providing
TAU would act more like the team providing the experimental
intervention over time.
Implications for service provision and research
Interventions for people with schizophrenia in LAMI countries
should primarily involve the families as more than 90% of patients
in these countries live within a family unit.5 This study provides
preliminary evidence that a package of care based on a brief
educational intervention for the families, and supervision and easy
access to medication as envisaged in the DOTS strategy using a
simple treatment regimen can be used to improve services for
people with schizophrenia in LAMI countries. Adopting a model
of care devised essentially to treat an infectious disorder like
tuberculosis for a chronic illness that may run a lifelong course
will require certain modifications. Neither health systems in most
LAMI countries nor caregivers can be expected to provide the
lifelong commitment required for a STOPS programme.
However, the initial 2 years in the course of schizophrenia have
been described as the ‘critical period’. The treatment status during
this period is the strongest predictor of long-term outcome and
disability.29 Even a gap as small as 1–10 days in medication
adherence over a 1-year period has been found to be significantly
associated with an increased risk of hospitalisation with an odds
ratio of 1.98.30 Based on this evidence and recommendations from
a systematic review of interventions to address non-adherence in
schizophrenia that clinical interventions targeting non-adherence
should continue for at least 18 months,8 we suggest an approach
for early intervention for psychosis in LAMI countries. It is
proposed that people with schizophrenia should be provided with
an uninterrupted drug supply based on a public health
programme like STOPS for an initial 2-year period.
The present study sample consisted of participants with a
relatively chronic course of illness as recruiting a first-episode
sample would have taken much longer and was not feasible within
our resources. The approach suggested in this trial now needs to
be evaluated in first-episode psychosis, as effective intervention
during this period is likely to achieve maximum long-term gains
during the entire course of the illness. The effectiveness of this
approach in non-specialist health settings in view of the shortage
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of psychiatrists in LAMI countries, and the cost-effectiveness of
STOPS, will also need to be evaluated.
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education to educate the key some education may
care supervisor to be provided by
administer and therapist
supervise the drugs
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Data supplement
Table DS1 Studies of DUP from low- and middle-income (LAMI) economies classified using World Bank criteria
Study Country
Main
outcome
studied
Included
affective
psychosis
Onset
of
DUP
End
of
DUP
Diagnostic
system
Number
of
samples
Mean
DUP
of all
patients
in the
study
Upper-middle-income economy
Alpteken et al, 200517 Turkey Outcome DUP No Psychotic
symptoms
Antipsychotic
treatment
DSM–IV 2 48.4
Apiquian et al, 200218 Mexico Outcome DUP Yes Psychotic
symptoms
Contact with
services
SCAN 2 54.3
Fresa´n et al, 200322 Mexico Premorbid
functioning
Yes Psychotic
symptoms
Antipsychotic
treatment
SCAN/DSM 2 60.0
Gill et al, 200525 Malaysia Descriptive
DUP
Yes Psychotic
symptoms
Hospital
admission
SIPS 1 47.7
Galin´ska et al, 200524 Poland Cognitive
function
No Psychotic
symptoms
Antipsychotic
treatment
PANNS 1 31.3
Oosthuizen et al, 200535 South Africa Outcome
DUP
No Psychotic
symptoms
Antipsychotic
treatment
DSM–IV 2 32.7
Lower-middle-income economy
Ayres et al, 200719 Brazil Cognitive
function
Yes Psychotic
symptoms
Contact with
services
DSM–IV 3 37.7
El-Adl et al, 200721 Egypt Pathways
to care DUP
Yes Psychotic
symptoms
Contact with
services
ICD–10 2 30.1
Gorwood et al, 200826 Reunion Islanda Gender
and onset
No Criteria for
schizophrenia
Contact with
services
DSM–III–R 2 51.6
Kurihara et al, 200228,29 Indonesia Mortality
DUP
No Psychotic
symptoms
Hospital
admission
DSM–III 1 124.8
Lieberman et al, 200330 China Drug trial No Psychosis
symptoms
Antipsychotic
treatment
SCID/DSM 1 79.1
Ran et al, 200136,37 China Outcome of
psychosis
No Psychosis
symptoms
Contact with
researchers
PSE 3b 236
Ranjbar et al, 200638 Iran Pathways
to care DUP
Yes Psychotic
symptoms
Hospital
admission
DSM–IV 2 45.5
Selten et al, 200539 Suriname Incidence No Psychosis
symptoms
Contact with
services
IRAOS 1 88.1
Tang et al, 200740 China Pathways
to care DUP
No Psychosis
symptoms
Hospital
admission
ICD–10 2 116.5
Low-income economy
Calvo de Padilla et al, 200620 Argentinac Temperament No Psychotic
symptoms
Contact with
researchers
SCAN 1 468
Gangadhar et al, 200223 India Gender
and onset
No Psychotic
symptoms
Contact with
services
– 4 98.8
Gureje & Bamidele,199827 Nigeria Gender
and onset
No Nuclear
symptoms
Contact with
services
RDC 2 152.4
Mbewe et al, 200631 Zambia Descriptive
DUP
Yes Psychotic
symptoms
Hospital
Admission
DSM–IV 1 48.1
McCreadie et al, 200532;
Tirupati et al42
India Movement
disorder
No Psychotic
symptoms
Contact with
researchers
DSM–IV 1 556
Murthy et al, 199833 India Gender
and onset
No Psychotic
symptoms
Contact with
services
DSM–IV 2 85.8
Naqvi et al, 200534 Pakistan Gender
and onset
No Psychotic
symptoms
Contact with
services
– 2 110.2
Thirthalli et al, 200541 India Outcome
DUP
No Psychosis
symptoms
Contact with
services
ICD–10 1 97.2
DUP, duration of untreated psychosis; IROAS, Instrument for the Retrospective Assessment of the Onset of Schizophrenia; PANNS, Positive and Negative Syndrome Scale;
PSE, Present State Examination. RDC, Research Diagnostic Criteria; SCAN, Schedule for Clinical Assessment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM–IV;
SIPS, Structured Interview for Prodromal Symptoms.
a. Overseas department of France.
b. One sample of intermittently treated patients was excluded, those with contact with traditional healers only regarded as untreated.
c. Classified as low-income as the study was conducted in a remote indigenous community.
2Table DS2 Studies from high-income countries used as a control group
Studya
Country in which
the study was
conducted
Includes
affective
psychosis
No.
samples
usedb
DUP weighted mean of
all included participants
in samples used,c weeks
Addington et al,1 2004 Canada No 1 84.2
Altamura et al,2 2003 Italy No 2 52
Altamura et al,3 2001 Italy No 2 83.4
Archie et al,4 2005 Canada Yes 1 91
Ballageer et al,5 2005 Canada No 2 69.6
Barnes et al,6 2000 UK No 1 59
Beiser et al,7 1993 Canada Yes 6 33.4
Birchwood et al,8 1992 UK No 1 30.3
Black et al,9 2001 Canada No 1 75.5
Carbone et al,10 1999 Australia Yes 2 29.1
Carlsson et al,11 2006 Sweden No 2 55.6
Caton et al,12 2006 USA No 2 51.3
Chen et al,13 2005 Hong Kongd No 1 73.3
Chong et al,14 2005 Singapore No 1 137.6
Chow et al,15 2005 Hong Kongd Yes 1 34.3
Clarke et al,16 2006 Ireland No 1 76.5
Cohen et al,17 2000 Canada No 2 91.2
Compton et al,18 2006 USA No 1 65.3
Cougnard et al,19 2004 France yes 1 187.2
Craig et al,20 2000 USA No 3 MNR
Crespo-Facorro et al,21 2007 Spain No 1 61.5
de Hann et al,22 2003 The Netherlands No 1 37
Drake et al,23 2000 UK No 1 38
Fannon et al,24 2000 UK No 1 28.1
Friis et al,25 2004 Norway No 1 MNR
Fuchs et al,26 2004 Germany No 1 71
Gunduz-Bruce et al,27 2005 USA No 2 69.5
Haas et al,28 1992 USA No 3 98.8
Hafner et al,29 1993 Germany No 1 109.2
Haley et al,30 2003 UK No 1 53.2
Harrigan et al,31 2003 Australia Yes 2 26.4
Harris et al,32 2005 Australia Yes 3 42.6
Hides et al,33 2006 Australia Yes 1 16.7
Ho et al,34 2000 USA No 1 74
Kalla et al,35 2002 Finland and Spain No 2 28.1
Kampman et al,36 2004 Finland Yes 1 40
Keshavan et al,37 2003 USA Yes 1 95.7
Kinoshita et al,38 2005 Japan No 1 42.6
Lambert et al,39 2005 Australia Yes 1 12.2
Larsen et al,40 2001 Norway No 1 114.2
Linzsen et al,41 2001 Netherlands No 1 23.22
Loebel et al,42 1992 USA No 2 51.9
Loranger,43 1984 USA No 2 88.4
Madsen et al,44 1999 Denmark No 2 36.7
Mauri et al,45 2006 Italy No 1 72.3
Melle et al,46 2005 Norway and Denmark No 2 49.1
Meng et al,47 2006 Germany Yes 1 30.5
Milton et al,48 2001 UK Yes 2 MNR
Møller,49 2001 Norway No 1 38.4
Morgan et al,50 2006 UK Yes 1 58
Moscarelli et al,51 1991 Italy No 1 81.7
Pek et al,52 2006 Singapore Yes 2 70.1
Peralta et al,53 2005 Spain No 1 169.4
Perkins et al,54 2004 USA No 3 67.9
Petersen et al,55 2005 Denmark No 2 MNR
(continued)
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5Table DS3 Multiple linear regression of factors associated with log10 mean DUP, weighted for the number of participants in each
sample
Unstandardised Standardised
B s.e. Beta t P
Constant 2.127 0.220 9.648 50.001
Study from a LAMI economy 0.237 0.063 0.295 3.749 50.001
Samples of schizophrenia-related psychosis 0.238 0.061 0.298 3.922 50.001
Proportion of male participants 70.001 0.001 70.091 71.186 0.237
Mean age at onset of psychosis 70.011 0.008 70.112 71.416 0.159
DUP, duration of untreated psychosis; LAMI, low- and middle-income.
ANOVA regression: sum of squares=332.6, d.f.=4, mean square=83.17, F=9.72, P40.001; ANOVA residual: sum of squares=1223, d.f.=143, mean square 8.56.
Table DS4 Relationship between GDP purchasing power parity and mean DUP of all samples that had contact with services
from LAMI countriesa
Unstandardised Standardised
B s.e. Beta t P
Constant 114.2 12.7 8.99 50.0001
GDP purchasing power parity 70.006 0.002 70.497 73.337 0.002
DUP, duration of untreated psychosis; GDP, gross domestic product; LAMI, low- and middle-income.
ANOVA regression: sum of squares=977 170, d.f.=1, mean square=977170, F=11.13, P=0.002; ANOVA residual: sum of squares=2 984 387, d.f.=34, mean square=87 776.
a. Samples of patients who had not received treatment (contact with researchers only) omitted. Dependent variable mean DUP. Linear regression weighted by sample size.
Table DS5 Relationship between GDP purchasing power parity and mean DUP of samples of patients with schizophrenia-related
psychosis from LAMI countriesa
Unstandardised Standardised
B s.e. Beta t P
Constant 135.5 13.66 9.92 50.001
GDP purchasing power parity 70.009 0.002 –0.644 74.212 0.001
DUP, duration of untreated psychosis; GDP, gross domestic product; LAMI, low- and middle-income.
ANOVA regression: sum of squares=1 274 546, d.f.=1, mean square=1 274 546, F=17.74, P40.0001; ANOVA residual: sum of squares=1 796 477, d.f.=25, mean square=71 859.
a. Samples of patients who had not received treatment (contact with researchers only) omitted. Dependent variable Mean DUP. Linear regression weighted by sample size.
